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The north road from Casterbridge is tedious and lonely, especially 
in ‘winter time. Along a part of its course it connects with Long-Ash 
Lane, a monotonous track without a village or hamlet for many miles, and 
with very seldom a turning. Unapprized wayfarers who are too old, or too 
young, or in other respects too weak for the distance to he traversed, 
hut who, nevertheless, have to walk It, say, as they look wistfully ahead 
"Once at the top of that hill, and I must surely see the end of Long-Ash 
Lane!" But they reach the hilltop, and Long-Ash Lane stretches in front 
as mercilessly as before.
Thomas Hardy 
May 188U
ABSTRACT
The role of lipophilicity in governing the kinetics of absorption, 
distribution, metabolism and excretion of selected aliphatic carbamates 
has been investigated.
The use of a series of aliphatic carbamate homologues of general 
structure R-O-CO-RH^ was the basis of these studies since these compounds 
show regular incremental changes in, and cover a wide range of, apparent 
partition coefficient. The carbamate homologues are also stable and 
unionised in aqueous solution and can thus be considered as a single 
entity in kinetic studies.
Studies on the interaction of the carbamates with a phosphatidyl­
choline model membrane system (liposomes) showed that increasing carbamate 
chain length produced increasing destabilisation of the liposome membranes.
It was found that the destabilisation was associated with incorporation of 
the carbamates into the lipid membrane.
Four radiolabelled carbamates were used to investigate further the 
previously demonstrated parabolic relationship between intestinal absorption 
rate and partition coefficient. The in situ small Intestine preparation of 
either fed or 18 hour starved rats showed that the "lipophilicity parabola" 
was still operative using very low carbamate concentrations.
The colonic absorption of the carbamate series has been studied in 
situ. The absorption process appeared to be passive and no metabolism by 
the colon membrane was detected. A linear correlation between the 
absorption rate constant and partition coefficient was found. The marked 
difference between the absorption profiles obtained for the colon and small 
intestine indicate that the absorptive process is much simpler in the 
colon. Concurrent water flux was found to have no effect on the absorption 
of the homologues from the colon.
The pharmacokinetic disposition and overall metabolic fate of four 
radiolabelled carbamates have been investigated. Consideration of the 
proportions of dose excreted in the expired air and in the urine indicated 
that carbamate metabolism took place by two competing pathways. A  hydrolytic 
route of metabolism appeared to be favoured by the shorter chain carbamates 
whereas various metabolic transformations on the intact carbamate molecule 
took place extensively for the longer chain carbamates.
To Suse and 
r$y parents
ACKNOWLEDGEMENTS
I am deeply grateful to Dr J W Bridges and Dr D G Upshall for 
their consistent help and encouragement during the last three years.
I would also like to thank the Director of the Chemical Defence '
Establishment for allowing me the use of the facilities of the 
Establishment, and Prof D V Parke, University of Surrey and 
Dr L Leadbeater, Chemical Defence Establishment, in whose laboratories 
the work was carried out. My thanks must also go to Liz Annetts for 
some splended typing. Finally I wish to thank the Ministry of Defence 
for a research studentship.
CONTENTS
.PaS-e.
Chapter 1 General introduction. 1
Chapter 2 Materials and Methods. 46
Chapter 3 Interactions of carbamates 65
■with'liposomes.
Chapter ^ Intestinal absorption of 83
carbamates.
Chapter 5 Colonic absorption of carbamates. 100
Chapter 6
Chapter 7 Final discussion. 152
Pharmacokinetic profiles for 115
four radiolabelled carbamate 
homologues.
References 161
GLOSSARY
absorption rate constant.
metabolism rate constant.
excretion rate constant.
elimination rate constant.
rate constant for transfer from central to 
peripheral compartment.
rate constant for transfer from peripheral to 
central compartment.
• r •fast disposition phase.
slow disposition phase.
plasma concentration at time zero. ■■■-- -
maximal plasma concentration.
volume of central compartment.
total volume of distribution at steady state.
volume of distribution at pseudo-equilibrium.
fraction of dose in central compartment.
area under the curve.
CHAPTER ONE
: GENERAL INTRODUCTION
A. PHYSICO-CHEMICAL ASPECTS OF DRUG ACTION
i. Introduction to the processes governing drug levels in the "body
ii. Structure-activity relationships. . ■ . "
B. GASTROINTESTINAL ABSORPTION OF DRUGS 
i. Absorption mechanisms
a. Passive diffusion
b. Active transport ■
c. Pore transport '
- ii. Physiological factors influencing drug absorption
/
a. Morphology of the gastrointestinal tract
b. Gastrointestinal motility
c. Circulatory systems.
d. Interactions with endogenous substances
e. Intestinal metabolism
f. Drug formulation ~
. iii. Model membrane systems * • - - ;
C. THE DISTRIBUTION OF DRUGS
i. Compartmental analysis.
ii. Localisation of drugs in tissues.
iii. Drug binding to plasma proteins.
D. DRUG ELIMINATION
i. Drug metabolism
a. The liver drug metabolising enzyme system
ii. Factors influencing drug metabolism  ----  — - ----— —
a. J Genetic factors
/ ; ' : V
b. Physiological factors
c. Environmental factors '
iii. Biliary excretion and enterohepatic circulation
iv. Renal excretion
E. PHARMACOKINETIC MODELS FOR DRUG CHANGES WITHIN THE BODY
i. Kinetics of distribution,.metabolism and excretion after a .
drug reaches the general circulation. '
a. One compartment model
b. Two compartment model
ii. Kinetics of processes prior to a drug reaching the general, 
circulation.
a. One compartment model :
b. Two compartment model
c. First-pass effect
2
PROPERTIES AND USES OF SIMPLE CARBAMATES
i. The chemical and physical properties of carbamates.
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INTRODUCTION TO PRESENT WORK *
A. PHYSICO-CHEMICAL ASPECTS OF DRUG ACTION
There are two facets to the problem of biochemical and physical aspects 
of drug action - the influence of drugs on the body and the influence of the 
body on drugs (Brodie and Hogben, 1957)* To be effective, a drug must not 
only be capable of interacting with a particular receptor but must possess
characteristics which .enable it to reach the receptor in an adequate
\ ■
concentration. Both these aspects of drug action will, be largely dependant 
upon the physico-chemical properties of the drug.
i/ Introduction to the processes governing drug levels in the body
— y
Since it is usually not possible to administer the required amount of 
drug directly at the receptor site, the drug will be administered at a 
location remote from this site of action. After administration.the necessary 
vital functions of the body will delay the transport of drug molecules across 
membranes, dilute .them'into various compartments of distribution, transform 
them into metabolites and finally excrete them. These factors which will 
affect the plasma levels of a drug in the body are shown in the following 
scheme. vl-
Site of drug action
Absorption*
Tissue
In this model the body is conceived as a collection of discrete 
compartments, each containing some fraction of the administered dose of 
drug. The transfer from one compartment to another is associated with a 
specific rate constant, the magnitude of which determines how fast the 
transfer will occur. Usually these transfer rates have been found to obey 
first order kinetics (Riggs, 19^3; Wagner 1975) where rate constant is a 
proportionality constant between the transport rate and the concentration 
of drug.
Drug bound to plasma proteins 
Drug free in plasma
-^Elimination
In order to gain access to the site of action, a drug must penetrate 
a succession of body membranes. Unless the drug is administered 
intravenously it will be introduced in a physical form or vehicle which 
may modify the. release and availability of the drug molecules to the 
absorption sites; the first steps in their long journey to the receptor 
sites.of drug action. The importance of lipid solubility and the degree 
of ionisation of a drug in-controlling passive diffusion-and other transport 
processes will be considered in the subsequent section on gastrointestinal - 
absorption (section B).
\ ,
All distribution processes are reversible and the drug in the blood
/
exists in diffusion equilibrium with the drug in other body fluids. 
Consequently changes in the blood concentration of a drug are indicative of 
concentration changes in other tissues (including the active drug site). 
However blood concentration-time curves may give a false impression of the.
.amount of drug available to produce a therapeutic response because of 
plasma protein binding. Only the unbound drug is available for diffusion • 
out of the blood for receptor site interaction and for tb„e processes .of 
distribution, metabolism and excretion. The various aspects of drug 
distribution will be discussed in section C of this chapter.
Elimination processes, are. by definition irreversible. The elimination 
rate constant (k ) of a drug represents the sum of each rate constant
0J_
associated with the loss of active drug from the body. It therefore includes
the excretion rate constant of the intact drug (k ) and the metabolism rate
ex
constant (k ), m
The factors controlling elimination of a drug from the body will be 
discussed in section D of this chapter.
ii/ Structure-activity relationships
The enormous difficulty in finding new drugs has been analysed by
Spinks (1973), who estimated that one new drug arises out of each 200,000
new compounds. He suggested that one can expect to find an effective
anticancer drug out of each ^-00,000,000 randomly tested compounds. This
is about 100 times the number of known organic compounds. Structure-
activity studies have been fundamental in the rational evolution of new 
*
drugs, either from first principles or by the perfection of chance 
discoveries (Albert, 1971)*
-For over 100 years chemists and pharmacologists have been intrigued
by observed changes in biological effects of chemical congeners paralleling
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minor alterations in chemical structure. Crum-Brown and Fraser (1868) first 
demonstrated such a relationship and presented the equation, .
. biological response = f(c)
By this they meant that biological response (BR) was a function of 
chemical structure (C). The real barrier to solving this equation in 
early work was that of defining the significant parameters of chemical 
• structure in numerical terms. A major, breakthrough came in applying to 
biological systems.the techniques used in physical organic chemistry, 
where a. successful approach to the correlation of chemical reactivity with 
substituent parameters was discovered by Hammett in 1937« One form of the 
Hammett equation is shown below,
log k- = per ')■ log k o s 0 o
Here k^-and-k are the equilibrium constants for reactions of substituted 
and unsubstituted compounds, respectively, the constant p is characteristic 
of the reaction conditions and the parameter cr is a measure of the electronic 
^effect of the substituent on the .reaction centre. The Hammett equation 
clearly illustrates the linear relationship between the substituent constant,
or, and the logarithm of the reactivity of the compound .(k )• Since the
£>••• •
logarithm of an equilibrium constant is proportional to the -change in . Gibbs, 
free energy (Klotz, 1950), the Hammett equation and others like it are 
”free-ene*rgy related” (Wells, 1968). The biological equivalent of the 
Hammett equation usually expresses biological activity as an enzymic rate 
constant (Hansch et.al., 1965a) or as log where C is the molar 
concentration required to produce a standard response (Hansch et.al., 1965b). 
Such approaches are fully consistent with modern theories of drug action 
(Ariens, et.al., 196*0 in which drug activity is proportional to the free- 
energy of formation of the drug receptor complex (Tute, 1970)*
On the assumption that the reaction between bioactive compounds and 
bioreceptors could also be directed by electronic factors, several attempts 
were made to correlate c^values with:changes in biological response. These 
attempts were largely unsuccessful and only a few successful correlations 
were reported (Hansch, 1971)• However, recognising the physicochemical 
nature of biological reactions and realising the importance of partitioning 
of a drug in reaching its site of action ((Hollander, 1937; 195*+) 5 Hansch
and co workers expanded the linear free-energy related expression in 196*1. 
to include additional physicochemical parameters. Recently Hansch (1976) 
has rewriten the original equation of Crum-Brown and Fraser, by incorporating 
these parameters as
ABR = f(Aelectronic + Asteric +■ Ahydrophobic + Apolarisability). -
The terms on the right of this equation refer to changes produced 
in a parent drug by the addition of substituents. . Very few examples are 
available where it is necessary to use all these parameters (Hansch, 197T) 
it is often sufficient to consider only the hydrophobic properties of a 
compound.
Hansch and Dunn (1972) have shown that biological actions of a wide 
variety of compounds can be correlated with the simple equation.
T
log = a log P + b
where P is the partition coefficient of the;compound, usually measured in 
an octanol and buffer system, which is taken as a measure of the hydrophobic 
property of the compound. Hansch (1976) has pointed out that the slopes 
(a) of such equations are dependant on the system used and not on the type 
of congener.
■Medicinal chemists have long been aware that one cannot go on forever 
making a parent structure more lipophilic to get more activity. It has
been proposed that drugs reach their site of action by-s. '’random walk”
process (Penniston et.al., 1969)• During this process they may act ■
reversibly or irreversibly with lipids, proteins, water and other cellular 
constituents before eventually reaching their site of action.. Therefore 
as P approaches infinity, binding of the drug to the first lipid phase 
with which it comes into contact will be very firm. Thus the drug which 
will not readily cross aqueous phases tends to localise in this first >1
lipoid phase.' Conversely as P approaches zero, the drug becomes so water
soluble that it tends to localise in the first aqueous phase into which.it 
is placed. Somewhere between zero and infinity there will be a value of P 
where there will be least hindrance in the "random walk” of a drug through \ 
the biophase to the site of action; this value is designated Po. The 
concept of an optimum log P as the maximum, of a parabola, has how been 
mathematically justified (Penniston et.al. 1969) and has found wide 
applicability. Numerous examples have been quoted by Hansch and Clayton 
(1973) which fit such a-parabolic equation,
Optimum log P values obtained for a given system provide useful 
guidelines for the synthesis of potential drugs since they Indicate 
quantitatively the lipophilic-hydrophilic balance to be preserved in any 
series that is transported by passive diffusion. Conversely the use of
2
a log P + b log P + c
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be. considered if optimum parameters have already been achieved in the compound 
tested (Purcell and Clayton, 1971)*
Corre3.ations between structure'and activity can be used for predictive
purposes as stated above. Perhaps of more interest to the biochemist is
the approach developed by Hansch that the parameters used have a physical
meaning. If this is the case it may be possible to give the regression
equations a physical interpretation in terms of mode of action of the relevant
series. Verloop, (1972) has however indicated the caution with, which such
. \
interpretation should be viewed. For example P values may be related to 
-electronic parameters, having been correlated with two quantum mechanical 
■indices (Rogers and Cammarata, 1969). These quantum-mechanical indices 
are more independant and fundamental in nature and they can be calculated
— "  S -
more specifically for different positions of the relevant molecules. It - 
may thus be expected that regression equations containing these theoretical 
constants will provide a better base for mode of action studies (Verloop, 
1972). . ':
- Recently, Randic (1975) has devised-a-"molecular connectivity index" • 
which relates to the degree of branching, or connectivity in a molecule and 
which may have more fundamental significance than partition coefficients.
In the short time since its introduction the index has been shown to relate 
to polarisability, non-specific local anaesthetic- activity (Kier, et.al. - 
1975a), water solubility, boiling point, (Hall et^jal^, 1975)> partition 
coefficient, barnacle larvae narcosis, (Murray, et.al., 1975) enzyme 
inhibition (Kier, et.al., 1975b) and density (Kier, et.al., 1976). It would 
appear that encoded in this connectivity index, which results from a simple 
mathematical operation, is the molecular structure of the chemical species 
and as such the index may achieve great importance in structure-activity 
relationship studies.
i/ Absorption mechanisms
A drug enters the circulation either by "being injected there directly 
via'the Intravenous route or by absorption from depots-in -which it has / 
been placed. The most common such depot is the gastrointestinal tract, the 
drug either being taken by mouth or.administered by rectum. Since the 
general principles governing the absorption of drugs through the gastro­
intestinal membrance are the same as for the passage of drugs across any 
biological membrane,'the structure of these cellular membranes has assumed 
great importance in absorption studies. *
The cell membrane was recognised as a barrier _long before.; .
it could be observed with the- electron microscope or analysed chemically.
The demonstration of a systematic relationship between anaesthetic potency 
and oil-water partition coefficients by Overton (l899; 1901) and the 
correlation between the permeability of plant cells to various organic 
molecules and their partitioning properties (Collander and Barlund, 1933)5 
led to the view that the cell boundary was essentially lipid in nature and 
dispersed with small aqueous channels (Hober and-Hober 1937;• Collander^ 19^9)* 
Comparison of the surface area of red blood cells with the quantity of 
lipid extracted from them suggested to Gorter and Grendel (1925) that the 
lipid in the cell must exist as a bimolecular layer. Later, on the basis 
of surface tension studies Danielli and. Harvey (1935) postulated that the 
hydrocarbon surface, assumed to be the basis of the cell membrance, was 
covered by a layer of protein. These considerations led to the widely 
accepted Davson - Danielli (1935; 1952) theory which was later 'expanded by
the electron microscopists. . In this model the centre of matrix of the 
membrane consists of two molecular layers of phospholipid with their, 
hydrocarbon portions directed towards the centre and with their- outer 
hydrophilic surfaces coated with protein. Whilst this is an attractive 
model it has not gone unchallenged in recent years and more recent proposals 
have been reviewed (Bernhard, 19&9; Coster and Hope, 197^ -) s For example- 
in the fluid-mosaic membrane model of Singer and Nicolson (1972), globular 
protein units are embedded in a biomolecular lipid leaflet. However even 
though the unit membrane model does not account for all the available data 
on membrane transport, it does satisfactorily account for the permeability 
of a large number of compounds for which specific mechanisms of active or 
facilitated transport do not exist (Levine, 1970).
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The great majority of drugs are transported across the gastrointestinal 
membranes hy the process of simple diffusion, (Schanker, 1971)* .In this 
case drug molecules diffuse from a region of. high drug concentration 
(gastrointestinal lumen) to a region of'low drug concentration (blood) . 
According to Ficks first law the rate of diffusion (j) is dependant upon the 
concentration gradients across the membrane (AC), the area (A) and thickness 
(X) of the membrane and the partition of the molecule between membrane and 
aqueous phase P.,
T _ DR A. AC ‘ . • 'J = ———  / *
X : . ■
In the above eauation-the diffusion coefficient (D) is defined as the * /
number of moles of drug that diffuse across a membrane of unit area in 
unit time when the concentration gradient equals unity. Since it is often 
difficult to evaluate R and X, a permkbility constant P is defined,
and thus Ficks law, in terms of permeability, becomes
‘ J = -PAAC • ' ;A:7 . _
Since the drug is distributed into a large volume upon entering ;the
blood, the concentration of drug in the blood will be very low with respect
to that in the gastrointestinal lumen. As a result, a large concentration
driving force is maintained during the absorption process and the rate of
absorption is essentially proportional to the drug concentration in the
lumen (C ),
L*
J = -kaC^
where ka is the first order absorption rate constant which will thus be a 
function of the permeability of the membrane to the drug, the area of the 
absorbing membranes and the diffusion coefficient, of the drug.
As previously mentioned, the gastrointestinal epithelium, like other 
biological membranes, is essentially lipid in nature. It is not surprising, 
therefore, that it permits the passive absorption of lipid soluble drugs 
but imposes a barrier to the absorption of lipid insoluble drugs. Most drugs 
are either weak acids or weak bases and since it is the unionised form of
10
ux-ug ouau. uas greater npia soiuDiircy ana unus is *tne more readily absorbed 
form of. the druga the absorption rate of these drugs is related to the 
fraction of total drug in solution in the unionised form. Such observatations 
are the basis of the "pH-partition hypothesis” (Shore et.al., 1957)* This 
hypothesis relates the lipid solubility, dissociation constant and the pH 
at the absorption site with the absorption rate of the drug throughout the 
gastrointestinal tract.
In the acidic environment of the stomach, weakly acid drugs (pKa>2.5) 
exist primarily in the unionised form and would be readily absorbed^
Conversely weakly basic drugs would exist essentially in the ionised form 
and absorption would be negligible. Such effects have been demonstrated 
both in rat (Schanker, et.al., 1957; Kakemi et.al., 1967) and man (Hogb.en, 
et.al., 1957)* Further studies showed that" when the gastric lumen was 
made alkaline with bicarbonate ions, the absorption of weak acids was 
depressed and the absorption of weak bases was enhanced.
The pH of the small intestinal fluids (about 6.5) favours the 
absorption of weak bases over weak acids because a greater fraction of the 
drug is in the unionised form.* Even so the absorption of weak acids with 
pKa values greater than 3 is quite rapid (Brodie, 196k). For example 
salicylic acid (pKa - 3) is well absorbed from the small intestine even
though the drug is almost completely ionised. In order to explain such 
findings it has been proposed that the pH close to the mucosal surface is 
more acidic than in the lumen. This "virtual pH11 (Hogb.en, et.al., 1959) 
also explained why the minimum pKa of an acidic drug for rapid absorption 
was 3 whereas the corresponding pKa for a weak'base was about 8.in a 
medium of pH6.5* If the "virtual pH is about 5*3? the minimal ratio of 
no.hLonised to ionised drug needed for rapid intestinal absorption would be 
the same for both acids and bases.
If a "virtual pH" of 5*3 does exist it has never been demonstrated ,
and the validity of this concept has been criticised (Smolen, 1973;
Wagner, i960). An alternative therory proposed by Benet, discussed by 
Wagne^<f"l968), explains the discrepancies in the pH partition hypothesis 
by considering the ionised species to possess some degree of permeability.
The : ^ chanism by which the ionised species of a drug is absorbed is not • 
clear but the absorption of several bases has been shown to be enhanced by 
complexation. with a. counter-anion (Suzuki et.al., 1972; Gibaldi and 
Grundhofer 1973). Deviations from the pH partition hypothesis of a number 
of barbituric acid derivatives has been explained in terms of a binding 
process to the small intestinal muscosa as a determining step in the 
absorption of these compounds (Kakemi et.a l , 1967 and- 1969) •
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1959) has revealed an absorption pattern very similar to that of the small 
intestine. Weak acids and bases are generally well absorbed whilst more 
highly ionised drugs are poorly absorbed. In agreement with-these findings 
Michelsy et.al., (197*0 reported a correlation between colonic absorption 
of certain drugs and their partition coefficients although details of this 
correlation were not included. These isolated reports reflect how little 
attention has been focussed on the absorptive capacity of the colon for 
drugs. Many countries routinely use suppository drug formulations and 
although part of such a preparation may be absorbed via the distal colon, 
the extent to which this occurs is not well documented. Suppositories are 
also absorbed via the rectal muscosa and rectal absorption of drugs .has 
been reviewed by Wagner- (1-971)® - : : .
Few studies have been made of the permability of the mucosa in the
human colon. Levitan and B5.11ich (1968) suggested that the effective
diameter of "pores” in the mucous membrane of the colon was smaller than 
o . . „
2.3A, on the basis of the relative rates of diffusion out of the lumen of.'
molecules of different sizes. 'These pores are smaller than those thought
to exist in the jejunum and ileum (Fordtran, et.al. , 1965) ana the colon
appears to be less permeable to water and small ions than the small
. intestine. . : . \/.v, f - - }
The most important function of the colon is the conservation of water, 
and electrolytes. Water transport in and out of the colon is closely 
linked to solute transport, particularly sodium, which is actively transported 
across the colonic mucosa (Cummings. 1975)- The human colon has an 
enormous capacity for water absorption; Levitan et.al. , (1962) calculated 
that the colon could absorb up to 2.5 litres of water per day although the
usual rate is nearer 0.5 litre/day. Bile acids are absorbed from the
human colon (Morris and Heaton, 197*0 by passive diffusion and more rapidly - 
after deconjugation and dehydroxylation (Schiff et.al., 19if2) and since up 
to 20% of the bile salt pool enters the colon each day a significant 
portion may be absorbed. A number of other substances may be absorbed 
by the colon including amino acids and sugars (Robinson et. al. 1973),
oxalate (Binder, 197*0 and medium-chain triglycerides (Pihl et.al., 1966). 
Vitamins K^, (Hollander et.al. , 197*+s 1976) and thiamine (Wajjar and 
Holt, 19*+3) may all be absorbed from the colon after first being synthesised 
by the colonic bacteria.
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lumen, ■'"which in man have been estimated to total 1.5kg (Sill and Drasar, 
1975)* If such quantities do exist then the colonic bacteria may be 
worthy of consideration as an "organ"- of the body in their own right and 
may be important in the metabolism of foreign-compounds in the colon 
(Scheline, 1973). In fact, the bacteria seem able to metabolise almost 
any organic compound "which is accessible
Many studies have reported linear logarithmic relationships between 
gastrointestinal absorption rates and the partition coefficients of unionised 
forms of foreign compounds (eg Kakemi et.al., 1967; Schanker, 1971)•
Recent studies using two homologous series of unionised carbamate esters 
(Houston et.al. , 197** and 1975) have confirmed that such a relationship 
exists for the rat stomach but found a parabolic logarithmic relationship 
for the absorption -of these compounds from rat small intestine. These 
latter results were explained in terms of a two compartment model where 
a hydrophilic barrier and'lipoidal membrane control the rate of absorption.
A similar parabolic relationship was reported by Kitao et.al., (1973) to 
describe the small intestinal absorption of a series of heterocyclic 
sulphonamides in the rat. Statistically, however, this latter parabola 
was not a significant improvement on the linear correlation for the series.
b. Active transport
Although most drugs are absorbed from the gastrointestinal tract by 
passive diffusion, a number of lipid insoluble compounds are absorbed via 
an active transport mechanism’. This is a process where molecules are 
transported against a concentration gradient with the expenditure of energy. 
The exact mechanism of active absorption is not clear but It would appear 
that some carrier substance, either an enzyme-or another coimoonent of the 
mucosa, is involved. For example the anti-tumour agents 5-fluorouracil, and . 
5-bromouracil are actively transprcfted across the rat intestinal epithelium 
by the process which transports the natural pyrimidines uracil and thymine 
(Schanker and Jeffrey, 1961 and 1962). Some studies concerning polar 
glycosides such as puabain and digoxin have yielded evidence for an 
active transport mechanism (Lauterbach, 19&9; Ruiz-Torres and Ohlmeier, 
1970). However in a possibly unique report concerning a quite lipopholic 
compound, digitonin, a transport process fulfilling the criteria for 
active transport was found (Damrn, et.al., 1975).
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The effective radius of the aqueous-filled pores or channels, 
associated.with biological membranes has been estimated to be of the . 
order of kft. (Lindemann and-Solomon, 1962). As a result, transport through 
these pores is generally restricted to small molecules (eg water, urea) 
and thus this, type of absorption mechanism appears to', be of only minor 
importance in the absorption of relatively large drug molecules. However 
there is some evidence that a gradient of‘pore radius exists along the 
intestinal tract (Fordbran and Ingelfinger, 1968) and if this is the 
case significant drug absorption may occur via pores in the upper small 
intestinal tract.
ii/ Physiological factors influencing drug absorption
a. Morphology of the gastrointestinal tract
The gastrointestinal tract may be divided into three major sections: 
the stomach, the small intestine, and the_colon. Of these sections, the 
small intestine with its -unique morphological features of the mucosal 
surface has by far the greatest available surface from which absorption 
can take place. This large epithelial surface results-from the existence : 
of the mucosal folds of Kerkring (Valvulae conniventes), the villi and 
the microvilli of the brush border. It has. been estimated that all these 
structures increase the surface area of the small intestine, '.relative to 
the area of a simple cylinder, by a factor of 600, (Wilson, 19^2).
As previously mentioned, the rate of passive absorption of drugs is 
directly proportional to the surface area of the absorbing membrane. Thus 
the extremely large total surface area in the small intestine potentially
provides conditions for rapid drug absorption. Ho villi occur in the
stomach or colon, although numerous small microvilli occur in the colon 
(Riffaat et.al., 1965) * an<3- consequently the available surface area in these 
two regions is significantly smaller than that of the small intestine. Even 
though the total surface area of the gastric mucosa is small, drugs 
possessing the correct physicochemical properties (eg weakly acidic drugs) 
are efficiently absorbed from the stomach.
The-colon may serve as the site for the absorption of part of a 
dose of drug which has not been absorbed from the stomach or small intestine 
Such a situation may arise when a drug is particularly insoluble or as the 
result of the slow release of the drug from the dosage form (eg enteric 
coated or sustained release dosage.form). Significant absorption of a drug 
from the colon may also occur when suppository dosage forms are used..
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Tne plasma memorane runs continuously over the microvilli' and the 
outer leaflet is covered by the surface coat, "glycocalyx", (Bennet, 19&3) 
or "fuzzy layer" (ito, 1965 and 1969) the wholb structure being called 
"the greater membrane". This surface coat is firmly attached to the outer 
leaflet, indeed only papain is known to dislodge it (Johnson, 1967)*
There is little doubt that this surface coat, of mucopolysaccharide is an 
integral part of the greater membrane and not a layer of mucous produced 
;by nearby goblet cells. Extensive studies have shown that both plasma 
membrane and surface coat are highly dynamic in nature (ito, I969K  
Morphologically the surface coat is the first .barrier presented to the 
intestinal contents.and thus may retard the'diffusion of certain molecules.
b. Gastrointestinal motility
—— x
In view of the vast differences in surface area along the length of 
the gastrointestinal tract, the residence time of a drug in each region 
may affect the overall efficiency of absorption.
Hunt (1959) observed that the stomach empties liquid test meals or 
dosage, forms in ah apparently first-order fashion; the rate of gastric 
emptying being directly prop^dtional to the volume of liquid remaining; 
in the stomach. Unless absorption is usually very slow, gastric emptying 
is likely to be a rate limiting step in the absorption of drugs regardless 
of whether they are weak acids, weak bases or neutral compounds. Gastric 
emptying may account for much of the observed individual variation in drug 
absorption since it is influenced by many factors, such as emotional state, 
pain, posture, autonomic and hormonal activity, food, food volume,pH, and 
many commonly used drugs (Prescott 197^)*
Drugs such as 1-dopa, methyldigoxin and peniciUins are metabolised 
or inactivated in the stomach and if emptying is delayed they may be 
ineffective because less unchanged drug is available for absorption 
(Bianchine et.al. , 1971) •>
Many drugs have intrinsic effects on gastrointestinal motility and 
can modify the absorption of drugs taken at the same time. Thus compounds 
with anticholinergic activity such as atropine, tricyclic antidepressants 
(Consolo et.al.v 1970) and propantheline (Himmo et.al, 1973) can slow 
down or reduce the absorption of other drugs, whilst stimulation of gastric 
emptying by metoclopromide may have the opposite effect (Goodhart and . 
Eichman, 1976). Conversely, the absorption of drugs or formulations with 
slow dissolution characteristics and compounds actively absorbed from a 
limited area of the small intestine may actually be enhanced if the 
gastrointestinal transit time is reduced by propantheline (Manninen et.al.,
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absorption.
The normal rhythmical-peristaltic-movements of the-small intestine can 
also influence the. absorption of drugs. These peristaltic movements will 
generally produce a more intimate contact between the drug in solution and 
a larger portion of the intestinal surface area. The motility of the' 
intestine should also aid in the dissolution process of drugs from solid 
dosage forms and reduce the thickness of the "unstirred" fluid layer in ; "
contact with the absorbing epithelium (Prescott, 197^)* Thus the mean free 
diffusion path of drug molecules to reach the ^ Intestinal mucosa will be : 
reduced and absorption should be enhanced.
c. Circulator?/’ systems
The whole length of the gastrointestinal tract is very well supplied 
with blood receiving approximately 30$ of the cardiac output (Texter et.al.,
1968). Estimates of the amount of this total intestinal blood flow diverted 
to the mucosa, range from 17$ (Winne, 1966). to 60$ (Lungren, 1967). The work 
of Ochsenfahrt. and Winne (1969) and Ochsenfahrt (1971) has shown that the 
absorption rate for lipid soluble compounds varies with blood flow while 
absorption of water-soluble compounds is more or less independent of flow. 
These observations reflect the.permeability characteristics of the intestinal 
epithelium, being barely permeable to water soluble compounds having a 
molecular weight exceeding 100, whilst lipid soluble solutes easily cross 
the epithelium. Hence for most water-soluble substances, the passage across 
the epithelium represents the rate limiting step for absorption.
It has ’been proposed that a gradient of blood supply exists - along the 
intestinal tract being high at the duodenum and progressively declining, to the 
distal colon (Geber i960; Steiner and Meuller 1961). However this theory 
has been challenged in recent years (Delaney and Custer 19^5; Goodhead
1969).
The rate of intestinal blood flow was found to play an important part 
- in absorption of sulphaethidole absorption from an in situ canine intestinal 
preparation (Crouthamel et.al., 1975)* The reduced rate of absorption of 
several drugs from the intestines of rats starved for periods in excess of 
2k hours was also interpreted as being the result of reduced blood flow 
(Diamond et.al., 1970).
Although the intestinal lymphatic system is known to play an important 
role in the absorption."of cholesterol (Treadwell and Vahouny, 1968) and 
long-chain fatty acids (Simmonds, et.al., 1968) little information is 
available regarding the factors which are of importance in the absorption
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or roreign compounds by the intestinal lymphatics. Since it. is known that 
in the rat "blood, flow is about 500 times greater than lymph flow in. 
capillaries of the villus (De Marco and Levine 19&9) it might he expected 
that absorption via the lymphatics would play only a minor role in the 
overall absorption of a drug. -This has been shown to be the case for a -
variety of drugs administered intraduodenally in the rat (oieber et.al.,
197*0 ■> However these authors made the point that although the role of the 
lymphatic system in the intestinal absorption of most drugs appears to be 
. minor, the lymphatic, system may play an important role in the distribution 
of these compounds. Because a drug absorbed by the intestinal lymphatics 
bypasses the liver, such absorption would permit direct distribution to 
the entire body without first subjecting the drug to the possibility of 
metabolism by the liver (liver first-pass effect, Section E). In a study 
of the lymphatic absorption of lipophilic carcinogens, Kamp and Neumann 
(1975)5 found that in addition to lipid solubility, specific structural 
requirements contribute in determining the_ extent to which compounds enter 
the lymphatics.
d. Interactions with endogenous substances
The mucosal surfaces of the gastrointenstinal tract are lined with 
mucin,.a viscous mucopolysaccharide. Normally this mucin layer1will not -
hinder the passive absorption, of drugs, but in some disease states {eg 
cystic fibrosis) there is an increase in-the amount and thickness of the mucin
coating which may inhibit the absorption of certain drugs (Reuning and Levy,
1967). Mucin has been shown to complex with streptomycin compounds and thus
may inhibit their absorption (0fReilly and Nelson, “1959)• By a similar
mechanism, reduced absorption of quaternary ammonium compounds has been 
noted (Levine and Pelikan, 196*0*
Conjugated bile salts, which are. secreted into the small intestine via 
the bile duct, may have a pronounced effect on drug absorption. Reduction 
in absorption rate may occur with drugs that form insoluble complexes with 
bile salts, such as*certain antibiotics, (Faloon et.al., 1966). Conversely 
an enhancement of drug absorption may occur where these surface-active 
compounds enhance the dissolution:rate of poorly soluble drugs (Gibaldi and 
Feldman, 1970) or because of an effect on the permeability of the mucosal 
membrane, (Feldman and Gibaldi 1969).
e. Intestinal metabolism
The capability of the epithelial cells of the intestinal mucosa to 
carry out various foreign compound biotransformations is not very well 
understood and is often overlooked in absorption studies. In particular the■.
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drugs in the organism.. The. majority of salicylazni.de (Barr and Reigelman, 
19.70)5 phenol (Powell, et.al., 197^) and 1-naphthol (Bock and Winne, 1975) 
crossing from the intestinal mucosal-to the serosal side has "been shown to 
he in the form of glucuronides. The enzyme(s) responsible for this 
glucuronidation can be saturated at quite low concentration (>10"3M) -(Barr 
and Reigelman, 1970) - and thus such metabolic activity- of the intestine may 
only become important when a drug is slowly absorbed or is present in; low 
concentration. .
\ ■
There are practically no sterile regions, in the gastrointestinal , 
tract of the rat , the- number of microorganisms increasing generally from the- 
duodenum downwards. The microflora are capable of numerous types of 
biotransformations but particularly degradative processes such as hydrolysis 
and reduction (Scheline, 1973) • & possible reason.why some drugs are so
poorly absorbed is because of the metabolic activities of the intestinal 
epithelia and microflora. _
f. Drug formulation
Since absorption occurs only after the drug is in solution, drugs 
administered via the alimentary tract must first dissolve into the 
gastrointestinal fluids. Drugs. administered in solid form as ‘capsules or 
tablets need to disaggregate before dissolution can occur more readily.
Drug in 
capsule
Drug'in 
tablet
Disnersion^
Solid . ...‘ ■ ----- : Drug >
drug Dissolution^ iny
Disintegration^ particles solution
Absorption
In many instances the dissolution rate is slower than the membrane 
transport rate of the dissolved drug and thus becomes the rate limiting step 
in the absorption process.
Some of the. agents added to formulations can influence the extent of 
.drug absorption and .these include fillers, binders, lubricants, -suspending 
agents and surfactants, (Chasseaud and Taylor, 197^5. Of these agents,. 
surfactants are probably. the most important in producing alterations in the 
absorption of drugs. In a review on the effects of surfactants on drug 
absorption, Gibaldi (1970) pointed out that there are. as many reports claim­
ing enhanced drug absorption by surfactants as there are claiming inhibition 
of drug absorption. Many factors contribute to the effects of surfactants,
membranes and with dosage forms. These various factors may produce opposite 
effects and the net result will depend on the relative magnitude of the 
influencing variables.
iii/ Model membrane systems
Because of the ubiquitousness and biological importance of membranes, 
many different experimental membrane systems have been devised to shed light 
on the mechanisms of membrane'permeability and transport.
Lipid bilayers probably represent' the most realistic approach to the 
problem of cell membrane models. These bilayers possess an ordered 
bamolecular array, of lipid molecules separating two aqueous phases with the 
polar groups of the lipids orientated in the aqueous phases. Thus the 
core of these models consists entirely of hydrocarbon chains. Most 
investigators have concerned themselves with the electrical properties of 
such bilayers and only isolated attempts to study drug effects on these 
models has benn made (Zutphen, et.al., 1966). Phospholipid vesicles 
(liposomes) have been used extensively as models for natural membranes 
(Bangham, 1972). Liposomes consist of single or concentric shells of . .
bilipid membranes separated by aqueous compartments and may thus be regarded 
as primitive cells. Much use has been made of the liposome model to . 
delineate the mode of action of compounds which may produce their effects 
via membrane stabilisation or destabilisation, x^articularly in this respect 
to the mode and site of action of anaesthetics (Lawrence and Gill, 1975;
BoSSs et.al.-, 1976). Such lipid vesicles may also have great value in the 
future as carriers, for introducing pharmacological'agents into;-cells (Colley 
and Ryman, 1975; Poste and Papahadjopoulos 1976).
Model systems for studying the transport of drugs through lipoidal 
barriers, as opposed to the action of drugs upon these membranes, have also 
been proposed. Sophisticated three phase (water-oil-water) diffusional 
models' have been used by Stehle and Higuchi' (1972a; 1972b) and have shown
the importance of aqueous diffusion barriers, which may assume significance 
in vivo as obstacles to drug absorption. Such* three phase systems have the 
drawback that there is no concentration gradient within the "membrane” and 
in fact these studies may only reflect relative rates of partitioning into 
the oil layer. Diffusion across continuous polymeric films may provide a 
more valid model since such membranes have structural integrity and provide- 
a barrier with an internal gradient, (Flynn and Smith, 1972).
. Recently the use of suspension cultures of mammalian cells, to quantify 
certain transport parameters and physical factors important to the passage of
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1975c). .The data from these experiments could he explained in terms of 
rapid equilibration of the drug within the cell after permeation through 
the rate-determining plasma membrane harrier.
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After a drug has entered the body either by intravenous injection or by 
absorption through any of'the various routes used to introduce drugs into the 
body, there are membranes that must be crossed, before the drug can penetrate, 
into body cells and eventually reach the receptor sites. Theijnanner in which 
the drug is distributed throughout the body is influenced by factors such as 
blood 'flow through different tissues, the mass of tissue and the partitioning 
properties of the drug between the plasma and the tissue. The rate of blood 
flow varies between tissues from 2ml. to 500ml o f blood per 100ml of tissue 
per minute (Riegelman, et.al.., 1968). The partitioning properties of the' 
compound between the various tissues will be 'affected by factors such as pH, 
the lipid solubility of the compound and its molecular weight. Thus the distri­
bution of a compound is a very complex, .and dynamic process in which the -
compound is circulated, taken up by the tissues, released from the tissues 
and then recirculated. Eventually the compound will be eliminated from the 
body, usually partly biotransformed.
i/ . Compartmental analysis .
The body tissues can conveniently be divided into groups which are 
distinguishable by different blood flow rates per unit volume of . tissue and 
by the solvent characteristics of the tissue (Eger, 1963). There is a highly 
perfused lean tissue group consisting of tissues such as the heart, lung, 
liver and kidneys and a poorly perfused lean tissue group consisting of the 
large mass of muscle and skin tissue. A fat group, consisting of the adipose 
tissue and bone marrow is distinguished from the muscle group by solvent 
characteristics alone, since blood flow rates are comparable . A neglible 
perfusion tissue group consists of bone (not marrow) ligament tendons 
cartilage and hair. This latter classification can be misleading with some 
drugs since some of the named tissues take up appreciable amounts of drug, for 
example lincomycin penetrates bone very readily (Wagner, 1975)*
The subdivision of body tissues in such a manner has been used to 
advantage in pharmacokinetic 'analysis to describe the distribution of drugs 
in terms of kinetically distinguishable "compartments’*. Usually the most 
appropriate model is that comprising two compartments (Riegelman et.al.,
1968a) and this approach will be further discussed in Section E.
ii/ Localisation of drugs in tissues
Extremely lipid soluble compounds tend to become localised in adipose 
tissue by simply partition between intracellular lipids and body water. The 
best-known examples include the organochlorine pesticides (Radomski, et.al.,
1968) which may attain an almost constant level in the body due to their
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extensive worldwide usage.
The-ultra-short action of intravenous anaesthetics such as thiopentone 
is now recognised as being the result of a more rapid rate of equilibration 
between plasma and brain than between plasma and the other tissues in which 
a large proportion of the drug will ultimately be localised. . Eventually 
thiopentone becomes localised in the body liJpids and because of the 
reversible nature of this localisation, thiopentone is slowly released into the 
. bloodstream and subjects receiving large doses of the drug may. feel its 
depressive effects for some time after administration (Chassea ud, 1970).
The components of some tissues have a particular affinity for certain 
foreign compounds. Chlorpromazine is localised in the brain* particularly 
in the cerebral, cortex and hippocampus (Cassano et.al., 1965) and salicyl- 
azo-sulphapyridine has been shown to bind to connective tissue (Kanngren 
- et.al. , 1963). The antibiotic, tetracycline is taken up in bone, 
presumably by binding with calcium (Kelly and Kanegis, 1967).
iii/ Drug binding to plasma- proteins •
Plasma albumin is.unique among proteins in.its capacity to undergo. 
strong reversible interaction with a large number of compounds of low 
molecular weight and of the most diverse chemical structures. Most drugs 
interact to a significant extent with albumin and many drugs that bind . '
extensively to albumin do not bind to a significant extent to other plasma 
proteins or to intracellular proteins. The extent of this binding may be 
altered by pH changes since the ionisation of both protein and drug may be 
affected (Keen, 1966). ;
Compounds that readily bind to albumin include weak acids or anions, 
such a salicylates (Ali and Routh, 19&9) and- barbiturates which possess 
lipophilic substituents (Goldbaum and Smith, 19^8). At neutrality, serum 
albumin carries a net negative charge but cationic groups are accessible 
4 because anions are bound. The total number of binding sites for drug
molecules per albumin molecule is generally much lower than, the total number 
of charge groups and varies with the structure of the drug. Some neutral 
substances such as steroids and coumarins also bind as do basic compounds 
such as atropine (Meyer and Guttman, 1968).
Although drugs that firmly bind to plasma proteins cannot diffuse into 
tissues and other extravascular areas, they may be displaced from their 
binding sites by other drugs that are more strongly bound (BrQ die, 1965).
Such interactions may have clinical implications since patients receiving an ' 
anticoagulant, like warfarin, may haemorrhage if given a drug, like phenylbuta­
zone, that displaces it from the plasma proteins (Eisen, I96U).
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function of their free (not protein hound) concentration (Anton, 19bU;
Shoeman and Azarnoff, 1975)- This effect may become important in certain 
disease statess such as hypoalbuminaemia, where adverse drug effects may 
become apparent because the unbound fraction of the drug is unusually high. 
Levy (1976) has shown theoretically that maximum plasma.levels of drugs may 
be elevated substantially when their free concentration is increased by this 
mechanism. Indeed5such effects have been noted when phenytoin is administered 
to nephrotic patients with hypoalbuminaemia (Gugler and Azarnoff s 1976).. - •
The proportion-of a drug bound to protein is related to the drug 
concentration,•to the affinity of the protein for the drug and to the. protein 1 
concentration and its binding capacity (Martin, 19&5)* The dissociation of 
a plasma-protein bound drug in response to a. fall in free drug concentration .. 
never restores the original, concentration of' the drug and the rate of this 
dissociation is not a limiting factor in the removal of a drug through a 
membrane since binding on one side of a membrane would decrease the concentra­
tion of free compound and would thus increase the concentration gradient 
across the membrane, resulting in more rapid penetration.
• The period that foreign compounds remain in the body is often related 
to their reversible binding with biological substances and without such 
binding and concomitant localisation, many compounds would be biotransformed 
and exreted more rapdily. Thus many drugs would otherwise appear to have 
negligible pharmacological activity. If most drugs were not largely protein 
bound they would have to be administered so frequently that their plasma 
concentrations would fluctuate between toxic and ineffective levels (Brodie,
1965). ■ '
D. DRUG ELIMINATION
A drug.is eliminated from the -e inflation by metabolism, excretion and 
accumulation in tissues. The rates of. these processes contribute to the 
termination of drug action and are determined by the physicochemical properties 
of the drug and its interaction with.the specialised tissues responsible for 
the elimination reactions. The kidney plays a major role in drug excretion 
but other routes, such as via the bile or lungs, may be-important in the 
'elimination- of some- drugs. - The liver is of prime'importance in drug 
metabolism, but drugs are also degraded in other tissues. Often metabolic 
alteration of structure is a prerequisite to renal excretion. •
i/ Drug metabolism .
The duration of action" of many drugs is often limited by the rate at 
which they are metabolised to inactive, water soluble metabolites. In the 
absence of the drug metabolising enzymes drugs would have.to be excreted 
unchanged in the bile or-urine and for extensively protein bound, lipid 
soluble drugs.the rate of elimination by. the kidneys would be exceedingly 
low. Indeed given these circumstances drugs such as chlorpromazine or 
thiopental would act for virtually a' life time and make much of drug therapy 
as we now know it impossible (Davies and Thorgeirsson, 1971)*
Living systems abhor foreign lipophilic compounds because the 
macromolecules - involved in important biochemical processes use lipophilic 
pockets to~trap and position their substrates as well as to orientate them­
selves in their microenvironment (Hansch, 1976). 1^ is thus pr obable that the
enzymes that catalyse foreign compound metabolism-biotransformations have been 
specifically evolved for this process of metabolism (Brodie and Maikel, 1962).
a. The liver drug metabolising enzyme system
The oxidative metabolism of many drugs and also of steroid hormones is 
mediated by enzymes located in the microsomal fraction of the mammalian liver, 
consisting of fragments of endoplasmic reticulum (Gillette et.al.s 1972). The 
microsome fraction obtained from homogenised liver contains a haemoprotein, 
or a family of closely related haemoproteins (Huang et.al., 1976), known as 
cytochromes P -^90 which act as terminal oxidases for the variety of oxidative 
reactions that drugs undergo. The term P^50 refers to the ability of the 
reduced from of the haemoprotein to react with carbon monoxide,, yielding a
complex with an absorption peak at ^50nm. -
In an in vitro system containing liver microsomes, various drugs can be 
oxidised, providing NABPH, oxygen and magnesium ions;are present (Gillette 
et.al., 1957). This requirement for'reduced pyridine nucleotide and molecular
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the term "monoxygenase" is sometimes used (Hayaishi, 1962), One molecule of 
0^ is consumed for each molecule of substrate (foreign compound) -oxidised; 
one atom of oxygen is introduced into the substrate and the other is reduced, 
forming H^O. The overall reaction may be formulated as follows (Brodie et. al,,
1958) 5
R~H + NADPH + H+ -5 0o — > R-OK -5 XIADP* * Ho0d ... - d
where RH is the substrate and. R~OH is the hycLroxylated product* '•
: According-to Remmer (1975) ’ the drug -metabolizing-enzyme consists of
six major components. One component is cytochrome PU50 and another
cytochrome PH50 reductase, a flavin enzyme, which carries two electrons from
2 #»,
NADPH to the haem iron. One electron reduces Fe to Fe ' , now being able
to bind molecular oxygen, and the other electron reduces the 0^, forming the 
radical 0^ ,/which is now able to oxidise compounds bound to cytochrome P^50.
The third and fourth components should be regarded as cytochrome and 
its specific NADH dependant reductase which are also able to provide electrons 
to cytochrome PU50 and the bound oxygen. However, the purpose-of this, second 
transport chain is not completely understood. Glycuronyltransferase is.-’ - 
closely associated to the hydroxylating system and should be regarded as the 
fifth component of this enzyme complex (Bock et.al., 1973')*. The enzyme 
epoxide hydrase may be considered the final component of this metabolising
system. Epoxides are formed during the hydroxylation of aromatic substances,
; , .1 ^ '
being very unstable yet highly reactive they may covalently bind with 
glutathione or proteins. The epoxide hydrase prevents the accumulation of 
these toxic intermediates by converting them to dihydrodiols (Oesch et.al. ,
3.971) • ■ ’ .■■■
The proposal that the hydroxylating reaction involves the binding of
the substrate to cytochrome P -^50 has been inferred from the spectral changes
that accompany the addition of compounds that are substrates for the 
microsomal enzymes to microsomal suspensions. Drugs such as hexobarbihal 
and aminopyrine give "type I" difference spectra which are characterised by 
the appearance of a trough at U20nm< "Type II" spectral changes are produced 
by compounds such as aniline and are characterised by the appearance of a ; 
peak at about ^30nm, (Kemmer et. al. - 1966). The magnitude of such spectral 
changes have also been shown to be dependant on the substrate and microsomal 
protein. The existence of these two main types of difference spectra (a 
third type, named ".reverse type I" is sometimes found) probably means that there 
are two types of binding site on cytochrome pJ+50 or, possibly, that there are 
two or more kinds of cytochrome PU50 differing slightly in the protein
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ligand of the haem-iron because these'compounds displace ear.bunuGonoxide from 
the CO-cytochrOme ?150 complex. The interaction of type I compounds is 
thought to. take place at a different site since no displacement of C0; is 
observed using type I substrates. Further evidence for the dissimilarity of 
the two -sites was provided by Chaplin and Mannering'(1970) who noted that 
digestion of microsomes with phospholipase C destroyed type I binding but 
did not decrease Type II binding. Thus the type 1 binding site is thought 
to be located in ah undetermined hydrophobic-region o‘f the - cytochrome 
P^ i50-protein or in the lipids of the microsomal membrane. -'
The general pattern of biotransformation can be presented as,
include (Phase I) aromatic hydroxylation, aliphatic oxidation, deamination.
(1970) and Brodie and Gillette (l'97l)«
Th'e lipid solubility of substrates may be quite,important in determining 
the rate of metabolism (Martin and Hansch, 1971) although in some cases, such
relationships between lipophilic character of drug molecules and their 
metabolism by microsomal enzymes have been reviwed by Hansch (1972).
ii/ Factors influencing drug; metabolism
There are many factors that may affect the metabolism of a drug, 
including those of genetic, physiological or environmental origin. These facto 
have been the subject of numerous reviews and will only be outlined here.
a. Genetic factors
People vary greatly in their ability to metabolise drugs and genetic 
factors are thought to account for most of this variability (Evans, 1971)• A
Foreign metabolism 
compound PHASE. I
oxidation, reduction 
and/or 
hydrolysis products
PHASE II
synthesis >  conjugates
The wealth of enzymic reactions carried out by this enzyme system
N-oxidation, sulphoxide formation and N- and 0- dealkylation. Such reactions 
have been extensively reviewed by Williams (1959) •> Parke (1968) and Brodie I
and Gillette (1971).
Conjugations or phase II- reactions are biosyntheses involving the 
addition of molecules or groups of endogenous origin (eg, glucuronic acid.5 1
sulphate, acetyl) to functional groups (eg hydroxyl, amino) of drugs or th4ir 
metabolites. These reactions have also been extensively reviwed by FishmaA
as the ^-hydroxylation of substituted anilines, other physicochemical 
parameters may be more important (Ichikawa, et. al., 1969)* The quantitative
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consequence of this variation is that persons •who are less able "do metaoonse 
drugs than is usual have a greater liability to develop toxic effects. 
Conversely persons with more speedy metabolism may under certain circumstances 
not obtain the desired therapeutic effect of a drug; such rapid metaholism 
may also lead .to increased toxicity where toxic metabolites are formed. 
Interspecies differences in drug metabolism may assume importance in animal 
screening programs for drug development. A compound selected on the basis 
of—animal—sereening-may—turn-out—■to-be—useless_iriJinan, becuase of the vide- 
differences in drug metabolism by different species {Hunker, 1910% Mellet 5
1969). ' . ' • - v • ■■' ■
b. Physiological factors
Quantitative differences in the ability of hepatic enzymes to metabolise
— * y
drugs can arise due to changes in diet and hormone levels as well as disease. 
(Parke, 1968; Campbell and Hayes 5 197^). Age can have a pronounced effect 
on drug metabolism since many enzymes develop only after birth (Fonts and 
Hart 9 1965) and their activity becomes reduced-with advanced, age (Kato et .al.
1970).
c. Environmental factors
Significant amounts of foreign compounds enter mammalian systems as 
smoke particles5 toxic gases, dyes, preservatives and may Interfere with the 
metabolism of a drug. Similarly patients receiving multiple drug therapyy 
may metabolise these compounds in a different fashion to that pertaining when 
only one drug is administered. Drug-induced changes in drug metabolism-are 
recognised as one of the most serious complications_JLcudrug.therapy 
(Robinson, 1975).
Closely related to^  the problem of drug interactions Is that of induction 
and inhibition of drug metabolising enzymes . In a discussion of enzyme 
induction in different species, Remmer (1970) suggested that, apart from 
lipophilicity, an important factor in enzyme induction is the maintenance 
of a high drug concentration for ascertain time in the liver celll 
Stimulation and inhibition of hepatic drug-metabollsing enzymes by environ­
mental contaminants have been reviewed by Fouts (1970) and the effect of 
drugs on the metabolism of foreign compounds and of normal body constituents 
by Juntzman (1971)•
iii/ Biliary excretion and enterohepatic circulation
Because the membrane of hepatic parenchymal cells is highly permeable 
substances may be present in blood and in bile in similar concentrations. 
However, highly polar compounds, such as the bile salts and certain dyes and
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conjugates 01 ioreign compounds may oe secretea m  tne Diue in nigner 
concentrations than they are present in the plasma, prohahiy by an active proces 
.(Brauer, 1959)* That this process is active was indicated.by transport into 
bile against high concentration gradients, saturation of the transfer processes 
by excess substrate and competition for transfer between certain substrates 
(Sperber, 19&5)• i
The extensive studies of Smith, Millburn, 'Hiram and coworkers have 
elucidatedhnany~of ~the factors that influence-the *extent-of biliaryexcretiori 
of foreign compounds.• Both physicochemical factors, such as molecular weighty 
polarity and molecular structure (Hirom et.al.  ^• 1972a).. and biological factors 
such as species and metabolic transformations' (Hirbm et.al, 1972b) are 
deemed important. The two most important factors to emerge from-the above 
studies are that an organic molecule requires both a polar ionisable group 
(either, anionic or cationic) in its structure and a minimum (or threshold) 
molecular weight for its biliary excretion to be appreciable. It is probable 
that the threshold molecular weights found-for the appreciable biliary 
excretion of organic anions and cations - (Hirom et.al. s 1972b; Hughes et ..al. 
1973) reflect the underlying physicochemical property of the lipid solubility 
of these polar organic molecules and indeed this.-has. been shown*to be the case 
for a series of mono quaternary ammonium ..compounds (Hirom et.al., 197^)- Since: 
a compound must cross at least two liver cell membranes on its passage from 
the.blood into the bile,.the. lipid solubility of polar organic molecules may 
be a crucial factor-in determining, their extent of hepatic eleminatiori.
Hirom et.al.,.(1976) have investigated the relationship between bile, 
and urine as excretary routes for organic compounds. They proposed that urine 
and bile are complementary pathways. The extent of urinary excretion was 
found to be greatest for compounds.of lowest molecular weight and.-tends to de­
crease as molecular weight increases and biliary excretion becomes more 
extensive.
Conjugates of foreign compounds that are excreted into bile may be 
hydrolysed by enzymes present in the bile (Slater and Griffiths, 1965} or* 
more often, in the intestine, produced either by the intestinal secretions or 
by the gut flora (Drasar et.al., 1970). Thus the conjugate itself may only 
rarely be passed-down the intestine-to be excreted in the faeces. The free 
compound may be partly reabsorbed and taken to the liver, possibly reconjugated 
and excreted again into the bile. The cyclic process thus set up is known as 
enterohepatic circulation and may markedly effect the kinetics of elimination 
from the liver and the kinetics of metabolism in the gut.
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3.v/ inena-L excreuiuii.
The kidneys provide the most important route of excretion of foreign 
compounds and their metabolites" from the body. Kenal excretion occurs by 
three different, but complementary, mechanisms,- which are-glomerular filtration* 
active tubular secretion of ionised substances and passive tubular reabsorption 
of unionised substances. Ultrafiltration of blood plasma takes place in the 
glomeruli, and the ultrafiltrate passes into the kidney tubules where lipid 
solubleuriicniseduompounds- are reasborbed into-the' bloodstream -by_pGshive_-____:. 
diffusion and with, decreasing lipid solubility of the unionised compound 
reabsorption decreases. Certain cations and anions are actively transported 
across the tubular epithelium, from the plasma to the glomerular filtrate 
(Chasseaud, 1970)*
Only foreign compounds that are not bound to plasma proteins are 
filtered'in the glomeruli since although the glomerular membrane is Very 
porous hardly any protein is filtered. The renal tubules reabsorb much of 
the filtered water, some of the dissolved inorganic ions and other 
endogenous substances. Lipid soluble unionised drug molecules can pass, in 
either direction through the lipoidal tubular epithelium, depending on the 
direction of the concentration gradient. Thus, usually, such moleculs will 
be reabsorbed into the bloodstream and will not appear in the .urine to any 
extent. Conversely lipid-insoluble ionised molecules, such as glucurcnide 
conjugates of foreign compounds are poorly reabsorbed and are more readily 
excreted in the urine than are their precursors.
Active tubular secretion of ionised foreign compounds is the process by 
which the compound diffuses against the concentration gradient from the blood 
capillaries across the tubular membrane to the tubule. This active process 
accounts for the very rapid elimination of certain drugs, such as penicillins, 
by renal excretion despite extensive binding to plasma proteins (Gibaldi,
1970). Active tubular secretion has been reviewed by Cafruny (1971)*
Variation in the pH of tubular urine will alter the excretion of weak 
acids and weak bases in accordance, with the pH-partition theory. Thus 
reabsorption of weak acids has been shown to be depressed under alkaline 
conditions (Kostenbauder, et.al., 1962) whereas the reabsorption of weak 
bases was similarly affected by acid conditions (Beckett,'et.al., 1965).
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E. PHARMACOKINETIC MODELS FOR DRUG CHANGES WITHIN THE BODY
i /
a.
Kinetics of distribution, metabolism and excretion after a drug reaches 
the general circulation
One compartment model •
The most commonly employed appraoch to the pharmacokinetic characterisation 
of a drug is-to represent the body as a system of compartments, even though these 
compartment often have no. appabhnt~physluTo“ginal"'or—^ahatom5;cal^realityi— -Often— 1 
the rate of concentration change for a drug is the blood, plasma or serum can 
'be described as a single first order.process after an initial rapid*distributive 
phase. In such cases the logarithm of the plasma concentration decreases 1  
linearly with time after intravenous injection of the drug and this is considered 
indicative of a one compartment model. . f ‘ -
instant
input drug m  body
k
el
The rate of loss of drug from the body is given by.
dD.B
dt = "k i Kel B (1)
'where D,, is the amount of drug in the body at time t after injection. The a
apparent first order elimination rate constant for the drug (K^) is. the sum 
of all the rate constants associated with elimination, such"as metabolism, renal 
and biliary excretion. Eq. (l) can be integrated to give the usual first, order 
expression.
-p, _ y. . -k ntD„ “ D e elB o (2)
where e represents the base of the natural logarithm, and Do is the amount 
injected (ie dose).
Eq.(2) can be converted to natural logarithms,
log Db = log Do - k ,t el
2.303
(3)
Although the body is obviously not homogeneous, if the relative binding 
of a drug to tissues such as heart, muscle, fat and other tissues is essentially 
independant of drug concentration, then the ratio of drug concentrations in the 
various tissues and fluids is constant. Consequently a constant relationship
The proportionality constants V, .happens. to have units of volume and 
is known as the apparent volume of distribution. Despite this name, the constan 
usually has no direct - . physiological meaning and does not refer , to a real 
volume. This relationship in Eg. (k ) enables the conversion of Eg.(3) from
an amount-time to a concentration-time relationship which can be expressed as
log Cp - log Co k -t
/ 6l
2.303
(5)
Where Co is the plasma concentration immediately after injection.— #   - #
a plot of log Cp versus t will be linear and Co may be obtained by 
extrapolation of the plot to time zero.
Thus
l°g
plasma
concentration
Co
lope
time
Since at time zero the amount of drug in the body (i.v. dose) is 
related to the-plasma concentration at this time, the volume of distribution 
may be estimated.
V = i.v. dose (6) '
The apparent first order eliminatm rate constant, k , can be determined
from the slope of the line that equals -k n/2.303. It is often easier, however
el
to determine k ^ by using the relationship
k _ = 0.693
e l  —
2
(7)
Where t-, is the biological or elimination half-life of the drug. 
Additionally, a plot of the logaritm of tissue drug concentration versus time
u « v i x u c c u  u u u  5 i v c  c A a u  o x ^  o n e  SctlUS SXUpe cio uilS pj_asma COnceUCrUUlLOn-
time curve.
Often it is possible to determine the elimination kinetics of.a-drug 
from urinary excretion data. The rate of appearance of unchanged drug in 
the urine may be described by the following differential equation
dD = k- D • fo\ u ex B \o)
dt
V
where Du is the amount of unchanged drug - eliminated in urine to tine t and k :
• . • • ■* . ex
is the apparent first order rate constant for renal excretion. Substituting 
for D 5 according to Eq„(2) gives
.D
dDu ■ = 'k D^e^el* (9)
dt ex
Integrating Eq.. (9) gives
D. = k D. - y \  'ts r- _ % •
ex o (In* el ) (10 ) ‘
el
Therefore a plot of log excretion rate versus time gives a negative 
slope equal to k _/2.303 which is compltely analogous to the blood level case, 
except that the intercept on the ordinate will equal k So. Thus the 
.elimination rate constant of a drug can be obtained from either plasma 
concentration or urinary excreti-on data, although is must be noted that the 
urinary excretion rates must be plotted against the “midpoints~cf~the urine 
collection periods.
It .is consistent with the one compartment model that the total amount of 
drug excreted unchanged will be proportional to the dose, with a 
proportionality‘constant equal to k /k ,. This can be seen from Eq. (10)6X 6 JL
which, when time equals infinity become
= k Dr (11)ex o
k , el
This Eq. (n) can also be used to calculate k from k In a similar
ex el
fashion, the metabolism rate constant, m can be calculated from the totalm
quantity excreted, D
This is valid for each metabolite formed and no rate constants for 
metabolite excretion are necessary. Since the excretory products are in 
constant ratio to each other* it is possible to calculate relative rate 
constant ratios when only the total amounts of metabolites and intact
drug excreted are known. By taking the ratio of Eqs (ll) and (12) the
V
fol3,owing expression is obtained.:
m
ex (13)
This relationship is valid regardless of the kinetic order of the process* 
assuming only that excretion and metabolism are of the same order.
b. Two compartment model
Many drugs appear to confer upon the body the characteristics of a two 
-compartment model. There are three possible types of two compartment systems 
which differ in that elimination occurs either from the central compartment* 
from the peripheral compartment or from both these compartments. On the ' 
basis of the usually available data these three types of two comijartment 
models are mathematically indistinguishable. Thus in the absence of 
information to the contrary it is usually assumed" that "drug “elimination 
takes place exclusively in the central compartment, as depicted below, and 
all subsequent equations in this section are based on this assumption.
excretion and metabolism
The central and peripheral compartment are two kinetically 
distinguishable "pools, k ^  is the rate constant for transfer from central
the reverse process. The central compartment consists of the blood system
central
compartment
^ peripheral
compartment
to peripheral compartment and k is the first order rate constant for
and highly perfused tissues. The adipose tissue and other poorly perfused 
tissues make up the peripheral compartment. It should be noted that the
central compartment contains the major sites of metabolism an■excretion, 
collectively described as This model has been extensively discussed
by Riggs (1963), -R.escigno and Segre (196.6), Gibaldi and Perrier (.1975) and 
Wagner (1975)* . - ■ = ' . ' . ' ■
Shown below is a semi-log, plasma drug concentration-time, plot for a drug *: 
whose disposition in the body follows that of a two compartment model after 
rapid intravenous injection. . . .
log
A
plasma 
concentration
B
time
The plasma levels measured at early time intervals show, a rapid 
sharp decline before, the slope gradually becomes linear. The linear section 
is known as the 3 phase, where 3 is the "slow disposition rate constant” 
(Riegelman et.al.» 1968). Extrapolation of this line to the ordinate gives - ' 
the intercept B. If the values from the extrapolated line are subtracted 
from the experimental values at the earlier time periods, another straight 
line, representing the "fast disposition phase" with the associated rate 
constant a, is obtained and the ordinate intercept in this case; is A. This 
technique for separating two exponential functions is known as "feathering"
(Garrett, 1970). ,
Accordingly, the entire plasma concentration versus time curve may be. 
described by. the following biexponential equation.
Cp = Ae at + Be 3t (l*0
Where Cp is the drug concentration in the plasma at any time t. The 
mathematical solution of the' two compartment model has been presented by 
Mayersohn and Gibaldi (l97l)•
The specific rate constants associated with the two compartment model, • 
^125 ^21 an<^  ^el °an 130 es^^ma^e^ using the parameters A and B obtained from 
the intercepts, and a and 3 obtained from the slopes of the separated • 
exponentials, using the following equations (Mayersohn and Gibaldi, 1971)*
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A+B
k , = M  . ' ■ ' (16) V
-  Xr - •
21 .
k l s  = a - k2 1 - kfei . (r?) . y
Determination of these rate constants permits an assessment of the 
relative contribution of distribution ancl elimination processes" to the drug 
concentration-time.profile of a.drug. It may; also aid i n ‘the elucidation of 
the mechanism of drug interactions, and of the effects of disease and age,
etc*on drug dispostion, (Gibaldi and Perrier, 1975)*
- —” ^ y
The apparent volume of the central compartment, Vc* can be calculated 
in a similar fashion to that for a one compartment model- Since at time zero,
Eq ■ (-lU) reduces to . __ \ ’ •
Cp° = A * B (18)
then ' . ... . \
Vc = Do ’ (19)
A -i B - ,;. ::.. ;yy'
Where Cp° is the theoretical plasma concentration of the drug- • at 
time zero..
The total apparent volume of distribution Vdss, that is V^ plus the 
volume of the peripheral compartment, Vp, at the steady state of. 
equilibrium is given by
Vdss = Vc (*21 * W  i20 ;
' k2i ■ :.y; ■
However Gibaldi et.al., (1969) have pointed out that Vd is only of
SB
limited use as a proportionality constant for relating plasma concentrations 
to the total amount of drug in the body. Vd multiplied by Cp only equals
S 3 ' '
the amount of drug in the body at one instant, that is when the’ rate of 
change of the amount of drug in the peripheral compartment is zero. At all 
other times D,, is either overestimated (before steady state) or underestimated
-D  -
(after steady state). Nagashima et.al., (1968) showed that a psuedo-distributior 
equilibrium occurs when the plasma concentration-time curve becomes linear 
(3 phase). This concept has been used by Gibaldi et♦al., (1969) to derive 
the constant Vd^ .vhich relates the. drug concentration in the plasma to the ^
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total amount or arug m  tne do ay at a n  times aunng tne terminal 
elimination phase
Vd. = Vckel (21)
6 ■ T “
Vd„ has also "been shown to be identical to the apparent volume of 
p
distribution obtained from the area under the plasma curve equati.on for 
a two compartment open system (Gibaldi et.al., 19&9)
. . - Vd 'dose ’ - (22)* area----- -r—7--- r* ' v.
The two compartment model can also be depicted in terms of urinary 
excretion data (Janko and Krebs, 1971)• The amount of drug excreted 
unchanged* Du is described by the following differential equation
dDu = k VcCp ’ (23)
dt eX
Substituting for Cp from Eq. (l*+) gives
dDu = k V (Ae"®'t + Be"3t) . J  (2*1)
,, ex cdt
Thus a semi-log plot of drug excretion rate versus time will be
biexponential with the same a and 3 phase slopes as in the plasma
level plot.Jbut with intercepts equal to k V A and k V B.^ ^ ex c ex c
Integration of Eq. .(2*0 to time infinity yields Eq.(ll) which is
thus true for either a one or two compartment model,
Dr kexDo (ll)
k -vel -
■ Similarly the metabolism rate constant(s) k^ can be calculated«fr.om 
the total amount of metabolite(s) excreted as given in Eq.(l2).
Three compartment models have been used to describe drug disposition 
into deep depots such as bone or where particularly tight binding to 
other tissues occurs (Loo et.al., 1968; Nagashima et.al♦, 1968). Blood 
concentration time curves for drugs exhibiting such behaviour can be . 
described by the general equation
Cp = Ae“at + Be“gt + Ce_Vt (25)
The mathematical treatment of this model has been undertaken by
Rescigno and Segre (.1965.) and Wagner (.1975) •
ii/ Kinetics of processes -prior to a drug reaching the general circulation
When a,drug is administered by any route of administration other than
rapid intravenous injection, many processes may he involved before it
reaches the general circulation. Among these are dissolution, diffusion, 
gastric emptying and intrinsic drug absorption rates at the different 
sites after the drug has dissolved. These processes and the factors which
influence them have been discussed, in section B of this chapter.
\ . ■
a. One compartment model
A very large number of plasma concentration-time curves after oral or 
intramuscular administration vof drugs can be described by a one compartment 
model with first-order input- and output, /
Do ka Drug in 
body —
k .
The following differential equation describes the drug changes in the 
body for the model represented above,
dDB = ksDo, - k -D ' r - (26)
TT" el Bdt
where D_ and k are as defined earlier, ka is the apparent first- B el 5
order rate constant and Do., is the amount of drug at the absorption site. 
Integration of Eq. (26) yields '   .
D -. kaFDo (e“kelt-e"'fcat ) ' (2f)
' a k'-k" 'a el -.p' v p . ,
Where F is the fraction of the total dose, Do that is absorbed.
In concentration terms Eq.(27) becomes
Cp = la Fib (e kel^ - e kak ) (28)
In many cases the absorption rate constant is significantly larger
than the elimination constant, thus at some time after administration
"fc • • • / \the term e a approaches zero and, written in common logarithms Eq.(2o)
becomes ■
log Cp ~ log taFDp - k&l.t (29)
VOk k ) 2.303a el . - ■ - -
A plot of the logarithm of plasma concentration versus time yields
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a biexponential curve, the terminal portion of which is linear and 
described by Eq. (29) •
Thus an estimate of. the elimination rate constant can be obtained 
from the slope - kel/2.303 in this terminal linear segment.
log
plasma
concentration
el 
2.303
“ ka 
X 2.303
time
In cases where is greater than k^, an estimate of the absorption
rate constant may be obtained from the "feathered” slope -ka/2.303. If k
.— .
is not greater than k^,-exactly-the same type of curve is observed*
However the rate constant of the linear portion of the curve is now .the 
absorption, and not the elimination, rate constant. Such a "flip-flop" 
(Gibaldi and Perrier, 1975) model may be observed for drugs that are very 
rapidly eliminated or for dosage forms that slowly release drug in an 
apparently first order fashion. In such instances the "feathered" slope 
will be equivalent to the elimination rate constant. Recently, Byron. 
and No tar i (197&) have criticised the use of this technique in "flip-flop" 
cases and suggest that k . must be at least twice the value of k for;. • 0-L cl
such analysis to be valid.
Availability rate constants can also be calculated from urinary 
excretion data by the manipulation of Eq. (28) similar to that shown for 
intravenous admiministration.
Another commonly used method for calculating k is by the so-called
St. -
"Wagner-Nelson equation" (Wagner and Nelson 19&3)* Here the percentages 
absorbed versus time relationships are calculated from plasma level or 
urinary excretion data. The fundamental equation is based on the following 
material balance at any time.
Amount absorbed 
(Ab)
Amount in 
body 
(CoV)
+ Amount eliminated 
(Du + Dm)
where the amount of drug eliminated, D ^ is
plasma concentration
Ab
V
C-D + kel Cp dt (31)
to
Integration of the final term in Eq. (31) at various times up to 
infinity will thus yield data for an absorption rate plot.
b. Two compartment model
Where a two compartment model is required to describe the 
disposition of a drug in the body after rapid intravenous administration, 
the application of the Wagner—U'elson method is not valid for calculating 
the availability rate constant for administration via the oral or 
intramuscular route. In this cases the following model is applicable
k
k„
a
D.o- • Central Compartment
12 — —— 1—
— :— x Peripheral
• Conroartment •
■ . V l
} k .....
&  el .
In order to calculate k In this situation Loo and Riegelman (1968)
ct • ,
modified the basic Wagner-Relson equation,
Amount absorbed = amount in + amount in +■ amount
central peripheral eliminated
compartment compartment .
These and other methods of deriving absorption rate constants have 
been reviewed by Wagner (1975)« Many of these methods are very time 
consuming and subject to a lot of calculating errors, The method proposed 
by Dost (1969) uses the ratio of area beneath the plasma level-time curves 
after oral administration to that following intravenous administration of th 
same dose as a- measure of absorption of the drug administered. This method 
provides a simple method for determining the extent of absorption, though 
as pointed out by Galeazzi and Berm et (1976) , the extension of this 
method to calculate k may yield erroneous results for multicompartment 
systems.
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c. Jirst pass enecu
In comparing areas under plasma level-time curves, a .reduction in 
area after an oral dose, compared to that of an equivalent intravenous 
dose, may not he due solely-to only partial absorption., Drugs administered 
orally gain access to the peripheral venous circulation almost exclusively 
"by way of the hepatic portal system. Thus, a drug that is rapidly 
metabolised by the liver may undergo substantial biotransformation before 
reaching the systemic circulation if it is administered by the hepatic 
route. Drug uptake and elimination in the liver during the first passage 
of a drug into the circulation after hepatic route administration may * 
effectively preclude a significant fraction of the administered dose from ' 
reaching the peripheral sampling site.- This phenomenon is generally 
referred to as the "first-pass effect".. x
The pharmacokinetic models discussed in this section are inadequate 
to predict the disposition of a drug subjected to a first-pass effect and 
thus new models have been proposed to incorporate this phenomenon and these 
have been summarised by Gibaldi and Perrier (1975)• Basically, these 
models assume that elimination occurs, at least in part, from;a compartment 
distinct from that containing the vascular sampling site, this site being . 
analogous to the hepato-portal system. The first—pass concept has recently 
been expanded by Chiouv; (1975) to include, for some drugs, the gastro­
intestinal tract and the lungs, in addition to the liver, as sites for 
the first pass effect. ;
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One of'the earliest preparations of the then new science of organic 
chemistry was Wolher’s nrenaration in 18U0 of ethyl carbamate, C^H-O-CO-EK^,:a p .<
from urea and ethanol. Since that time numerous carbamate "esters have been 
synthesised and some possess useful biological properties.
i/ The chemical and •physical properties of carbamates
The esters of carbamic'acid exhibit some of the characteristic properties 
of carboxylic esters and amides. Some of their reactions are those of 
esters3 amides, enols and apparently of cyanic acid. Carbamic acid itself 
has never been isolated, since its formation in aqueous solution would lead to 
its immediate degradation to carbon dioxide -and ammonia. The properties of 
simple carbamate esters have been comprehensively reviewed by Adams and 
Baron (1965K  . ^ v-
Carbamic acid esters are reasonably stable compounds and form crystalline 
solids. Their stability increases as the E position is substitutedj 
E-monosubstituted carbamates are more stable than H-unsubstituted carbamates, 
and E ,E-di.substituted carbamates are more stable than E-mono substituted 
carbamates. - These esters are very stable under acid conditions but may 
undergo hydrolysis under alkaline conditions. In alkaline solution, 
hydrolysis of all disubstituted carbamates and mono- and unsubstituted 
carbamates derived from aliphatic carbamates has been reported by Dittert 
and Higuchi (1963) to proceed by the following path.
carbamate ion
>ROH + R 2NC00
Ij ^ e c o o hJR"ECOO
P r/ ecoo^
Carbamates derived'from phenols hydrolyse more rapidly than 
aliphatic carbamates and apparently by a different mechanism.
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Ethyl carbamate inhibits mitosis, thus slowing cellular growth,
especially of bone marrow cells and this inh5.bi.tion of cellular growth
has prompted its use as an antileukaemic agent. Used in such a manner,
3g per day have been administered in the treatment" of multiple myeloma.
(Paterson et.al., 19^6) although gastrointestinal irritation often .
results from oral ingestion (Loge and Bundles, 1951)* Simple carbamates
have been used medicinally as antiseptics, local anaesthetics, anti,-.
convulsants and antipyretics, but with little success.
• ’ v
As a hypnotic and duiretic the action o£ ethyl, carbamate is weak
and immunity towards it is rapidly squired.' Hbwwer simple carbamates 
such as secondry amyl carbamate (hedonal) and-similar derivatives such- 
as.aleudrine and aponal have been employed clinically as hypnotics and 
sedatives. - -■ :
" . . .  cl- •
1 *.■
CH -CH-OCONH- CH -C-*OCONH ' CH ~CH-OCONIU- .3 | 2 3 | 2 * 3 1 2
C0H_ . CH0C1 , C0H,. •3 T 2 - 2 p
' hedonal aleudrine aponal . :
. Although ethyl carbamate inactivates the enzyme acetylcholinesterase 
only slightly (Adams and Baron, 1965), carbamates such as neostigmine 
and carbachol are very much more active acetylcholinesterase inhibitors 
and are used extensively as parasympathominetic agents in disorders such 
as glaucoma and myathenia gravis. These and similar anticholinesterase 
agents have been reviewed recently by Koelle (1975)*
(CH ) NCH2CH20C0NH2
carbachol neostigmine
A major therapeutic application of carbamates, is the use of 
meprobamate and related dicarbamates of propanediols as muscle relaxants. 
The structure-activity relationship and pharmacological properties of 
this group have been reviewed by Ludwig and Potterfield (l97l)*
3h7 ' H
H2N-C0-0CH2-C-CH20-C0-NH2 1 -
meprobamate
(CH )/- -0C0N(CH^)2
. Other "biological applications or various carDamaues nave oeen rneir 
uses as blocides such as herbicides, insecticides,. insect repellants and 
fungicides. The metabolism of insecticidal carbamates in animals has 
been reviewed by Dorough (1970) and Fukuto (1972). From these reviews 
it is evident that carbamate insecticides act as typical foreign 
molecules in biological systems and are metabolically transformed by a . 
variety of chemical reactions into molecules with increased polar 
properties. The initial step in carbamate ester metabolism appears to. 
be oxidative in nature and probably involves the mixed function oxidases.
In most cases, the oxidative reaction, introduces a functional- group, usually , 
a hydroxyl moiety5 which serves as a centre for secondary conjugation 
reactions. Because of the.labile nature of the carbamate ester group, 
hydrolysis of the carbamate,-linkage also is^an important metabolic 
reaction, usually leading to phenolic compounds which are also conjugated 
to water soluble products.
Of all the carbamates only ethyl carbamate’ has been found to have 
a significant carcinogenic effect on mammals. Ethyl carbamate is converted 
into-and excreted partially as ethyl-N-hydroxycarbamate, and N-acetyl-N-* 
hydroxycarbamate by mammals. " These hydroxy carbamates, formed in vivo- 
can act as alkylating agents towards mercaptoamino acids, giving rise 
to .the observed radiomimetic effects (Boyland et.al., 1963a). Ethyl 
k-hydroxycarbamate has been found to have a carcinogenic action comparable 
to that of ethyl carbamate (Boyland et.al., 1963b), whilst methyl and 
n-propyl carbamate appear to lack most of the physiological effects of 
ethyl carbamate (Pound, 1967). . ..__________ _ ___
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■The..-aim of the work:described ,here was to. gain information on the 
physico-chemical-factors that control the kinetics of absorption, 
distribution, and elimination of foreign compounds in rat, using an 
homologous series of simple aliphatic carbamate esters as model compounds.
The extensive work of Houston (1973) has shown that "the carbamates 
selected for this study possess a wide range of physico-chemical properties 
that make them suitable model, compounds for the study of the behaviour of 
foreign compounds in biological systems-. The choice of an homologous 
series was particularly appropriate since the members of such a series 
show regular and incremental changes in their physico-chemical properties. 
The use of aliphatic carbamate homologues of general structure R-O-CO-NH^ 
also had additional advantages. Since they^were stable and unionised in 
aqueous solution they could be considered’as a single entity in kinetic 
studies. They could also be conveniently assayed by direct application 
on gas liquid chromatography, which separated the carbamates both from 
each other and from their parent alcohols. Furthermore these compounds' 
could be synsthesiged easily from the appropriate alcohol, and urea.
The partition coefficient of drugs between lipoidal and aqdeous 
environments has long been regarded as an important property controlling 
the transfer and localisation of such compounds within the body. The 
carbamate homologues show a progressive increase in partition coefficient 
as the chain length is incrementally extended by additional methylene 
groups.. The role of lipophilicity could thus be investigated over a 
very wide range since an increase in chain length"between "a methyl and 
n-octyl group increases the partitioning properties of the carbamates 
by nearly four orders of magnitude. Additionally, the effect of further 
molecular modification, such as the branching Of the side-chain, could 
be assessed. By such one step modifications of the basic carbamate 
molecule the contribution of different physico-chemical parameters could 
be assessed as independant factors in a given biological system.
ill .
Four carbamates were also synthesised with a C radiolabei and 
it-was envisaged that the increased sensitivity of detection provided . 
would enable the small intestinal absorption profile for the series to 
be repeated at a concentration well below the solubility limit of the 
higher carbamate homologues and preclude the use of solubilising agents 
for these compounds. A previous, study using this homologous series has 
shown major differences in absorption profile btweenthe rat stomach and ■ 
small intestine and so, to complete the characterisation of the influence 
of lipophilicity on the absorption of foreign compounds throughout the
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was planned. Little is known of the factors affecting the absorption of 
foreign compounds from the colon and it appears that no such systematic 
investigation has been prev iously undertaken. .
.One factor that is .often overlooked-in studies on the passage of 
foreign compounds through biological membranes is the possible effect 
of the compound on the actual membranes. Some compounds may so affect 
the membrane structure as to alter the permeability characteristics of 
that membrane and thus increase or decrease their own absorption as well 
as that of other compounds. It was decided to.investigate the interaction 
of the carbamate series on the permeability charactsLstics of an artificial 
membrane system. The phosphatidylcholine liposome model was chosen since 
it would appear to be the model system most^closely resembling a. biological 
cell membrane. Since this model membrane has been used to provide an 
insight into the mode of action of anaesthetics, additional information 
might be provided in such a study sines the carbamate homologues possess 
anaesthetic properties . . . ;,r . •  ' - . : • •
It was proposed.to undertake a pharamcokinetic study ofJthe four 
carbamates radiolabelled, these being ethyl, n-butyl, n-hexyl and n~ 
octyl carbamate, in the rat following different routes of administration. 
Such a study.could provide information on the extent to which 
lipophilicity contributes to the overall processes of absorption, 
distribution, metabolism and excretion of foreign compounds in the whole 
animal. Few such studies appear to have been undertaken previously and, 
information provided by this study may be valuable in the prediction of 
the disposition of drugs in the body based on their physico-chemical 
properties.
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CHAPTER TWO
MATERIALS AND METHODS
MATERIALS
METHODS
- CONTENTS
A. GLC assay for aliphatic carbamates.
B. Procedures, used for radioactively labelled carbamates.'
C.. Determination of surface activity of" aliphatic
carbamates. '
22 ■ • . •D. ■ Determination of- Na leakage from liposomes.
E. Determination of absorption rates from the small
intestine and colon of the rat.
. I k
F. Determination'of plasma levels of C-labelled
carbamates.
G. Determination-of metabolism and excretion profiles.
H. Analysis of data.
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Carbamates of general structure R-O-CO-NH^ .
Methyl (Koch-Light Labs. Ltd., Bucks, England), ethyl (BDH Ltd.,
Poole, Dorset, England), n-propyl and n-butyl (Kodak Ltd., Liverpool, 
England) were obtained commercially and were reagent grade. .The purity 
of these chemicals was at least 99% as determined by GC. Tert--butyl •
(1,1 dimethylethyl; m.pt. 10^-6°C), tert-pentyl (2,2 dimethylpropyl; 
m. pt. 80°C), n-pentyl'(m.pt. 53~5^°C), tert-hexyl (3,3 dimethylbutyl; 
m.pt. 55”56°C), n-hexyl (m.pt. 59°C), n-heptyl (m.pt. 62°C) and n-octyl 
(m.pt. 6T0C) carbamate were synthesised by the Chemistry Division of 
the Chemical Defence Establishment.
Radiolabelled compounds 
lU
C-carbonyl labelled ethyl carbamate was supplied by Fluorochem 
Ltd., Glossop, Derby; England, specific activity 31.^ mCi/mMol.;
35^ liCi/mg. n-Butyl, n-hexyl and n-octyl carbamate, all C-labelled in 
the carbonyl group of the ester linkage were synthesised by the Chemistry 
Division, Chemical Defence Establishment, (specific activity 1.5iaCi/mMol). 
The radiochemical purity of each carbamate was found to be not less than 
99% as checked by TLC and subsequent liquid scintillation counting of 
scraped Sections of the whole plate.
General chemicals and solvents ' . ■ v
Unless otherwise stated, all chemicals and solvents were of analytical 
reagent grade and were obtained from BDH Ltd., Poole, Dorset.
48
A. GAS CHROMATOGRAPHIC ASSAY FOR ALIPHATIC CARBAMATES.
All aliphatic carbamates were assayed using a Pye 10.U gas 
chromatograph (GC), (Pye Unicam Ltd, Cambridge', England) fitted with a 
flame ionisation- detector. An 18M x l/V glass column packed with 
Porapak type P (Phase Separations Ltd, Flintshire, Wales) of mesh size 
100-120 was used and gas flow rates were nitrogen, 120 ml/min; hydrogen,
35 ml/min; air 500 ml/min. One microlitre samples of test solution 
containing internal standard were injected directly on to the column.
No clean up of test solutions was found necessary. Carbamate concentration 
was determined by the ratio of the carbamate peak height to the peak 
height of an internal standard and reference to a standard curve which 
was checked daily.
Table 2.1 lists the retention times, oven temperatures and internal 
standards used. All carbamates gave characteristic peaks which could be 
separated from their parent alcohols. ~ '
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GC CONDITIONS FOR ASSAY OF ALIPHATIC CARBAMATES US ING 
A PORAPAK P COLUMN a
Carbamate
Column
Temperature
(°c)
Rentention 
Time^ 
(min)
\
Internal 
Standard. . .
Methyl Carbamate 160 h • ‘ Ethyl Carbamate
Ethyl Carbamate 160 6 Propyl'. Carbamate
Propyl Carbamate 180 M . 5 ■n-Butyl Carbamate
n-Butyl Carbamate 180 , 1 n-’Pentyl Carbamate
n-*Pentyl Carbamate 200 6 n~Hexyl Carbamate
n-Hexyl Carbamate 200. 9 . nHPentyl Carbamate
n-Heptyl Carbamate 220 ?. 5 n-Hexyl Carbamate
n-Octyl Carbamate 220 11 n-Hexyl Carbamate
t-Butyl Carbamate 200 6 n-Butyl Carbamate
t-Pentyl Carbamate 200 7 n-Butyl Carbamate
t- Hexyl Carbamate 200 9 n“Pentyl Carbamate
a Gas flows; 35 ml/min; N^j 120 ml/min and Air, 500 ml/min,
b . .
The retention times of the alcohols corresponding to the carbamates
"were in all cases less than 1 min.
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B. PROCEDURES USED FOR RADIOACTIVELY-LABELLED CARBAMATES
liquid. Scintillation Counting'
A Packard Tricarb 3375 Liquid Scintillation Counter was used for all 
radioactive assays. Efficiency of sample counting was determined by 
automatic external standardisation and was between-70$ 'and 85$- A 
dioxan-basea scintillation cock-tail (10 mis per sample) was used comprising 
of •
Naphthalene (BDH Ltd.9 Scintillation Grade)
2,5-Diphenyl©xazole? PPO (Koch-Light Labs Ltd)
1 5 V-Di[ 2- (5“phenyl«sxazolyl)] benzene, POPOP 
(Koch-Light Labs Ltd. )_' ■ ■
—  S '
Ethyleneglycol Monoethyl Ether (Koch-Light Labs. Ltd) 
l sU-Dioxan (Koch-Light Labs. Ltd)
2 1 %
7.2g
0. 2g
300ml
1,500ml
Thin Layer Chromatography. _
"20 x 20 cm glass plates pre-coated with Silica Gel 60 (Merck 
Darmstadt, Germany) of 0.25 mm. layer thickness were used. , Plates were run 
in ethyl ace tat e-benzene solvent systems and these systems and the Rf values 
are quoted in table 2.2.
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- • TAELE 2.2
SOLVENT SYSTEMS M D  Bf VALUES . FOB TLC OF CARBAMATES
Carbamate Benzene:Ethyl Acetate 
(v/v)
Bf .
Ethyl Carbamate 1:1 0.51'
n-Butyl Carbamate ‘ 1:1 0.67
n-Hexyl Carbamate 3:1 -V . ,/ 0.55
n-Octyl.Carbamate 3:1 0.72
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The "dynamic" (Exner„ et.al., 1976) surface tension of carbamates
(10 M) was determined in lUW M  HaCl-l6mM Tris-Hcl (buffered saline, pH
J.U). Solutions -were pumped at a flow rate of 7*8 ml/hr maintained by a
Gilson Minipuls II peristaltic pump (Gilson Ltd, France) equipped with
0.5nun internal diameter silicone rubber tubing to a Gilson Microcol TDC 80 .
(Gilson Ltd, France) combined drop counter and fraction collector® The
pump intake tube was covered with a plug of cotton wool to prevent the
intake of particulate .material. Samples were collected in lml polyethylene
\ .
tubes weighed accurately before and after colleqting 30 drops, (Exner5 
et.al., 1976). The collection of 30 drops was also automatically timed and 
recorded on a servoscribe Is chart recorder (Smiths Industries, London) 
connected to the fraction collector. -
The linear relationship between sample weight and sampling time is 
shown in Fig. 2.1.
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Liposomes were prepared using grade I egg lecithin (BDH) which was 
stored as a 30mM solution in chloroform at -20°C. Purity of the lecithin . '
was checked by TLC before each experiment. Silica gel G plates were-run 
in chloroform:methanol:water:ammonia. (75:.30:k:0.5) sprayed with 50$ 
sulphuric acid and developed by heating at 110°C for 15 minutes (Papahadjopou3.os 
D. and Miller, N., 19^7)* The egg lecithin used always ran as one spot 
(Rf value 0.6l). , ;
For the preparation of liposomes 5Q ymoles of lecithin were taken to
dryness in a 25 ml round bottomed flask. The dried films were then
2?  / • 
shaken with 0.9 ml l60 mM NaCl (25 yCi/ml) and 0.1 ml 160 mM Tris-HCl
(pH 7*^) for 5 min. The flask was exhaustively flushed with nitrogen before
shaking to prevent oxidation~df the lipid.- The resulting suspension was ^
then sonicated for 60 min in ’a Pulsatron 50 bath (Kerry Ultrasonics Ltd,
Herts, England). The temperature of the bath water was kept below 28°C
and the flask flushed with nitrogen every 10 min. TLC-of the lipid .
showed no presence of oxidation products. After soni.cati.on the lipid was
allowed to equilibrate at room temperature and under nitrogen for 2k hr
22before use. Untrapped Ka was removed by column chromatography; the 1 ml
sample of liposomes was passed over a column of '3 g of hydrated Sephadex 
G-50 prepared in non-radioactive 1^ 1+ mM NaCl - 16 mM Tris-HCl (buffered 
saline, pH 7*^)» Liposomes were eluted in the 12th — 15th 1 ml fraction 
from the column and these fractions were pooled and diluted to 27 ml with 
buffered saline.
Series of dialysis bags (8/32 Visking tubing), previously washed, 
tied at one end and left soaking overnight in buffered saline were then
prepared containing 1 ml of the liposome suspension. Further aliquots -
. . 22 .
were taken for estimation of the total liposome- Na content by liquid 
scintillation counting. Liposome-containing dialysis bags were then
i placed in 10 ml screw-top test tubes contining 8 ml of buffered saline
• —3 ~7or:-various concentrations (10 - 10 M) of carbamates in buffered
saline. Tubes were then slow rotated at 37°C at 10 rev/min. Tube
contents (diffusate) were removed when required for liquid scintillation
counting and to permit calculation of sodium leakage from the liposomes.
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THE RAT
Procedure used for In Situ Intestinal. Absorption Studies
i/ Unlabelled carbamates '
Rats were anaesthetised with pentobarbitone (50 mg/kg; i.p.) - -
(Nembutal, Abbott Labs., Kent) the intestine exposed by means of a midline 
abdominal incision and c annul at ed at the duodenal and ileal ends ’with -
polyethylene cannulas (internal diameter 2«5 mm; external diameter 3.5 mm).
A 50 ml syringe, equipped with a three-way tap (Rocket Ltd., London) and 
containing perfusion solution at 37° C was' attached to the duodenal cannula 
and the intestinal lumen was cleared of particulate matter by slowly ,
introducing the solution from the syringe. The stomach and the caecum 
were closed off by ligature, care being taken not to ocdulde any major 
blood vessels. Any perfusate solution remaining in the lumen after the 
washing procedure was removed by pushing air through the lumen of the 
syringe.- The ileal cannula was then also fitted with a three-way tap* and 
■50 ml syringe (see Fig 2.1). The compound being investigated was then
introduced into the lumen (in 10 ml 0.1 M c5.trate~phospha.te buffer, pH 6
. . . ib ,
and containing 0:5 yCi C-polyethyleneglycol 4000 as a non-absorbed
...monitor for lumen water loss) via the duodenal three-way-tap with a 10 ml
syringe (see Fig 2. id. The lumen was emptied for sampling and this was
carried out alternately via each three-way tap. and samples were removed
every three minutes. Twenty-five microlitres of each sample was prepared
. . . . .  . . lb
for liquid scintillation counting for the estimation of C-polyethyleneglycoi
bOOO (Radiochemical Centre, Amersham). This procedure was based’ upon that 
of Doluisio,' et.al., (1969K
After completion of each in situ experiment the.pH of the lumenal 
fluid was measured and a 10 cm section of intestine removed. This section 
was washed in saline, sonicated in chloroform:methanol (3:l) and the 
carbamate present m  the tissue determined by GLC.
.. , lb2.1/ C-labelled carbamates
In these studies the basic procedure was as for unlabelled carbamates 
but no internal monitor for water absorption was used, any reduction in 
volume being noted visually when the lumen contents were emptied into the 
syringe for sampling.
After completion of each experiment the pH of the lumenal fluid was 
measured and the whole intestine excised, washed with saline scissor-minced 
and 0.5 g amounts solubilised in NCS solubiliser (Amersham/Searle USA) and
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the radioactivity present determined by liquid scintiiia-cion counting.
Procedure used for In Situ Colonic Absorption Studies
Bhts -were anaesthetised with pentobarbitone (50 mg/kg; i-.p."). The
colon was exposed, washed out with saline and cannulated by a method based
on that of Doluisio, et»al., (1969) in a similar fashion to that described
for the intestinal absorption.studies« Hats were starved for 20 hours
prior to the experiments, in order to reduce the faecal content in the colon,
but were allowed free access to water. .
\ • 
In the colonic absorption experiments 5 ml of carbamate solution
was introduced into the colonic lumen in a weakly buffered perfusldon
solution (pH 7-2) which consisted of the following salts in mmol per 1: ‘
HaCl 11*5, KC1 H.56, CaCl2 1.2-5, Ha^PO^ '1.33,and 3MaH2?0^ 0„33, (Schanker,
19i9)» Samples were removed' every three minutes for as'say and at the end
of each experiment the colon was excised and carbamate present was
estimated as described previously.

U XJJ UiLKJD.41vm.TtiO
Male rats -weighing between 250 and 350 g were anaesthetised with 
pentobarbitone. (50 mg/kg; l.p.). A midline incision was made in the 
neck region as shown in Fig 2.2. The carotid artery was exposed by 
blunt dissection and adhering tissue removed. The cranial end of the 
exposed artery was tied off by ligature and an artery clip applied to the 
end leading to the heart. A small incision in the artery was then made 
and a 5 cm length of Portex tubing (PP50) (Portex Ltd . 5 Hythe, Kent) was 
introduced and secured by ligature. A 2ji G x 5" hypodermic needle 
attached to a male adaptor plug with intermittent injection site (Abbott 
Labs., Kent) and filled with heparinised saline (100 units heparin/ml 
0.9$ saline) (Evans Medical. Ltd. , Liverpool) was fitted into the free end 
of the Portex tubing. The needle assembly provided a leak-free fit which 
was easily removeable for sampling of blood and through which heparinised 
saline could be injected after.sampling to clear the tubing of blood 
(see'Fig 2.2). _ • AV-.' -
Administration of intravenous doses of carbamate was made into the 
femoral vein by means of a 25 G Butterfly Paediatric Infusion Set (Abbott 
Labs., Kent). The needle was secured by ligature and a three way tap 
fitted to the free end of the tubing. This enabled the entire infusion 
set to be flushed with heparinised saline following administration of 
the radioactive dose. Intraduodenal dosing was carried out using a 2^ G 
needle puncturing the intestinal wall and injecting directly into the 
lumen. The needle hole was sealed with Eastman 910 tissue adhesive (
(Ciba Plastics Division, Cambridge) to prevent leakage. -
Blood samples (0.5 ml) were taken at appropriate time intervals
following dosing. Plasma was harvested immediately by centrifugation at
600 g (MSE minor, MSE, Sussex), a 100 yl sample prepared for liquid
scintillation counting a further 100 yl sample prepared for TLC.
Preparation for TLC involved protein precipitation by the addition of
200 yl methanol, followed by mixing and centrifugation. Two hundred
and fifty microlitres of the resulting supernatant was then applied to
TLC and run with a known amount of standard extracted from control plasma
lU
to ensure that all of the C was parent carbamate.
The recovery , of radioactivity from the plasma after protein precipitation 
ranged between 80-83% as determined by extraction of radioactivity from known 
amounts (2,000 to 50,000 dpm/ml plasma) of carbamate in plasma controls.
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FIG 2.2
CAIGIUIATIQN OF CAROTID ARTERY'
89
Male rats (250 - 300 g) were placed in metabolism cages (Jencons 
Ltd., Heme! Hempstead, Herts) designed for the collection of carton, 
dioxide, urine and faeces (see Fig 2.3).
Administration of intravenous doses was carried out on anaesthetised . 
rats by injection into the femoral vein and oral dosing was carried out by 
gavage. It was found necessary to administer n-octyl carbamate in 5$ 
ethanol in saline in order to keep this compound in solution.
C-labelled carbon dioxide was trapped, in a solution of ethanolamine 
and 2-ethoxyethanol (l:2).- Aliquots of trapping fluid and urine were • 
prepared for liquid scintillation counting and faeces were solubilised in 
ION sodium hydroxide and aliquots counted. .
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Regression Analysis
Linear and-quadratic equations describing the Lest line of fit 
between two variables were' fitted by the method of least squares. An ICL . 
I9OO computer was used in conjunction with the ICL statistical analysis 
Mark 2 library programme. - -
Analysis of Pharmacokinetic Data
The plasma concentration data indicated that'the time course for the
intact carbamate, in the body might be adequately described by a two-
compartment open model (Riegelman et.al♦, 1968).
. k12 .
Carbamate m  -— -— — — :--^ Carbamate m  tissue
central compartment ^  r~  —  V  compartment
■ 21- •
k . ;el
4/ . . ' ' , ‘ ' “
Chrbamafce eliminated
In the intravenous studies, the plasma concentrations (Cp) of 
carbamate declined biexponentially with time according to equation 2.1:
Cp = Ae~at + Be“3t (2.1)
A s B3 and 0 'were used to calculate the rate constants for the transfer 
of carbamate from the central, to the tissue compartment (,'ka p ) 5. for the 
back-transfer from the tissue to the central compartment (k^  ) and for 
the elimination from the central compartment (k -^) means of the 
following equations (Mayershohn and Gibaldi, 1971)9
fc21 = A0 -fr Ln (2.2)A + B
k = a:8 (2.3)
el k~^21
k12 = + 0 - k21 ~ kel
The terminal (0) slope was fitted by eye and the initial distributive 
slope (n) was "feathered". The fraction of carbamate in the central 
compartment (F ) in the post-distribution (0) phase was calculated from 
the ratio B/k^ (Gibaldi et.al., 1969). ,
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The volume of the central compartment (V ) was obtained'using 
equation 2.5:
■' - V = D _  . (2.5)
Cp°
where D was the administered dose given intravenously and Cp° the 
carbamate plasma concentration at time zero (the sum of equation 2.1. para­
meters A and B), The total volume of distribution at steady state-(Vd --ss
Riggs, 1963) and at pseudoequilibrium after the attainment of steady 
state (Vd3 - Gibaldi et.al. 1969) were calculated using equations 2.6 and 
2.7 respectively;
Vd --■= ^12 , + k21 ^ Vc (2.6)ss v
21
Vd3 = kel Vc (2.7)
The areas under the plasma.level versus time curves, from zero to 
infinity (AUC) were determined using the trapezoidal rule for the time 
from zero.to-the last determined plasma level , and from that point to 
infinity by using the law of corresponding areas;
ADC = ' C eT (2.8)
AUV-*co 3
where CpT-is the last determined drug concentration. The fraction of 
carbamate reaching the central compartment (0 ) following administration 
intraduo'denally was assessed from the ratio of AUC for the intraduodenal 
route to AUC for intravenous injection via the femoral vein.
The metabolism rate constants (k _ and k _) were calculated fromml m2
equations 2.9 and 2.10 (Cummings et.al., 1967);
k = kel (1’,C02) (2-9)ml D
k = kel (U-l!tC) (2.10)
m 2
D
/lU / lU lUwhere ( CO, j and (U- C) are the total amount of C dose recovered as
CO^ and in urine, respectively at time infinity (using 2k hour data).
'x'
CHAPTER THREE .
INTERACTIONS OF. CARBAMATES WITH. LIPOSOMES
UTl'KUl)LKJTIUP'I TU LIFUSUMES AMJ ‘THE IK APPLICATIONS
Theimportance of membranes in living cells is paramount. The view 
held by most investigators is that membranes consitute the.larger part of 
cell structure, not only separating the individual cells but also con^istut- 
ing a large part of their internal structure. In contrast to the wide variety 
of membrane.functions, the basic, structure of all biological membranes appears 
to be simi3.ar, consisting of a bimolecular. lipid leaflet in which are embedded 
globular protein units (Singer and Nicholson, 1972)« It is because of this 
recognition of the functional role of membranes and the difficulty in studying 
complex biological membranes., that membrane studies using model membranes 
have achieved such importance.
Disability
. This
model system consists of enclosed vesicles formed by sonicating or mechanically 
agitating a-suspension of phospholipid. These lipid vesicles, or "liposomes" 
are of special interest since their limiting structure is also of bimolecular . 
thickness. Such liposomes are thought to consist of completely closed single 
or concentric shells of bilipid membranes separated by aqueous compartments, 
into which radioactive salts or other materials can be incorporated by 
inclusion in the sonicated solution (Bangham, 1968). Sonicated liposomes 
probably exist as single membranes of 25O-5O0S diameter (Papahadjopoulos. 
and Kimelberg, 1973)*
Phospholipid liposomes with incorporated markers have been used 
extensively for investigating the membrane effects of many series of compounds. 
Bangham et. al., (19&5 "b an<i c) reported that this model membrane system 
paralleled the behaviour of biologically excitable membranes in its response 
to two chemically unrelated groups of narcotics. An increase in cation release 
from liposomes caused by some steroids (eg corticosterone, diethylstilboestrol) 
was also closely related with their ability to liberate acid phosphatase 
‘ from lysosomes. Cortisol and cortisone however reduced cation leakage, this 
effect correlating well with their stabilising effects on lysosomes and red 
cells. Additionally, the molecular effect of a wide variety of steroids on. 
potassium permeability of liposomes was shown to be related to certain 
physicochemical properties of these compounds, (Heap et.al., 1970; 1971)*
An indication of the degree of sophistication possible using these membrane 
models can be found in the work of Eytan et.al. , (1975) who succeeded in 
incorporating biologically active proteins into the liposome membrane.
A simple model for studying the effects of substances on the per 
of lipid membranes has been developed by Bangham et.al. 0 (1965a, t.1967)
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nature of interactions of members of the aliphatic carbamate series with 
phosphatidylcholine liposomes. Such studies might provide additional 
information on.the membrane actions of.anaesthetics since the carbamate 
series posses&sanaesthetic properties. Although the aliphatic carbamates 
are relatively weak narcotics5.the narcotic potency of each successive 
member of this homologous series of aliphatic carbamates increases 
progressively as the carbon chain length increases (Harris', 19.51) < 
Secondly such information may be useful in the interpretation of results 
obtained from studies on the absorption of these carbamates through the 
gastrointestinal membranes (Chapters h and 5) and also in whole animal 
studies (Chapter 6).
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The effect of a series of aliphatic carbamates on the membrane
permeability of phosphatidylcholine liposomes has been investigated by_
. 22 + . ' . 
measuring the leakage of Na previously incorporated into these
microvesicles.
The preparation of the liposomes was carried out as stated in
Chapter 2D« After-sonication of the phosphatidylcholine with radiolabelled
22 . ’ . . . .
NaCl the resulting crude liposome preparation was purified by passage
. 22 .
through a sephadex G-50 columnc The distribution of Ha in' consecutive
fractions eluted from:the sephadex column is shown, in Fig '3.15 -illustrating
22 v 'the small amount (3~k% of total label) of Na. incorporation into the 
liposomes and showing that the^liposomes were free from the contamination . 
of untrapped label.
The leakage of the liposomal sodium into buffered saline was measured
over a twenty-four hour period and these leakage rates' are listed in Table
'3.1. These rates are plotted in Fig 3.2 and show that the rate of sodium
leakage was linear over the time studied. Using a twenty-one hour
equilibration time, the. leakage of. sodium from the liposomes in the
“3 —7
presence of a range of concentrations of each carbamate (10 M - 10 M) 
was investigated. At a concentration of 10 all the carbamates 
significantly increased the percentage of sodium leakage above that of the 
control and these values are shown in Table 3.2. Methyl, ethyl and n-propyl 
carbamate increased the leakage rate by a similar and comparatively small 
amount (<20$ increase). However n-butyl to nyoctyl carbamate caused a 
progressive increase in the leakage rate as the homologous series was 
ascended* The overall non-linear dependency of the leakage rates upon the 
octanol/buffer apparent partition coefficient is shown in Fig 3.3.
Except for n-heptyl and n-octyl carbamates, which, at a concentration
-h  . .
of 10 M, brought about a small increase m  sodium leakage, no carbamate 
was found to produce a significant increase (over controls) in sodium 
leakage over the concentration range 10 V- 10 (Table 3.2). Neither
was any significant stabilisation of the liposomal membrane (reflected by 
a decrease in entrapped sodium leakage) produced by any carbamate at any 
concentration studied.
Although being -unionised the higher carbamate homologues have 
structures resembling.known detergents, in having a long apolar chain 
attached to a small polar group, and thus might be surface active agents.
It was possible that the shorter chain homologues could also reduce surface 
tension which could result in the destabilisation of the liposome membrane,
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a modified drop-weight method (Exner et.al., 1976) as explained in Chapter 
2C. The times taken for thirty drops of each carbamate solution to pass 
off a drop counter-fraction-collector assembly are shown in Table 3«39 to­
gether with the "dynamic" surface tensions of these solutions relative to 
the buffer value. . The/"dynamic" surface tension approaches the "real" 
or static surface tension as the flow rate is decreased. In this respect 
the "dynamic" .value will usually be higher- than the real value--because time . 
is required for diffusion of the molecules of the foreign, substance into 
the interfacial layer-. For the purpose of comparison, concentrations of
Tween 80 (a non-ionic, detergent), whose static surface tensions were
. . . . .  ^
documented (Wan and Lee, 197^) were also passed through the system. The 
values obtained for. these.solutions are also listed in Table 3.3* Methyl 
and ethyl carbamate produced ho significant decrease in the surface tension 
relative to the buffer control. However a significant and progressive 
decrease in surface tension was shown by n-propyl to n-heptyl carbamate.
The linear relationship between relative dynamic surface tension of 
the carbamates and their ability to increase the -sodium leakage from lipo­
somes is shown in-Fig 3.^. The surface.tension value, for n-octyl carbamate
. . .
was however not included since it was not totally in solution at 10 .
the effective concentration was less than 0. 5 x 10 this figure being 
the aqueous solubility at 37°CL It should be noted though that the presence 
of liposomes increased the solubility of this carbamate in the dialysis 
experiments. The initial fine suspension became clear after a twenty-one 
hour incubation at 37°0 and the effective concentration was thus taken as 
10 in such cases. The two .highest- concentrations of Tween-80 also 
produced,a significant decrease in surface tnpsion, this decrease*being of 
the same .order as that'produced by n-heptyl. and n-octyl carbamate.
In view of the good agreement shown in Fig 3.^ the relationship 
between surface activity and leakage rate was further tested by the . . 
determination of sodium leakage from liposomes in the presence of Tween 80. 
The results obtained are shown in Table 3.H and indicate that no 
significant increase in the sodium efflux was produced by the. two ./ V
concentrations of Tween 80 which had shown similar surface tension lowering 
properties to those of the higher carbamate homologues.
Another mechanism by which the carbamates could have increased the 
permeability of the liposomes to cation was by their incorporation into • 
the membrane, producing structural alterations which result in a more
permeable membrane. This possibility was investigated by following the
lU y
distribution of four C-labelled carbamates (ethyl, h-butyl, n-hexyl and
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n-octyjL carDamaue ax; jlu w; into analysis Dags containing liposomes 
prepared in the normal manner hut using non-radiolabelled sodium chloride. 
Control experiments were carried out using dialysis.hags containing 1 ml 
of buffer only, and dialysed against buffered .saline containing radio- 
labelled carbamate. At the end of the twenty-one hour equilibration period 
in these control experiments, the radiolabelled carbamates were found to 
be evenly distributed throughout the total volume available. Less than 1% 
of the total activity was found bound to the dialysis bag.
Table 3.5 shows' the distribution of four carbamates between the 
dialy sate and the dialysis bag containing liposomes and also the ratio of 
carbamate molecules to phosphatidylcholine, molecules in the liposome 
membrane. n-Butyl, n-hexyl and n-octyl carbamate each appeared in higher 
concentration in the dialysis-bag than, in the dialy sate and the difference 
in concentrations permitted the calculation of the molar concentration of 
carbamate in the lipid (y.moles. carbamate/ymole lipid). The behaviour 
of ethyl carbamate, was different „ A -lower -concentration was . found in the 
dialysis bag than was found in the dialy sate,.‘thus for. this compound the 
carbamate/lipid ratio, could not be calculated.
This study on the interaction of the homologous series of aliphatic
. .  ’ ' . 22
carbamates with phosphatidyl choline liposomes containing Na has shown
that all the carbamates studied destabilised the liposome membranes wdien
present at-10 in buffered saline. The effect of enhancing Na
permeability through, the model membranes was increased, as the. series was
ascended, although not linearly related to partition coefficient over the
whole, series. The three lowest homologues produced similar membrane effects
although their partition coefficients ranged over an order of magnitude.
The membrane permability increase was found to be related to the 
relative dynamic surface tension of the carbamates. Many organic 
substances such as alcohols,-“aldehydes and fatty acids are surface active
in aqueous solutions,• lowering the surface tension in proportion to their
chain lengths (Jirgensons and Straumanis., 19&2). The behaviour' of the 
• carbamates would thus' appear to be similar, although methyl and ethyl 
carbamate might have been expected to reduce the surface tension 
significantly. . This may reflect the insensitivity of the method used and 
the behaviour of Tween 80 solutions in this system supports this conclusion.
Wan and Lee (197*0 reported the static surface tension of 0.005$ and
-“I
0.00025$ Tween solutions to be about 50 and 55 dynes, cm respectively at 
25°C. Afc£hough not reported, an extrapolation of their results indicates 
that 0.0001$ Tween 80 should, lower the surface tension to about 65 dynes
_ 1  . #  ^ - , . . . p
cm (surface tension of distilled water is 73 dynes cm ). However this 
lowest concentration of Tween did not-'significantly decrease the surface 
tesnion using the "drop-time" method. It would appear then that the method 
used is insensitive to small changes in surface tension and that the data 
for the short chain carbamates may not be valid.
That the Tween 80 solutions of similar surface activity to the higher 
carbamates did not significantly affect the liposome membrane permeability 
indicates that reduced surface tension is not the prime cause of membrane 
distabilisation. Even so, the large decrease in surface tension produced 
by the longer-chain carbamates is evident and whilst it is tempting to . 
accept the relationship between membrane destabilisation and surface tension 
as an indication of the mechanism of action, this effect may be non-specific 
and reflect only the hydrophobic nature of the molecules. Although surface 
activity per se is not likely to be solely responsible for the increase in 
membrane perm^bility, it can influence availability and possibly reactivity' 
of an agent at the site of action (Feldmeister, 1972) and in these respects 
nay assume importance,
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- The incorporation of the carbamates into the lipid membranes 'was 
investigated using four radiolabelled carbamates. For the three longest 
carbamates.used, the number of ymoles incorporated per ymole of lipid 
covered two orders of magnitude, increasing with chain length5 and is thus 
closely related to their known octanol/buffer partition coefficients 
(Houstons et.al., 197^). The behaviour1 of ethyl carbamate was anomalous 
in that following the 21 hour incubation with liposomes, a higher 
concentration of this carbamate was found outside the dialysis bag than 
was found inside. Failure to reach equilibration may be the cause of this
finding although no evidence of this behaviour was observed either for the .
A . . .
other carbamtes or m  control experiments. Thus the presence of liposomes 
*\
in the dialysis bag would appear to increase the equilibration time 
required for ethyl carbamate ~and possibly also for the other - short chain 
carbamates. .
In terms of overall effect the carbamates appear to produce a regular 
increase in membrane permeability to cation because of increasing amounts \ 
(expressed as ymole carbamate/ymole lipid) of carbamate incorporated into 
the liposome membranes, this incorporation being associated with their j : 
partitioning properties. These findings are in agreement with the lipid 
solubility theory of general anaesthesia which states that the narcotic 
potency of members of a chemical series is proportional to their oil/water 
partition coefficients and that the.narcotic action is due to the compounds 
becoming dissolved'in the cell lipids. This relationship between oil/ p . 
water partition and narcotic activity has been substantiated for many' 
compounds (Wood-Smith, et. al. , 1973). Furthermore—it--has-been-suggested 
by Johnson and Miller (1970) that during anaesthesia, membranes are 
swollen, with large pores and increased permeability. The increasing 
permeability to sodium ions of the lipid membranes observed in the studies 
presented here supports this suggestion and indicates the usefulness of 
liposomes as a model for biological membranes. •
No overall liposome stabilisation by carbamate was found in this
study although several previous studies have shown that some foreign compounds
wliich destabilise liposomes also stabilise these membranes when the compounds :
are present in lower concentration. Such biphasic effects might have been1
expected in this carbamate study and have been demonstrated for halothane :
•£/fe .
(Rosenberg^ 1975) and carbenoxolone (Symons, 1976). The composition of the 
liposome membrane may be very important in demonstrating these biphasic 
effects. Miller and Pang (1976) recently showed that the same concentration ‘ 
of pentobarbital either stabilised or destabilised phosphatidylcholine i 
liposomes depending on the proportions of phosphatidic acid and cholesterol
78
also incorporated into these membranes. The demonstration of biphasic 
behaviour may be predictive of biological activity of compounds that act 
via interaction with biological membranes (Miller and Pang9;19T6). and the 
narcotic carbamate series may exhibit such behaviour with liposomes of 
different composition to that, used in this study.
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Table 3.1
Leakage of g2H* from lecithin liposomes
Time (hours) 22Na Leakage (#)a
2 1.95 ±  0.36
. 1+ 1.20 ±  O.lO
6 -5'. 83 + 0.16
8 8.26 _£ 0.7l
21
, b 
19.11+1.10
2k 22.10 + 1.13
Mean + s.d of three experiments.
cl * —  .
expressed as sodium leakage as a 
percentage of total entrapped liposomal 
sodium.
TdMean _+ s.d of ten experiments.
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Determination of relative dynamic surface xension.
compound concentration
f}.
time required 
for 30 drops** 
(seconds)
relative dynamic 
surface tension 
(control =1.0)
control - 361.9 ±  0 .8 / 1.0 '
methyl carbamate H O
1
361.1 + 1.3NS 1.0
ethyl carbamate
1O 
! 
H 
|j
362.ll + 0.8NS 1.0
n-propyl carbamate, ' 1 0 ~ 3bl 359.^ +0.8** 0.993
n-butyl carbamate 10“^H 3^8.3 .+ 1.8*** 0.962.
n-pentyl carbamate- 10-3M , 3Ul.7<+-l.U**-*- 0.9^1
.n-hexyl carbamate io-3m 327.0 +1.3*** 0 ,90V
■ n-heptyl carbamate 1o-3m 297.0 + 3.'3*** 0 .821
h-octyl carbamate H 0
! 0 322.6 + 1.7***' 0.891
Tween 80 - 0 .0005$w/v 270.6 _+ 1.7*** O.7H8 .
Tween 80 0 .00025#w/v 301.0+1.2*** 0.832
. Tween 80 ' 0.0001$ , w/v 360.6 + 0.9HS
1.0
- 1
a determined in buffered saline at- 25° C _+ 2°
" ’ V' • ' v
mean _+ sd of four determinations
C ' * • •present as a fine suspension, effective concentration was less than 
0.5-x 10 (this is the aqueous solubility at 37°0).
Levels of significance are shown (using ^ t 1 test) of comparison with 
control value, p<0.01, ***p<0.001, WS no-significant difference from 
control value.
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Table 3.4
cLdL
Effect of Tween 80 on Na leakage from Ij-posomes
Tween. - 
' concentration 
(% v/v)
21 hour leakage 
(% total entranced 
Na ) -
% control - 
leakage 
(control =100)
control 19*^ + l.la " 100
°.l 63.2 + . 326 -
0.0005
NS
20.2 + 0.8 10k
0.00025
NS
20.3 + 0.9 10 5
0.0001 .19-9 + 0.7KS . 103
mean + sd of three experiments.
a .mean + sd of ten experiments. _ .
■***sign-ificantly different from control (using- *tl test)
p<0.001.
NS . . .. not significantly different from control. •
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Distribution of carbamates into dialysis bags containing; 
tinlabelled liposomes after 21 hour. equilibration
■ carbamate 
(concn.)
distribution
A • a ratio
■ !
carbamate/lipid 
ratid^ "tv
ethyl
(io-3m ) 0.90 + 0.02 '•
c
n-butyl
(10_3M) 1..02+0.01 0.01 . •
n-hexyl
(io~3m )
1.30 +0.01 0.13 •
■ n-octyl
(io-3m ) + 0 . 0 k 1.1'ly
mean _+ s.d. of three determinations. ~ r
01 • ■ • • • ' •
distribution ratio . = [carbamate in'dialysis bap;]
[carbamate in dialysatej -
b a , . . .
expressed as ymoles carbamte/pinole lecithin* using:-
pmoles carbamate in dialysis bag (l ml) ~ pinoles carbamate/ 
ml dialysate “ ■ pmoles carbamate associated with 2 pmoles 
lecithin.
C . • • *not determined since lower carbamate concentration inside- 
dialysis bag than outside. -
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XCHAPTER FOUR
INTESTINAL ABSORPTION OF CARBAMATES
IN'JL'KUJJUUT-LUiM TU TtUli U'JJLiiii u r  a. j.j.i
In the previous discussion of the various factors affecting intestinal
absorption (Chapter- 1, section B) it was indicated-that the degree of
lipid solubility of a drug can often be used to predict its absorption
. . ; " . 
characteristics. One of the first indications of the lipoid nature of the
intestinal epithelium was supplied by Hobber and Hober( 1937) , who showed
• that certain compounds were absorbed at rates in accordance with their oil-
to-water partition ratios. Support for the importance of lipophilicity in
drug absorption has been demonstrated by many investigators, notably
Hogben, et.al., (1959) who established'a rough-agreement between the- rates - -
of absorption of certain weak electrolytes and the lipid-to-water partition
coefficients of their unionised form. Furthermore Schanker (l97l) has
pointed out that ■unionised molecules are absorbed faster than ionised ones
because of their much greater lipid solubilities.
Linear correlations between the logarithm of the absorption rate and- 
the logarithm of the partition coefficient" have been shown for barbiturates 
(Kakemi -et.al.  ^1967a) , sulphonamides (Koizumi et.al., 196^ -0 and p-aminosal-- 
icylic acid derivatives (Kakemi^ et.al., 1967b) . Recently however a 
parabolic relationship between absorption -rate constant and. partition , . 
coefficient has been demonstrated for the'homologous .series of alkyl 
carbamatss (Houston, et.al., 197^ and-1975). T h i s  has been explained in 
terms of a two compartment system in which a hydrophilic barrier in 
addition to-a lipoid membrane determines the rate of absorption.
The work reported here was initiated in order to study certain 
aspects of this parabolic relationship in greater detail, using four 
radiolabelled carbamates (ethyl, n-butyl, n-hexyl and n-octyl carbamate).
In the original studies, because of poor GC sensitivity, a solubilising 
agent (Tween 80) was necessary to produce solutions of the higher 
carbamate homologues in detectable concentrations. This solubilising agent 
was found not to significantly affect the absorption rates of the lower 
carbamate homologues. The greater sensitivity of detection-afforded by 
these radioactive compounds enabled the study to be repeated at a 
concentration far below the aqueous solubility limits of the higher 
carbamate homologues and avoided the use of solubilising agents. It was 
also thought desirable to investigate the effect of using starved rats as 
apposed to fed rats used in the original studies since the bulk of preceeding 
investigations have reported the use of animals starved between 8 and 
20 hours before an experiment.
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In order to provide a. "baseline” for comparison with the results 
found in the original study, the absorption rates of four non-radiolabelled 
carbamates (ethyl, n-butyl, n-hexyl and n-octyl carbamate) were determined .
using the same procedure as that reported by Houston et.al., (197*0 hut
1I4. ■' .
including C-polyethylene glycol as a. non-absorbable indicator of wauer
loss. All carbamates exhibited monoexponential loss from the small
intestine lumen. Rate constants (ka) were calculated from the half-lives
(tg) of disappearance using the equation.,. -
ka ■» In2 y
1*2....
(Doluisiois et. al. , 1969). ""No hydrolysis or" other metabolites vere detected 
during the gas chromatographic assay although the methods used would have 
been expected to detect them. The rate, constants obtained are shown in 
Table -U.1 together with the amount found'bound to/within the intestinal : 
membrane (see Chapter 2, section E), and the equivalent rate constants 
obtained in the original study. No significant difference was found 
between the rate constants obtained .in the present study and those reported 
originally. -
Fig *+.1 indicates how well the results found in this study fit with 
the following parabolic equation derived by Houston, et.al. , (1975)5
logka = -0.0899 logP2 + 0.103 logP - 0.833 (H.l)
n = 10 ----- • r - 0.973 - s = 0 .126 . /
where? is the octanol/buffer partition coefficient, n is the number of 
data points, r is the correlation coefficient and s is the standard 
deviation. Carbamate binding to the intestinal membrane was found to be 
negligible, a finding also reported in the original investigation.
Because of solubility and detection problems i^ was found necessary 
to use a solubilising agent (Tween 80) for n — heptyl and n-octyl carbamate 
.in the initial study. To investigate the possibility that the parabola was 
a reflect, Lon of the decreasing aqueous solubility of the carbamates as ■ 
the series was ascended, the absorption rates of the four radiolabelled ; : 
compounds were determined at a concentration of 0.1 mM. This was well , 
below the aqueous solubility limits of the higher carbamate homologues 
and there was no requirement for a solubilising agent. The absorption rate
' 7 . ■
constants obtained using these four radiolabelled compounds are listed in ' 
Table k .2 . They were found not to be significantly different to those found 
previously. At such low concentrations carbamate adsorption on to
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intestinal membranes may become signiiicant. .however the amounts round 
were very small and are shown in Table i+.2. The absorption rate constants 
determined using the lower ’concentration, are shown fitted with equation 
U.l in Fig k / 2 . ... . . _ ..; . .
. Fed rats were used in the original investigation.. (although a washed- 
out intestinal segment was used), whereas almost all previously reported 
in situ small intestinal studies had used, rats s-tarve.d for 8-20 hours in 
an attempt to "clear the small 'intestine^of food"particles. " In order to 
discover what influence starvation would have on the absorption rate of 
the four radiolabelled carbamates, their absorption-rates were determined 
using rats starved between 16 and 20, hours, but with access to water. The 
results found are shown in Table U.3. Although-standard deviations were 
slightly greater than ..those previously found, *the absorption rate constants 
were not significantly different to those found in the studies -using fed . 
rats. Also included in Table lf.3 are the amounts, of carbamate found within 
the intestinal membrane at the termination-of experiments, which, as 
previously found, were negligible.
It: should be. noted here that very different absorption plots were 
obtained if only minimal mixing of the lumen contents was allowed. Fig -^.3 ■ 
shows a. typical plot of apparent carbamate disappearance from the lumen, with 
sampling only from a small volume of the total lumen contents from the distal 
end of the intestine, after introduction of the carbamate solution into the 
.proximal end. The initial rapid apparent loss of carbamate was . shown to be 
due to two factors; firstly to the actual absorption of carbamate from 
the lumen and secondly to a large dilution of the distal lumen contents by 
buffer- residing in the lumen prior to actual intro'duction- of carbamate 
solution. The existence of this second factor was confirmed in control 
experiments using solutions of the water-loss monitor alone. These 
experiments showed:that , ;after one minute, whereas the concentration of this 
indicator at the proximal end was • less than 2% lower than the original 
concentration, the concentration measured at the distal and vTas up to 30$ 
less.than initially. Furthermore, if only small-samples of the lumenal 
contents (about 2 ml) were gently removed for sampling at the distal end, 
the concentration of the water-loss monitor at this end changed less than 
5% from the value at one minute;, during the remainder of the experiment.
From these findings it was concluded that the linear phase shown -in Fig U.3. 
represented the true absorption of carbamate from the lumen under these 
conditions of minimal mixing. - I
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The absorption rate constants obtained using this method were very 
different to those ..obtained, from previous experiments and it was thus decided -• 
to investigate this phenomenon further with all four-radiolabelled 
carbamates. The rate constants obtained are listed in Table and. plotted 
against partition coefficient in.Fig b.k. Whereas the first minute dilution 
varied greatly in these experiments, the rate constants obtained for a given 
carbamate were in very good agreement. As noted in previous experiments the 
amount of .carbamate bound to.the small intestine was negligible (less 
than 3%)k The logarithmic relationship between absorption rate constant 
and partition coefficient was found to be linear and contrasts markedly with 
the data shown in Figs ^.1 and U.2. y .
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The parabolic relationship between log ka-and log P has been investigated 
using very low carbamate concentrations and also starved rats. In each case 
the results obtained fitted well with the original regression line for the 
parabola. A comparison.of the. studies using high and low initial - carbamate 
concentrations - showed no significant difference in the absorption rate 
constants. This indicates that the carbamates, used in the higher concentra­
tion experiment were in true solution and that no precipitation of the 
higher homologues had occurred. Obviously had precipitation occurred then.... 
dissolution may have become rate limiting, resulting in such a parabolic 
relationship as was found. That was not the case that has been confirmed in 
the present study, using an initial carbamate concentration between 50 and 
100 times lower than that in the first study, a level at which no danger of 
precipitation exists.
This study has also demonstrated that at a concentration of 3% v/v 
(well above the critical micelle concentration) the addiition of Tween 80, 
a nonionic detergent,- had no apparent effect on the absorption rate of n- 
octyl carbamate* Several workers have dealt with the effects of surfactants - 
on drug absorption (see Gibaldi and Feldman, 1970), although many of the . 
observations reported in their.-studies -appear contradictory. The .results 
presented in our study are in contrast to those of Yamada and Yamamoto ,
(1965), who found 3% Tween 80 to markedly decrease drug absorption, but support 
those of Hikal, ets.al.-j (1976) who reported 2% Tween 80 to have no effect 
upon salicylic acid absorption. The differences observed may result from 
the stability of the Tween 80 micelles formed in each case in the environment 
of the’small intestine. ■ -
Starvation of the rats for 16 to 20 hours before an experiment had.no 
significant effect.on the absorption rate of the four radiolabelled, 
carbamates (Table U.l cf Table ^.3). This finding is in agreement with those 
of Diamond, et,al., (1970) who found, significant decreases in intestinal 
absorption rates only in rats starved in excess of 2b hours. Reduced 
absorption rates after prolonged fasting are thought to be caused by 
inhibition of intestinal cell proliferation (Orr and Benet, 1975) and reduced 
mesenteric blood flow (CrOuthamel, et.al.,..1975). In view of these 
previously reported findings it seems, unlikely that the linear correlations 
between log ka and log P found by others workers are the result of this . 
method of pre-treatment of their animals. .
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. The markedly different absorption profile obtained from the minimally 
mixed distal small intestine may.in part be due to a larger or more stable 
"unstirred layer" of solution that might exist at the membrane surface in 
the poorly mixed system. However, such an unstirred layer would retard 
the diffusion of ;the larger carbamate molecules from the bulk solution to 
the membrane-surface and decrease their absorption rate-, whereas these 
carbamates were found to be more rapdily absorbed in the .minimally mixed 
preparations than in the well mixed normal sampling preparations. . Thus it 
is unlikely that alterations in the unstirred layer were responsible for 
the absorption differences found. *
J .  ' ' * ' ■
The permeability characteristics of the intestinal membranes adjacent 
to the distal cannula may have changed because of the trauma of insertion 
of the cannula inside the lumen. Since such^permeability changes would . 
probably be confined to a small section of intestine near the damaged area, 
these effects would not be detected when the total intestinal contents 
were sampled. When,, as in the minimally mixed situation, sampling of only ' 
about 20$.of the lumen contents close to the damaged area was carried.out, 
such permeability changes may well be- detected and he responsible for the 
absorption differences noted. .
The results obtained from the distal small intestine may be indicative 
of differences in membrane permability characteristics occurring along the 
length of the small intestine. Very- little‘ work has been carried out-on 
this aspect of intestinal absorption. The parabolic .relationship may be a 
feature of the more proximal regions of the small intestine whereas the linear 
relationship may assume importance towards the distal end of the intestine0 
Further -experiments may show whether the absorption rates of the carbamates 
do, in fact, differ in different sections of the small intestine.
If the parabolic dependancy of log ka upon'log P is a fundamental 
relationship,* it is perhaps not. surprising that it has not been demonstrated 
before since almost all previous investigations of this nature have used' 
series of compounds differing -diversely in their substitutent groups. Only 
when subst.ibufcents vary slightly and regularly and cover a wide range of 
.partition• -coefficients, as in the carbamate studies, will such a parabola ' 
become evident and not be "buried" in an overall linear relationship. Studies 
prior to. those of Houston, et.alo ,■ (197^; 1975) using closely related 
compounds are rare but the findings of Kakemi, et.al., (1967) may serve as 
an example.
The Kakemi study reported a linear relationship between the intestinal 
absorption rate of a series of barbiturates and their partition coefficients,
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in which data from oxy- and thio-barbiturates were pooled in the regression 
analysis* We have reanalysed this data -using partition coefficients in the 
octanol system, for ease of comparison, instead of the original carbon 
tetrachloride 'system and this revealed a similar linear relationship for -
the pooled data* However linear regression anal&ysis of oxy-barbiturate series 
alone showed the relationship not to be significant, whilst non-linear 
regession analaysis showed that the parabolic relationship shown in Fig -^<>5 
was^ significant (p<0eQ5). Unfortunately the original reports (Kakemi,
et*al09 1967a and c) do not provide full information on the partition
v
coefficients used in their regression analysis6 , The log P.(octanol) value 
were thus obtained using the data of Martin and Hackbarth (1976) • It is 
interesting to note that the optimal partition coefficient for the oxy- 
barbiturate series of about 35 is the same as. that reported for a series 
of fenethylated.carbamates {Houston Vet,al*, 1975)*
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log P (OCTANOL BUFFER)
PARABOLIC DEPENDANCY OF ABSORPTION RATE 
CONSTANT UPON PARTITION C O EFFIC IEN T FOR A 
SERIES OF O X Y -B A R B IT U R A T E S
(FROM K A KE M Let g l 1967 )
Table 4.1
Absorption rate constants from rat small intestine of four 
non-radio.labe3J.ed carbamates .
originally 
reported rate 
constants*
carbamate 
(concentration 
y mol/ml)-
rate constants 
obtained in 
this study
1 % carbamate 
bound to 
intestinal membrane 
after 30 mins
0.132 + 
0.005
ethyl
(10)
■0.129 '± 
0.019 0 .6 2 + 0.33
0.175 + 
0.007
n-butyl
(10)
■0.175 +
0.020 0.94 + 0.47/
0.099 + 
O.OOU
nyhexyl
(5)
0.093+
0.007
0.38 + 0 .2 6
0.058 +- 
0.002
i
n-octyl
(10)#*
0.054 + 
0.003 1.36 + 0.65
— i
mean + sd for four animals. .
determined in 0.1M citrate-phosphate buffer, pH*6 .
* From Houston, et,alCT, (1974), mean of five animals + Sp 
** 5$ Tween 80 used.
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Absorption rate constants of four■radiolabelbed carbamates
at a concentration of O.lmM-
Carbamate absorption rate 
constant (min
..... ------------ - ----
% carbamate
bound to
intestinal membrane
Ethyl
0 . 1 3 0  +  
0 o 0 1 3
i;2 2  4- 0 . 6 0
n-butyl
0 . 1 _ 8 6  +  
O o O l l
"  0 . 6 1 + 0 . 3 2
n-hexyl
0 . 0 9 7  +  
0 . 0 0 9
_  1 . 1 ^  ±  0 . 3 3
n-octyl
0 . 0 9 2  +  
0 . 0 0 2
l e 06 ±  0 t hk
mean + SD for four animals.
determined' at pH 6 in 0*lM citrate-phosphate buffer
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Absorption rate constants of four radiolabelled 
carbamates in 20 hour starved rats
Carbamate
(concentration
ymol/ml)
absorption rate 
' * ' constant 
(min
% bound to 
membrane
ethyl 0.1^0'+ v
(o.x) 0.021 S
* O.Ul + 0.17
n-butyl ' 0.182 + -
(0.1) 0 .0 2 k  '  . 0.89 + 0.32
n-hexyl* 0.101 +
(0.1) 0.011 1/38 + 0.73
n-octyl- 0.055 +
(0.1)
•
OiOOU
1
1.72 ±  0.52
mean _+' 3D using U animals.
determined at pH 6 using 0.1M citrate-pbosphate buffer
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Table h.k
. a
Absorption .rate, constarts forfour radiolabelled - carbamates .. .
from a poorly- mixed, distal small intestine in situ prepartion
carbamate
absorption ' 
ra/fce constant 
'(min-1) \
mean absorption ■ 
half life 
(min)
ethyl
0.01+31 + 
0,0015
16 .1
n-butyl
0"o055T i  
0o0027
1 2.:5 •..
n-hexyl
O.O876 + 
0.0056 v V  - 7.9 ;■ /
n-octyl
0.106 + 
0.006 . ■ 6 .5• I-
3# •inibial concentration O.lmM
»
Results are means of 3 animals + SD
Determined at pH 6 using 0.1M citrate-phosphate buffer
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sCHAPTER FIVE
COLONIC ABSORPTION OF CARBAMATES
The prime function ofv,the colon is the conservation of salt and
water and the. most important property, of the epithelkiim which allows
this is its ability to absorb sodium actively from bhe lumen (Cummings,
1975; Edmonds and Pilcher,- 1972). Curran and Macintosh (19&2) and 
Curran and Soloman (1957) have proposed that water transport by the 
intestine is a passive process resulting from active solute transport and in 
this respect colonic cells appear to offer less resistance to water diffusion 
than do the cells of the small intestine.(Fordtran and Dietsehy, ,19.66).
Under normal physiological conditions the colon will not play a major 
role in the absorption of body nutrients. A possible majpr exception to - 
the above may be the colonicjabsorption of Vitamin K compounds of 
bacterial origin (Hollander, Ct.al.,.1976). However the capability of 
the colon to passively absorb..sugars (Heaton, 1972), amino acids' (Binder,
1970), fatty acids (Pihl, etvalo_, 1966) and foreign compounds (Schanker,
1959) has been demonstrated. • . ■.
* The colon may serve as an absorption site for drugs that ar.e so
. slowly absorbed that a significant fraction of the dose is able to bypass 
the stomach and small intestine, or for drugs administered in a slow 
release dosage form (such as enteric coated-or sustained release types) .
It is generally believed though that if a drug is not absorbed.from the 
upper gastrointestinal tract, incomplete absorption is inevitable,
(Blanchard, 1975). Drugs administered via the rectum are absorbed to 
some degree from the colon but more, rapidly and efficiently when the drugs 
are administered in solution form (micro-enemas) rather than in suppository 
form (Wagner, 1971)•
Previous studies using this series of carbamates (Houston, et.alo,
197*0 have shown' differences in absorption profiles between the stomach 
and small intestine* In view of this, and because no. systematic study of 
colonic foreign compound absorption has been reported, it was decided to 
carry out the work .reported here to provide-a clearer picture of the 
factors governing absorption along the length of the gastrointestinal tract; 
and to indicate which membrane (if any) the colon most closely reserables :
as a barrier to absorption.
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The in situ preparation of Doluisio et,al», (2969) has oeen used 
to determine the co3.onic absorption rate constants for eleven carbamates * 
The disappearance rate of each of these compounds from the Colon lumen . 
was found to'be monoexponential* Fig 5*1 shows typical semi-logarithmic 
plots of the percentage remaining in the colon lumen with time,' Absorption 
rate constants were calculated from the half-lives - of disappearance, and 
are listed in Table -"5*lv No evidence of metabolism of the -carbamates was 
indicated by GLG. v- . *
The absorption rate constants showed a progressive increase as the 
series was ascended from methyl to n-octyl carbamate, as shown in Fig 5«2* 
Although the branched-chain carbamates were, absorbed, at a slower rate than
. .  s .  ,
their straight-chain analogues, this decrease was consistent with their ■ 
lower partition coefficients. The best line of fit was calculated by 
the- method of- least squares and yielded the following equation, -
log ka = 0,C76llog P - 1„29T 
n = .11' r = 0,956 s = 0„2^3
Where. ka is the absorption rate constant and P is th.e octanol/ 
buffer partition coefficiente' '
It -was found necessary to decrease the concentration of carbamate 
used for the higher homologues so as not to exceed their solubility limits* 
To investigate the possibility that the absorption .rate may be dependant^ 
on concentration, studies using n-propyl carbamate as a representative 
homologue were carried out over a concentration range from Q.5mM to 
50mM; The results shown in Table 5.2 indicate that no significant 
alteration, of rate constant was found over this concentration range.
The possibility that carbamate disappearance from the lumen being • 
monitored was not in fact true absorption but a membrane storage
phenomenon was investigated by-following the distribution into the colon
l^ fmembrane of four C~labelled carbamates. The amounts found bound to/ 
within the colon membrane and mucous after twenty minutes, snown in Table . 
5.3, were small and showed no distinct trend throughout, the series0
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COLONIC ABSORPTION OF ALIPHATIC CARBAMATES
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Fig. 5.2
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In order to find out -whether water flux from the colon lumen mio 
the blood was increasing the rate of absorption of this , series of 
compounds, especially of the lower homologues through any pores present 
in the colon membrane, absorption from solutions producing differing 
rates of water flux was examined. Since sodium .ion absorption is a 
prerequisite for water absorption, water flux was reduced using an 
isotonic mannitol solution and increased using hypotonic buffer*. The 
results obtained-are summarised in Table 5*^ and show that the percentage 
of water absorbed from the perfusate after, 20 minutes ranged from 
0,5 to 30c75%« No apparent effect of concurrent water - absorption upon 
the absorption of methyl, ethyl and n-octyl carbamate was found,
.Further investigation on the effect of water flux on absorption 
was carried out by following'"the absorption 6f ^C-labelled erythritol. 
Erythritol was chosen for this study because it has- been shown to be 
absorbed through pores in the small intestine and because this four- 
carbon. polyhydric alcohol has similar molecular dimensions to the Mower 
carbamate homologues. - The absorption rate constants of erythritol under 
varying, conditions of water flux are included in Table 5*5 and show that 
this alcohol was not significantly absorbed under any of the conditions 
studied.- -
Figure 5.3 shows the observed colonic absorption rates fitted with 
Equation 5*1 together with the previously discussed (Chapter h) gastric 
and small intestinal rate constants for the aliphatic carbamate series. 
The linear dependence, of carbamate absorption from the colon upon 
partition coefficient Is similar to the relationship .found in the stomach 
and is quite different to that found in the small intestine.
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GASTROINTESTINAL ABSORPTION PROFILES
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The results presented .here•suggest that- the carbamates studied are 
absorbed from, the colon by the mechanism of passive diffusion. The 
studies with n-propyl carbamate showed that no significant alteration in 
the rate constant was exhibited .over a 100-fold concentration range»
This indicates that, the absorptive process was indeed a passive phenomenon :
dependant upon the concentration gradient'between the colon lumen and the 
blood stream arid -that no saturable process was involved, This conclusion 
is further endorsed by the finding of only, small: amounts of carbamate in 
the colon membrane at the termination of an experiment. The very small 
amounts found confirm that the measurement of rate of disappearance from 
the lumen does reflect absorption through the membrane and that the rate 
constants obtained were true absorption rate constants.
Water absorption in the rat in situ gut preparation is known to be 
-a problem when studies are extended well in excess of thirty minutes •
(Pelzmann and Havemeyer, 1972), and although this can be corrected,for,
.as in the present .study, - by means of a no n-ab sorb able monitor, the possibility 
exists that solvent drag through aqueous-filled pores mayenhance 
absorption rate.
The ,w:ater , flux rates reported in this study are ~in good agreement 
with those reported by. Kitazawa, et.al., (197^) who stated that the small 
intestinal absorption rate of a. number of drugs,.including sulphanilaraide 
and metoclopramide, was enhanced by increasing concurrent water absorption
and decreased by influx of water into the gut lumens A  study-including
the same two .drugs (inui, .et.al., 197^) demonstrated that in the presence 
of short-chain fatty-acids the rate of absorption from rat small intestine 
of these and-other-compounds was increased. It was suggested that an. 
enhancement in water absorption rate also produced by the fatty-acids was'-, 
the cause. In contrast, differences in sulphaethidole absorption from, isotoni 
and hypotonic solutions were found to be accounted for by correcting the 
rate constants for volume and relative available surface area (Kajina,■et.al,, 
1972). ' '
The results of Kitazawa, et.al0, (197^) and Inui, ' et .al., (197^)* 
obtained using the in situ rat small intestine, would seem explicable in 
terms of solvent drag through membrane pores and are in conflict with the 
results obtained in this colon study. The carbamate absorption rate was 
found to proceed quite independently of even rapid rates of water flux0
fA.  ^  ^ ^
This indicates a major difference "te.the size or distribution of pores 
between the rattfi small intestine and colon membranes. \
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Evidence that a gradient or pore raaius may exist; aiong m e  
intestinal tract has been furnished by Fordtran and Ingelfinger (1968), 
who reported the effective pore radius of the jejunum to be twice that of 
the ileum as measured by erythritol absorption. Hollander and Truscotte 
(197^ a and b) confirm the rapid transport of erythritol from the rat small 
intestine^but found no “detectable-absorption from an in'Vitro rat colon 
preparation. -
The results presented here show that not only was erythritol 
absorption negligible-but also that increased rates of water absorption 
produced no change in erythritol absorption rate, From these 'results it 
is suggested that if the rat colon membrane contains pores then their effect- • 
ive radius must be small relative to the small intestine. It can thus be 
concluded that concurrent water absorption plays little or 1I0 part in the 
absorption of the aliphatic .carbamates from the colon.
In comparing the colon data with that from the stomach and small 
Intestine (Fig 5o3) several differences are apparent. The parabolic f ' 
relationship between log ka and log P found to be operative in the small 
intestine is not found in the colon and in this respect the linear relation­
ship shown in the colon-.is similar to that found in the .stomach. The 
•branched- chain carbamate homologues fit the linear- regression line very 1
well in the colon, as In the stomach, again a different finding to that 
in the small intestine where the branched chain homologues were absorbed 
at a much slower-rate than would be predicted from .their partitioning 
properties. These findings- are indicative that the structure and composition 
of . the colon and stomach membranes are similar, ~and“their "behaviour * 
regarding the bulky branched-chain homologues may be the results of the 
absence of pores, whereas pores may be present in the small Intestine.
A comparison of the intercepts of the regression lines shown. In 
Fig 5.3, taken at log P — 0 provides information regarding-the comparative . 
rates of absorption fromithe three organs. The values of the first order 
rate constants at this Intercept are shown in Table 5<>6, together with 
the comparative magnitude of absorption rate.relative to the.stomach. Although 
it Is-most--likely that the large differences In magnitude of absorption are 
due to physiological differences apparent along the gastrointestinal tract, 
it Is difficult to establish any one factor which is most important. It 
is more likely that several factors are involved;: these may include blood
supply and surface area differences along the gastrointestinal tract. The • 
relevance of these factors on carbamate absorption from the gastrointestinal 
tract will be discussed in Chapter 7- "
Table 5.1
Hate constants for colonic absorption of carbamates
Carbamate 
(cone, ymol/ml)
absorption rate 
• constant 
(min ^) •
methyl
■ (10) O.QbkZ ( ±  0.0020)
ethyl
"(10)” 0.0528 (+-0 .0028}.
propyl
(5)
0.0508 (+ 0 .002*+)
n-butyl
(5) 0.0 57**- (+ 0.0028
n-pentyl
.(5) •
0 .062U...(+ 0 .0052)
n-hexyl -
(2) 0.0707 (.1 0.0019)
n-heptyl
(1 ) 0,077*1 (± 0.00*+3)
n-octyl
(0 .2 ) 0 ,08*11 (+ 0 .0632)
tert-butyl
(5)
0.0559 ( + 0 .0016)
terf-pentyl
(5)
0 .0611* ( + 0 .0018)
tert-hexyl
(5)
0.0629 (+ 0 .0030)
Results are the means of H animals + SD
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T a b le  J.'d
In situ rate constants for the absorption of 
n-propyl carbamte'at varying concentrations
concentration of 
n~propyl carbamate 
(ymol/ml). •
! absorption rate 
constant 
(mill
\
50 O . O ^  (+ 0,0019)
10 0 .050if (+ 0.0022)
5 \ 0.0508 (+ 0.0021+ )a
1 0.0^91 (+ 0.0011) . .
0.5 0.0517.(+ 0 .0031) . . 
__ ________ _
.Results are means of 2 animals j+ range. 
Results are means of V animals + SD
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. . .  J 4 .Distribution of C-labelled carbamate m  the
colon after 20 minutes perfusion
% of
. " --- -
total found m  // ]
carbamate
.
washing
-
mucous membrane
ethyl 2.1*5 ±  0„25 <0.1 Oo,65 ±  0.13
n-butyl 2082 ± 0,53 <0.1
1 ■
0*89+0.03
_ . . .......
n-hexyl. . 1„71±0.59 <0.1/ . .0.77 ±  0.08.
n-octyl... 1.99 ±  0.16 . <0.1/. . . 2.10 ±  0.22.
/
Results are means-of 2 animals + range
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Table 5« 5
Effect of -change in rate of water
■ . . 0 .  absorption on erythritol rate constant
. perfusion 
solution .
- ierythritol
\
rate constant 
(min *~) 100- x ka
% water 
absorption after 
20 min
isotonic ' 0.25 6.25
Krebs buffer (+ 0 .0 2) (+1.99)
isotonic 0 ,2 6 - 0 .50b
mannitol (+ 0 .02) (+1.29)
isotonic Krebs: ' 0 .2 h if. 50
isotonic mannitol ( ± 0 . 0 3 ) ; . (+ 1.C0) .
isotonic Krebs: 0 .2 6 30.75
- distilled water ( ± 0 .0 2) .<1 7.13)-
T
mean + SD for k animals. 
erythritol concentration lOmM
Id negative value indicates net water influx into the 
colon lumen - :-----:-- -----
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Table 5> 6
organ
intercept* at • 
log P — 0 
ka(min ~)
.. „ L
magnitude of
absorption rate ■ - •
■ relative to stomach .
stomach 0.0059 -  ■ .1 ' , . .
small . . 
intestine 0.138 * 23 
> / .
colon [ 0.0505  
— —  -
. :8.5....
* extracted from the folloving equations:
stomach; log ka ■■= 0.l8l log P -- 2,228
small intestine; log. ka = 0.126"log P - 0*858
(postive slope) '
colon; log ka = 0.076 log P - 1.297
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CHAPTER SIX
PHARMACOKINETIC PROFILES FOR FOUR 
RADIOLABELLED CARBAMATE HOMOLOGUES
—  Introduction
Much useful information can he derived from a kinetic analysis of 
the levels of drugs in the hody. The biological half-life, the apparent 
volumes of distribution and the rates of metabolic and urinary clearance 
can be calculated from plasma and urine data. Ultimately these parameters 
may be useful in determining correct dosage regimens, avoiding adverse 
drug reactions, evaluating drug efficacy and comparing drugs of the same 
therapeutic class with respect to their time course of their retention in 
the body.
In a review of the effect of molecular modification of antibiotics 
on pharmacokinetics, Notari (1973) concluded that the pharmacokinetic 
parameters of these compounds could be modified by rather subtle structural 
changes which would influence biological response and be of critical 
importance in drug design.
Kinetic experiments in the dog with three structurally related 
bicyclic antidepressant compounds (Overo, 1973) indicated a relationship 
between chemical structure and the pharmacokinetic parameters reflecting 
the distribution and elimination characteristics of the drugs. It was 
found that a compound utilising an additional metabolic pathway produced 
the lowest drug levels and the most rapid elimination, whereas the _ 
compounds lacking this pathway had much slower elimination kinetics.
Overofs study also indicated a relationship between increased lipophilicity 
and increased localisation in the peripheral compartment, although the 
importance of other factors such as tissue binding was also indicated.
A study by Amin and Nagwekar (197*0 used mandelic acid analogues as 
model anionic compounds to investigate the effects of slight chemical . 
modifications on their distribution pharmacokinetic parameters. These 
anions are unusual in that they are neither metabolised nor reabsorbed 
from the renal tubules of rats and are negligibly bound to plasma proteins. 
Evaluation of the appropriate parameters suggested that the peripheral 
compartment for these compounds consisted of moderately perfused tissues 
and that transmembrane transport between the central and peripheral 
compartments occurred mainly by diffusion through aqueous membrane pores.
Although there have been many reports in which the effects of 
different'single substituent groups on pharmacokinetic parameters have 
been studied, it appears that no such study has been carried out using an 
homologous series of compounds covering a wide range of partition
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coefficient. The work presented here was therefore undertaken in an 
attempt to elucidate the role of lipophilicity in the pharmacokinetics 
of four radiolabelled aliphatic carbamate homologues in the rat.
RESULTS
Plasma concentration curves
Plasma levels of parent carbamate were determined at various times 
after administration of ^ C —labelled doses (5 pmole/kg) of ethyl, n-butyl, 
n-hexyl or n-octyl carbamate to male rats. Data from each animal, was 
analysed separately. Figures 6.1 to 6.^ show the plasma concentration 
time curves of parent carbamate after intravenous administration. Also 
'Shown are the levels of total radiolabelled plasma metabolites as determined 
by thin layer chromatography. No plasma metabolites were detected for 
ethyl carbamate but for the other three carbamates at least two polar 
metabolites (with smaller Rf*s than the parent carbamate) were detected.
The Rffs of these metabolites and their relative proportions are shown in 
Table 6.1. The plasma levels of both parent carbamate and total radio­
labelled metabolites at various times following intravenous administration 
are listed in tables 6.7 to 6.10. Following rapid intravenous injection 
into the femoral vein all four carbamates showed a biexponential decline 
in plasma concentration with time (Figs 6.1 to 6.U). All curves obtained 
for this route could be described by the following biexponential equation,
_ . -at , _ -3t
Cp = Ae + Be .. ^
the parameters for which are shown in Table 6.2.
The first order rate constants for the distribution of the carbamates 
between the central and tissue compartments (k.^ an& ) and for 
elimination from the central compartment (k^)' are shown in Table 6.3.
For ethyl, n-hexyl and n-octyl carbamate k ^ is the smallest of these three 
rate constants and thus for these carbamates elimination was rate limiting 
the carbamates levels in the body. For n-butyl carbamate k and k ^  were 
similar and thus for this compound both distribution and elimination were 
rate limiting.
Shown in Table 6.3 is the parameter Fc (fraction of carbamate in the 
central compartment in the post-distribution phase) which illustrates 
the greater importance of the tissue compartment in the disposition of n- 
butyl (Fc = 0.36) and n-hexyl carbamates (Fc = 0.35)- as compared: to
ethyl and n-octyl carbamates (Fc = O.U5) Furthermore, n-butyl and n-hexyl
4 . . .
carbamtes have the largest total volumes of distribution both at steady
state (Vd ) and at pseudoequilibrium after the achievement of the steady ss
state condition.
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After intraduodenal administration, the appearance of parent 
carbamate in the systemic circulation is rapid for all four carbamates 
(Figs 6.5 to 6.8). After reaching a maximum the plasma levels of parent 
carbamate show a distinct distributive phase before the terminal phase 
becomes apparent. Table G.b shows the pharmacokinetic parameters obtained 
from these curves. Figures 6 .6 to 6 .8 also show the plasma levels of total 
radiolabelled metabolites as determined by thin layer chromatography. No 
plasma metabolites were detected in the case of ethyl carbamate. The 
plasma levels of parent carbamate and total radiolabelled metabolites 
at various times after intraduodenal administration are listed in Tables 
6.7 to 6.10.
The areas under the curves for ethyl carbamate were similar for 
both intraduodenal and intravenous routes, however for n-butyl, n-hexyl 
and n-octyl carbamates the areas under the plasma concentration-time 
curves (AUC). between time zero and infinity for the intraduodenal route 
were lower than those obtained for intravenous administration. The ratio 
of AUC for the intraduodenal and intravenous route (9) shows that only 
8l% of the n-butyl, 80$ of the n-hexyl and k*j>% of the n-octyl carbamate 
doses reached the monitoring site intact (see Tables 6.2 and 6.3).
Metabolism studies -
The fate of radioactivity labelled doses of the four carbamates in 
male rats twenty four hours after intravenous or oral administration is shown 
in Table 6.5. Negligible amounts of radioactivity (less than 1$ of dose) 
were found in the faeces and total recovery of the dose from expired air 
and urine was between 90.8 and 97.1$. The accumulative amounts of radio­
activity excreted as CO^ for the four carbamates are shown in Figures 6 .9  
to 6.12 and listed in Tables 6.11 to 6.lU. For each carbamate a greater 
percentage of the dose was recovered in expired air in 2b hours following 
intravenous dosing than following oral administration. Conversely, for 
each carbamate the total amount of radioactivity recovered in urine after 
2b hours was greater following oral administration than following 
intravenous administration.
The rate constant for elimination of carbamate from the central 
compartment obtained from the plasma level data represents the sum of the
rate constants for metabolism (k ) and excretion of parent carbamate (k ),m *  ex 5
i.e. k = k + k . However, thin layer chromatography of the urine6J. 311 6X
showed that less than 5 l of the total urinary radioactivity was associated
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Fig.6.8
with parent carbamate and thus in this study k was considered 
insignificant. . The k may he subdivided into two rate constants, k ^  
and kmp , the former being the rate constant for hydrolysis of the 
carbamate, giving rise to labelled carbon dioxide, and the latter giving 
rise to a hypothetical metabolite group which is excreted in the urine
ill
with an intact carbamate group (therefore retaining the C label). Such 
a scheme is outlined in the following model,
ll+
C labelled carbamate
hydrolysis / k _ ml
lh .  .  .C carbamate metabolites m  urine
Table 6. ^  shows the values for k _ and k ~ obtained for the four
ml md
carbamates following intravenous administration.
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Fig.6.12
The pharmacokinetic disposition and overall metabolic fate of four 
radiolabelled aliphatic carbamates following different routes of 
administration has been studied in the male rat . On the basis of the 
plasma concentration-time curves following intravenous administration, 
the fate of all four carbamates could be described by a biexponential 
equation which is usually interpreted in terms of a two compartment open 
pharmacokinetic model consisting of a well perfused central compartment 
and a slowly perfused peripheral or tissue compartment. A diagramatic 
representation of this model is shown below,
i.v. central ^12 peripheral
dose — > compartment compartment
k21
elimination
However examination of both the plasma level and CO^ production 
plots for ethyl carbamate indicated that the usual two compartment open 
model may not be appropriate to describe the behaviour of this carbamate. 
Between the first and third hour after an intravenous dose approximately 
of the dose was metabolised to CO^, whereas during the same time 
period the plasma levels of ethyl carbamate remained virtually constant.
If the above model is correct for ethyl carbamate then the plasma levels 
would be expected to fall very markedly during this period as this large 
proportion of the dose was eliminated from the body.
Skipper etal,(1951) in a study on the fate of carbon-labelled 
sodium bicarbonate, showed that carbon dioxide released into the blood­
stream is almost instantaneously excreted into the expired air. It can 
therefore be concluded that the times shown on the carbon dioxide 
expiration plots coincide very closely with the times on the plasma level 
plots for the parent carbamate and that the carbon dioxide expired during 
the "plateau” in the ethyl carbamate plasma levels was not formed during 
the rapid initial decline in plasma concentration that followed the 
injection of the dose. It is also unlikely that high affinity plasma 
protein binding.was responsible for the maintained plasma levels of this 
carbamate since the work of Houston (1973) showed..that of all the
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carbamates used in the present study ethyl carbamate had the lowest 
binding affinity for bovine serum albumin*
A possible explanation for our findings for ethyl carbamate may be 
found in the work of Boy land and Nery (1965), who reported that ethyl 
carbamate is metabolised in the rat by N-hydroxylation to N-hydroxy 
ethyl carbamate and its N- and O-acetyl derivatives. Of particular 
relevance to our study is the finding of Nery (1968) that ethyl carbamate 
and N-hydroxy ethyl carbamate are interconvertible in rodents. Although 
only small amounts of the N-hydroxy ethyl carbamate are found in the urine, 
Boy land and Nery (1965) pointed out that these amounts may not be 
indicative of the extent to which N-hydroxylation actually occurs in the 
animals because small doses of N-hydroxy ethyl carbamate (equivalent to 
the dose of ethyl carbamate used in the present study) are almost completely 
metabolised.
The maintained levels of ethyl carbamate following both intravenous 
and intraduodenal dosing may thus be the result of partial metabolism of 
the dose to N-hydroxy ethyl carbamate which is then partly hydrolysed 
to carbon dioxide and partly reconverted to ethyl carbamate. These 
processes are illustrated below.
log
plasma
concentration
time
An alternative explanation of these findings is that during the 
preparation of blood samples for TLC any N-hydroxy ethyl carbamate ms  
chemically converted back to ethyl carbamate and thus was not detected. 
The addition of authentic N-hydroxy ethyl carbamate to control blood 
samples, followed by chromatography, would be of great value in future 
studies. This would determine both the stability of this compound and
/
observed
formation of ethyl 
carbamate from 
N-OH
non-metabolis ed 
ethyl carbamate
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whether it is separated from ethyl carbamate under the TLC conditions used, 
since co-chromatography of the two compounds would also explain our 
findings. Further investigation of this phenomenon beyond the three 
hours studied in the present work would show whether the plasma levels of 
ethyl carbamate decline as the formation from N-hydroxy ethyl carbamate 
ceases.
Following introduodenal administration the plasma concentration-time 
curves for all carbamates showed a distinct distributive phase before 
the linear terminal phase became apparent. The appearance of all carbamates 
in the plasma is very rapid and shows a peak at approximately five minutes. 
Such rapid absorption is entirely in agreement with the rate of absorption 
found in the in situ absorption experiments reported in Chapter 
Unfortunately insufficient blood sampling in the period immediately 
following dosing meant that specific absorption rate constants for the 
four carbamates could not be calculated according to the usual method of 
Loo and Reigelman (1968).
None of the pharmacokinetic values obtained from the analysis of the 
plasma concentration-time curves appeared to show a direct dependance upon 
the increasing lipophilicity of the carbamates from ethyl to n-octyl 
carbamate. However, in view of the uncertainty concerning the terminal;. 
phase of the ethyl carbamate plasma level curves, the pharmacokinetic 
values derived from the slope of the terminal phase may not be valid and 
should not be used in any overall assessment.
The curves for n-butyl and n-hexyl carbamates were very similar 
although the partition coefficients of these two carbamates differs by an 
order of magnitude. These findings may, in part, be explained by 
differences in the many processes, such as routes of metabolism, localisation 
in tissues and plasma protein binding, which influence the levels of 
foreign compounds in the plasma. Some of these processes may be more 
important for some carbamates than for others and would make any simple 
relationship between lipophilicity and plasma profile unlikely.
In view of the similarity of the plasma-level profiles for n-butyl 
and n-hexyl carbamate and the differences shown for n-octyl carbamate it 
is tempting to postulate the existence of a parabolic relationship between 
lipophilicity and pharmacokinetic profile. However as there is some doubt 
as to the validity of the ethyl carbamate plasma level profiles it is 
difficult on the basis of the data for only three compounds to substantiate 
such a parabolic phenomenon. Further investigation using the intermediate
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carbamate homologues not used in the present study would be needed to 
define such a relationship with confidence.
The influence of route of administration on the elimination of the 
carbamates was assessed by a comparison of AUC for the plasma concentration­
time curves (Harris and Riegelman, 1969). This method assumes that the 
parameters of distribution and elimination remain constant after 
administration of the same dose by two different routes. Except for the 
case of ethyl carbamate the areas were found not to be equal and it must 
therefore be concluded that more parent carbamate reaches the vascular 
compartment by the intravenous route than by the intraduodenal route.
Because only an insignificant percentage of the dose was recovered in the 
faeces during 2k hours this phenomenon is probably not due to incomplete 
absorption and thus the carbamates would be lost by metabolism either 
during absorption, by the intestinal muscosa, or during the first pass 
through the liver.
The metabolic studies carried out on these carbamates showed th^ -t as 
the chain length of the carbamates was increased, a decrease in metabolic 
hydrolysis took place (as indicated by the total excreted) and this
was accompanied by an increase in other metabolic conversions, the products 
of which were excreted in the urine. The increasing importance of the ;L 
non-hydrolytic route of metabolism with increasing chain length is also 
reflected in the plasma levels of the total radiolabelled metabolites.
As the series is ascended the rate of appearance of these metabolites in 
the plasma increases as does the peak plasma level attained.
Houston (1973) has investigated the interaction of this series of 
carbamates with cytochrome and found that these compounds showed an
increasing affinity of binding with increasing chain length. In view 
of this finding, the increasing urinary elimination of radiolabelled 
metabolites associated with increasing chain length found in the present 
study may represent those metabolites produced primarily as the result of 
interactions with cytochrome P^q» Such metabolism may include N-hydroxy­
lation, and oj and arl oxidations taking place on the aliphatic side- 
chain (Parke, 1968). Since ethyl carbamate has a very low binding affinity 
to cytochrome P ^ q  a^d is almost completely metabolised via hydrolysis 
it is probable that this hydrolysis is not Pj^q dependant. Thus as the 
carbamate series is ascended, this hydrolytic route would become less 
important as the carbamate affinity for P ^ q  is increased.
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It would therefore appear that the metabolic data can be explained 
in terms of two competing metabolic processes in which the lipophilic 
characteristics of the compounds determine the proportions of the carbamates 
at the two sites of metabolism. An extension of these studies using other 
carbamate homologues would show whether the relationship between the two 
metabolic pathways and lipophilicity holds for the whole series. The use 
of branched-chain and aromatic carbamates would evaluate the role of 
additional factors in this basic relationship.
TABLE 6.1
Location and relative amounts of carbamate metabolites
•  £Lusing thin-layer chromatography
Carbamate”*3
Rf
metabolite(s) 1
Rf
metabolite(s) 2
Approximate
ratio of AUC
(0-3hr)
metabolite(s) 1 
metabolite(s) 2
n-butyl origin 0.3 0 .2
n-hexyl origin 0 .2 ! ; 1
n-octyl origin 0.35 3 ■
cl
Solvent systems used and Rf’s of parent compounds are listed in 
Table 2.2.
*b
No metabolites detected by TLC for ethyl carbamate.
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TABLE 6.5
Excretion of four radiolabelled carbamates 2b hours 
after intravenous or oral administration (5 umole/kg)
Carbamate route of 
administration
% dose 
recovered as 
C°2
% dose 
recovered 
in urine
totala % 
recovery 
from CO^ 
and urine
ethyl
carbamate
intravenous .... 89.2+3.7 3.3 +1.0 92.5-
. oral. . ........ 83.6 + U . 2 . . 7.2 + 1 .8 . 90.8
n-butyl
carbamate
. intravenous .... 6 k . 2 .+ 2.8 .. 2 9 . 9 + 3 .6 9^.1..
oral. ........ 60.8 + 2 .6 . 3 b .6 +2.9. 95.1+ .
n-hexyl
carbamate
. intravenous .... .52.2 +3.1 k b .2 + 3.8 . 96.!+. .
oral ... 1+2 .6 + 2 .6 51.3+3.1. 93.9 .
n-octyl
carbamate
. intravenous ... 33.0+3.6 61+.1 + 1+.3 .. 97.1
, oral 29.1 +2.9- 66.3 +3.2. . 95.!+ ■
a Less than 1I  of any dose recovered in faeces. 
Results are the means of 3 animals + SD
TABLE 6.6
Rate constants for metabolism of four radiolabelled
carbamates following intravenous administration (5 ymole/kg)
Carbamate
... rate constant .............
kml (min_1) kfi2 (min_1)
ethyl
carbamate 0 .0 0 1 1 + 0.0002 0 .0000*1 + 0.00001
n-butyl
carbamate 0.022 + 0.001 0.010 + 0.001
n-hexyl
carbamate 0.017 + 0.001 0 .01U + 0.001
n-octyl
carbamate 0.036 + 0.001 0.070 +0.005
Results are the means of 3 animals + SD
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TABLE.6.7
Plasma levels of ethyl carbamate follo-wing either
intravenous or intraduodenal administration (5 nmole/kg)
time 
after dosing 
(min)
intravenous intraduodenal
plasma concentration 
(nmoles/ml)
plasma concentration 
(nmoles/ml)
2 11.39 ±  1*33 7.85 + 0.31
5 8.57+0.51 8.57 + 0.58
10 7.2 7 + 0 .U6 7.78 +0.33
20 6.66 j+ 0.50 6.98+0.30
1*0 6.1*3 ± 0 . k 3 ■: 6. h i +.0 .1U
6o 6.3b + 0 .1+5 6.23 + 0 .18
90 6.23 + 0.36 6 .1*1 + 0 .16
120 6.07 + 0.35 6 .0U + 0 .1 5
180 5.93 + 0 .U0 5.90 + 0 .16
Results are the means of 3 animals + SD
TABLE 6.8
Plasma levels of n-butyl carbamate and total radiolabelled
metabolites following either intravenous or intraduodenal
administration (5 ymole/kg;)
time 
after dosing 
(min)
intravenous intraduodenal
n-butyl 
carbamate 
(nmole/ml)
total
radiolabelled
metabolites
(nmole/ml)
n-butyl
carbamate
(nmole/ml)
total
radiolabelled
metabolites
(nmole/ml)
2 5.16 + 0.98 0 .5 2 + 0 .21 3.1U + 0.27 none detected
5 3.88 + O.kl 0 . 6k + 0 .27 3.37+0.26 0 .6 2 + 0 .1 6
10 3.06 + 0 .36 O .95 + O .29 2.66 + 0 .18 O.9 6 +O.I9
20 1.92 + 0.22 1.23 + 0.31 I .69 + 0 .2 1 1 .16 + 0 .23
^0 1.09 + 0.13 1.^3 + 0.22 0.80 + 0 .0 8 1.30 + 0.29
60 0.75 + 0.12 1.U5 + 0.27 0.60 + 0 .0 5 1 .2 7 + 0 .2 7
90 0 .5  ^+ 0.06 1.29 + 0.23 o.to + 0 .0 2 . 1 .19 + 0 .21
120 0.38 + 0.03 1.20+0.23 0 .32 + 0 .02 1.09+0.23
180 0.19 _+ 0.05 0.99 + 0.19 0 .17 + 0 .0 2 0.90 + 0.15
Results are the means of 3 animals _+ SD
' table 6 .9
Plasma levels of n-hexyl carbamate and total ractiolabelleti­
met abolites following either intravenous or intraduodenal 
administration (5 -umole/kg)
time 
after dosing 
(min)
intravenous intraduodenal
n-hexyl
carbamate
(nmole/ml)
total
radiolabelled
metabolites
(nmole/ml)
n-hexyl 
carbamate 
(nmole/ml)
total 
radiolabelled 
metabolites ~ 
(nmole/ml)
2 5.25 + 0.6U 1.18 + 0.2U 2.23 + 0.50 0 .52 + 0.12
■5 3.79 + 0.56 1.67 +0.36 3.2 5 + 0 .3 9 1.15 + 0.1*6
10 2.78 + 0 .26 2.13 + 0.1*1 2.1*6 ±  0.30 1.88 + 0 .32
20 I.87 + 0 .12 2.77 + 0.29 1.63 +0.30 2.33+0.39
: k0 1.20 +.0 .1 U 3.6 7 + 0 .26 0 .79 + o.ii* 2.87 + 0.36
60 0.93 + 0.17 3.78+0.21 0.53+0.05 ■3.03 +-0.26 1
9° 0.68 +0.10 3.73 + 0.31 0.39 + 0.01* 2 .96 + 0.33
120 0.51+ 0.09 3.6** + 0.28 0.28 + 0.03 2.85 + 0 .1*0
.180 0 .2 6 + 0.06 3.1*8 + 0.30 0 .17 + o.oi* 2.63 + 0.28
Results are the means of 3 animals + SD
TABLE 6.10
Plasma levels of n-octyl carbamate and total radiolabelled
metabolites following either ■ intravenous or intraduodenal
administration (5 ymole/kg)
time 
after dosing 
(min)
intravenous intraduodenal
n-octyl
carbamate
(nmole/ml)
total
radiolabelled
metabolites
(nmole/ml)
n-octyl 
carbamate 
(nmole/ml)
total 
radiolabelled 
metabolites 
(nmole/ml)
2 6.05 + 1.07 2.61* + 0 .36 0.1*7 + 0.17 0.52 + 0.23
■-■ ■ 5 ■' 3.18 + 0.3** 1*.28 + 0.1*9 1 .7  ^+ 0.22 3.11+0.72
10 2.01 + 0.28 5.35 + 0.38 1.31 + 0.22 5.00 + 0.92
20 1.16 + 0.20 5.1*6 + 0.30 0 .59 + 0 .06 5.1*7 + 0.60
b0 0.35 + 0.08 1*. 1*0 + 0 .1*0 0 .17 + 0 .02 1*.1*1* + 0.70
6o 0.15 + o.oi* 3.7 9 + 0 .32 a 3.20 + 0.1*7
90 a 3.32 + 0.1*3 a 2.51+0.33
120 a 2 .7 2 + 0 .27 _a 2 .21 + 0 .3 6
180 a 1 .86 + 0 .29 a 1.73 + 0.39
a none detected.
Results are means of 3 animals + SD
TABLE 6.11
1I4 . .
C02 excretion from ethyl carbamate following
either intravenous or oral administration (5 ymole/kg
time 
after dosing 
(hours)
intravenous oral
accumulative % dose 
excreted as CO^
accumulative % dose 
excreted as
0.5 3:2+ 0.9 1.1 + O.h
1 it.8 + 0.7 3.0 + 0.7
1.5 9.2 +1.6 6.2 + 0.8
23.2 + k .9 12.it + 2.6
2.5 36.9 + 3.2 19.7 + 3.0
3 50.6 + 3.8 2U.2 + 3.i+
3.5 59.2+3.5 30.3 + 3.1
k • 63.7 + 3.9 37.1 ±  2.7
5 69.5 + ^.1 i+7 .9 + 3.2
6 75.0 + 3.6 57.7 + 3.2
7 79.3 + 3.7 65.3 + 3.5
8 82.6 + k.O 71.8 + 3.7
12 86.1 + 3.5 78.U + 3.it
2k 89.2 +3.7 83.6 + it.2
Results are means of 3 animals + SD
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TABLE 6.12 .
CQ^ excretion from n-butyl carbamate following either
intravenous or oral administration (5 umole/kg)
time 
after dosing 
(hours)
intravenous ' oral
accumulative % dose 
excreted as CO^
accumulative % dose 
excreted as CO^
0.5 3.0 +0.5 1 .6 ±  0 .2
1 6.3 ±0.9 1+.6 ±  0.3
1 .5 16.1+ ±  1.7 7 .2 ±  0 .6
' ■ 2 ■ 26.7+1.9 13.5 ±1. 1
2.5 38.0 ± 1 .6 18.7 ±  1.1
3 1+2 .1 ± 2.0 25.1 ±  1 .6
3.5 1+6.9 ± 2 . 3 32.5 ±  1.7
1+ 51.0 ± 1 .8 36.5 ±  1.3
' 5 - ' 56.1 ±  2.2 1+5.2 ± 1 . 7
6 59.8 ±  2 .6 51.2 ±  2 .1
7 62.0 ± 2 .3 5^.8 ±  2.0
8 63.2 ± 2.2 57.0 ± 2 . 3
12 6U . 0 ±  2.5 59.2 ±  2.7
2h 61+.2 ±  2 .8 . 60.8 ± 2 .6
Results are means of 3 animals + SD
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CO^ excretion from n-hexyl carbamate following
either intravenous or oral administration (5 ymole/kg)
time intravenous oral
after dosing 
(hours) accumulative % dose excreted as CO^
accumulative % dose 
excreted as CO^ ,
0.5 2 .7 + 1 .0 1 .6  + 0.3
1 12.0 + 3 .3 8 .1 + 2 .3
22.1 + k .2 15.3 + 2.7
' 2 28.2 + 3 .9 21 .6 + 2 .7
2.5 33.8 + 2.7 25-7 + 2 .1
3 36.3 +2.3 29-1+ + 1.9
3.5 39.3 + 2.3 32.2+1.8
1+ 1+0 .8 + 2 .1+' 31+.3 + 1.9
5 1+3.7 + 2 .1 37.3+2.3
6 1+5.2 + 2 .6 39.0 + 2.5
7 1+6.6 + 2.9 1+0 .1  + 2 .1
8 1+7-1+ + 2 .6 1+0.7 + 3.0
12 1+9.5 + 2.5 1+1.9 + 2.9
2k 52.2 +3.1 1+2 .6 + 2 .6
Results are means of 3 animals + SD
TABLE 6.lU
ill
(XU excretion from n-octyl carbamate following
either intravenous or oral administration (5 ymole/kg)
time 
after dosing 
(hours)
intravenous oral
accumulative % dose 
excreted as CO^
accumulative % dose 
excreted as CO^
0.5 1 .3 + o .k 0.7 + 0.2
1 . 6.3 + 1.9 2.8 + 0.6
1.5 11.6 + 2.3 • 5*9 + 1.1
2 . ■15.8 + 2.1 8.6 + 0.7
2.5 19 .2 +1.8 11.1 + 0.9
3 22.2 +2.0 13.1 + 1.6
3.5 2U.0 +1.9 1*1.7 + 1.3 ' -
k 26.6 + 2.3 1 6 .6 _+ 1V;3
5 29-k +3.2 18 .7 + 1.9
6 30.0 + 2.7 20 .6 + 1 .5
7 30.9 + 2.7 22.5 + 1 .9
8 31.1 + 2.9 2h.k + 2 .0
12 32.3 + 2.0 27 .2 + 2 .6
2k 33.0 + 3.6 29.1+2.9
Results are means of 3 animals + SD
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CHAPTER SEVEN 
FINAL DISCUSSION
FINAL DISCUSSION
The investigations described in this thesis were carried out in an 
attempt to elucidate the role of lipophilicity in governing the kinetics 
of absorption, distribution, metabolism and excretion of selected aliphatic 
carbamates in the rat.
The carbamates used in these studies possess properties which make 
them particularly suitable model compounds for the study of the behaviour 
of foreign compounds in biological systems. The use of a homologous series 
enabled the introduction of defined incremental changes in these properties 
by increasing the chain length stepwise by one methylene group. The 
aliphatic carbamate homologues also possess the additional advantages of 
being unionised and stable in aqueous solution and of covering a wide 
range of partition coefficient. Four of the carbamates were also 
radiolabelled and this permitted greater sensitivity of detection.
The four radiolabelled carbamates (ethyl, n-butyl, n-hexyl and 
n-octyl carbamate) were used to investigate further the parabolic relation­
ship between rate constants for absorption from the rat small intestine 
and the partition coefficient of the carbamates between octanol and buffer 
originally demonstrated by Houston et al, (197^)* The use of these ..■ *  y- 
radiolabelled carbamates enabled low carbamate concentrations to be used 
(between 50 and 100 times lower than used in the original studies) and at 
these low concentrations, where the problem of the low aqueous solubility 
of the higher carbamates was overcome, the parabolic relationship was still 
found to be operative. Furthermore, the use of rats starved for up to 
twenty hours before experimentation had no significant effect on the 
absorption rates of the four radiolabelled carbamates. The two compartment 
system consisting of a hydrophilic barrier in addition to a lipoid barrier, 
which was originally invoked to explain the parabolic behaviour, would 
thus seem to be unaltered by starvation of up to twenty hours in the rat.
It was found however that the parabolic relationship was not detected 
under conditions of minimal mixing in the distal small intestine and a 
linear relationship between absorption rate constant and partition 
coefficient was found. The cause of these markedly different findings, 
depending on whether a well mixed or a minimally mixed intestinal preparation 
was used, was thought not to be due to an increased "unstirred layer", 
existing at the mucosal surface and in non-equilibrium with the bulk of the 
perfusion solution in the minimally mixed preparation. The presence of
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such a layer would be expected to retard the diffusion of & larger 
carbamate molecules and thus decrease their absorption rates and this was 
not found experimentally. It is possible, however, that insertion of the 
sampling cannula into the intestinal lumen caused localised changes in 
the permeability characteristics of the intestinal epithelium which were 
readily detected in the minimally mixed preparation because of the 
restricted sampling volume used.
Further studies would be required to investigate any differences in 
permeability to foreign compounds that may exist along the length of the 
small intestine. For example the parabolic relationship may be a 
characteristic of the upper reaches of the small intestine and the linear 
realtionship characteristic of the more distal parts of the small intestine 
There are certain physiological differences apparent along the length of 
the small intestine and these factors may play a role in any differences 
in absorption observed in different sections of the intestine.
Ochsenfahrt and Winne (1968) reported that the absorption rate of. 
the lipophilic drug antipyrine was closely related to intestinal blood 
flow. Similarly, the work of Crouthamel et al, (1975) showed that dramatic 
decreases in drug absorption occurred when small intestinal blood flow 
was reduced. These findings suggest that any differences in blood supply- 
along the gastrointestinal tract would be reflected in differences in 
carbamate absorption rates. Unfortunately the presence or absence of a 
blood flow gradient in the intestinal tract (with the blood supply 
gradually decreasing from the duodenum to the colon) is controversial.
Geber (i960), and Steiner and Meuller (1961) found such a gradient to exist 
whereas Delaney and Custer (1965) and Goodhead (1969) found no evidence 
for a blood flow gradient. There is also some evidence that a gradient of 
pore radius exists along the intestinal tract (Fordtran and Ingelfinger, 
1968) and if this is the case significant drug absorption may occur via 
pores in the upper small intestinal tract. Such absorption through pores 
would be important in the absorption of drugs of small molecular volume 
and may be used to advantage in the design of future drugs.
Many previous studies on the role of lipophilicity in the absorption 
of foreign compounds from the small intestine have indicated a linear 
relationship between absorption rate and partition coefficient. In'view 
of the findings in the present study in which a linear relationship was 
found under conditions of minimal mixing of the lumen contents it is 
possible that these previous studies were set up inappropriately to 
detect the parabolic relationship.
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Studies on the factors affecting the absorption of the carbamate 
homologues from the rat colon were carried out in order to provide an 
overall picture of the role of lipophilicity in foreign compound absorption 
along the length of the gastrointestinal tract. A well mixed in situ 
preparation was used to investigate the absorption of the carbamates from 
the rat colon and the results showed that there was a linear dependancy of 
absorption rate constant upon partition coefficient. It would thus seem 
that the colon membrane and the gastric membrane (for which a linear
relationship has also been demonstrated using the carbamate series) ...  ..
present a similar barrier to the absorption of foreign compounds. The 
similarity between colon and gastric membranes is further confirmed by the 
results found for the branched chain carbamate homologues, which are 
also absorbed at rates based only on their partition coefficients in the 
colon and stomach. In contrast to this additional steric factors appear 
to be operative in the small intestine (Houston et al., 197^) and on this 
basis the structure of the small intestine membrane seems to be more 
complex thaii the gastric or colon membranes.
The prime function of the colon is the conservation of salt and 
water and in view of this it was particularly important to investigate 
the effect of concurrent water absorption on the absorption of carbamates 
from this organ. It was found that the use of perfusion solutions- from - - 
which concurrent water absorption was quite rapid did not alter the rates 
of carbamate absorption. This indicated that little or no carbamate was 
absorbed through the membrane pores through which water is supposed to be 
largely absorbed. This finding was further checked by studying the 
absorption of erythritol, a very polar low molecular weight alcohol of 
similar molecular dimensions to the shorter chain carbamate homologues. 
Erythritol is thought to be absorbed almost entirely via pores and has 
been used to estimate the effective pore radius in the small intestinal 
membrane (Fordtran and Ingelfinger, 1968). However, the absorption of 
erythritol from the colon was negligible and this indicates that the size 
of the pores in the colon is very different to those found in the small 
intestine and that whereas water flux may not affect foreign compound 
absorption from the colon this may not be the case for the small intestine. 
Further experiments, carried out in the small intestine and based upon 
those used in the colon, would show how important this effect may be in the 
absorption of relatively large drug molecules.
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A comparison of the overall rates of cartamate absorption from different 
sections of the gastrointestinal tract showed that absorption was slowest 
from the stomach, faster from the colon and most rapid from the small 
intestine (considering the positive slope of the parabola). This finding 
can be explained largely on comparative surface area considerations. The 
considerable advantage in surface area of the small intestinal muscosa 
over that of a smooth surface like the stomach is readily shown. The 
existence of villi is estimated (Fisher and Parsons, 1950) to produce a 
four-fold, and the microvilli approximately a twenty-five-fold increase in 
surface area over a flat mucosa. This gives the intestine a one hundred­
fold increase in unit surface area over the stomach. The colon mucosa, 
however, contains no villi but does contain microvilli, although their 
size and number is less than seen in the small intestine (Rifaat, et al,
1965).
Thus the absorption rate comparisons along the gastrointestinal tract 
would seem to be dependant, to a large extent, on surface area although a 
much greater difference between rates of absorption from the stomach and . 
small intestine might be expected if this were the case. It is possible 
though that the mucous or "extraneous" layer which is known to coat all 
these membranes (Brandt, 1962) produces a reduction in effective surface 
area in those membranes containing microvilli.
Although it is unlikely that the colon would be the major site of 
absorption of an orally administered drug, the results found in these 
investigations indicate that definite advantages may be obtained in certain 
circumstances by administration of drugs into the colon via rectal 
suppositories. The colon would appear to be a convenient site of absorption 
for drugs causing gastric irritation or for those likely to be hydrolysed 
in the stomach. Similarly, colonic absorption following oral administration 
of a drug may prove to be an important and efficient means of achieving 
therapeutic plasma levels In patients with gut resections.
At very high log P values the absorption of carbamates proceeds at 
a very similar rate in both the rat colon and small intestine. Perhaps 
for such lipophilic compounds the colon should be regarded, alongside the 
small intestine,-as an efficient organ of absorption. This finding may be 
of some importance in drug design because although very lipophilic drugs 
may not be effectively absorbed after oral administration, their incorpor­
ation into the correct suppository base may lead to good absorption via 
the colon;.
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In view of the importance of biological membranes in any study on the 
transfer kinetics of foreign compounds, either in an isolated preparation 
or in a whole animal experiment, the interactions of the carbamate 
homologues with a model membrane system were studied. The system used was 
the phosphatidylcholine liposome membrane model, which possesses many of 
the properties of biological membranes. The liposome membrane model has 
been much used to elucidate the membrane effects of anaesthetic agents and 
thus these studies were particularly relevant because the carbamate 
homologues possess narcotic activity, whcih increases regularly as the __
carbamate chain length increases.
All the carbamates were found to destabilise the liposome membranes
“3 . - ■ ' .at a concentration of 10 M (as indicated by increasing permeability of
the membranes to cation), although the destabilisation produced was not
linearly related to partition coefficient. The amount of destabilisation
was.found to be related to the dynamic surface tension of the carbamates
but this relationship probably only reflected the underlying dependance of
surface tension upon lipophilicity. It is important to note however, that
the long chain carbamates are moderately surface active and although this
property may not in itself affect membrane permeability it could be
. ckfi-
important in increasing the availability of the carbamates at^membrane 
surface (Feldmeister, 1972). ..
The four radiolabelled carbamates were used to investigate the 
incorporation of the carbamates into the liposome membranes. From the 
results of these experiments it was proposed that the increasing 
destabilisation produced by the carbamates, as their chain length was 
increased, was due to increasing incorporation of the carbamates into the 
liposome membrane and that this incorporation was associated with the 
partitioning properties of the carbamates.
In view of the increasing anaesthetic activity of the carbamates 
with increasing chain length, the results found in the liposome studies 
support the lipid theory of anaesthesia which states that anaesthesia is 
produced by drug molecules dissolving in the cell lipids. If the liposome 
membrane is considered as a fair model of the biological cell membrane it 
couldbiiQW be further proposed that dissolution of drugs in the cell lipids 
is only the first step towards anaesthesia and that the permeability 
changes brought about as a result of this incor^ation into the membranes 
are more directly involved in the anaesthetic effect.
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It may be possible to use this model membrane system to learn more 
about the role of membrane composition in the process of gastrointestinal 
absorption by using membranes^
Cjmore closely resembling the gastrointestinal membranes in lipid 
composition. Further experiments would show whether the rate of incorpor­
ation of the carbamates into these membranes varied according to the lipid 
components of the liposome membranes used. Additionally, the use of 
branched-chain and aromatic carbamates in liposome studies would enable the
effects of steric and other parameters to be estimated. It would be of .. ...
interest to know, for the carbamate series, whether linear or parabolic 
relationships between the rate of incorporation into the membranes and 
partition coefficient would reflect the use of liposomes approximating in 
lipid composition, say, colon membranes or small intestine membranes.
Perhaps even more information would be obtained if experiments on the 
rate of incorporation of the carbamates into cells were carried out using 
suspensions of cells taken from various sections of the gastrointestinal 
tract. Studies on such cells could be seen as a useful compromise between 
the more basic liposome model and the intact biological membrane with which 
it is often very difficult to work.
The pharmacokinetic disposition and overall metabolic fate of the four 
radiolabelled carbamates was investigated in an attempt to elucidate the - 
role of lipophilicity in these processes. It was found that although the 
pharmacokinetic two compartment model adequately described the distribution 
and elimination of all four compounds, the pharmacokinetic parameters 
derived from the plasma concentration-time curves showed no apparent 
simple dependance upon the partition coefficients of the carbamates. Ethyl 
carbamate was found to have the longest apparent biological half-life 
(12^0 min) following intravenous administration although this may have 
resulted from the conversion of a metabolite (li-hydroxy ethyl carbamate) 
back to the parent compound either in vivo or during the assay procedure.
Both n-butyl and n-hexyl carbamates had similar biological half-lives of 
about 65 minutes and n-octyl carbamate was very rapidly eliminated (tg was 
lU minutes). ;
Following intraduodenal administration all the carbamates appeared 
very rapidly in the''bloodstream and this finding is in good agreement with 
the order of the absorption rate constants found using the in situ intestinal 
preparation. Comparisons of AUC showed that more parent cartjmate 
(considering the three longest chain, carbamates) reached the vascular compart­
ment by the intravenous route than by the intraduodenal route. Since this
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was not due to incomplete absorption some fraction of these carbamates 
must be metabolised either during absorption or during the first pass 
through the liver. Although Pekas (1971 a,b) demonstrated the metabolism 
of aromatic carbamate insecticides by the intestinal mucosa in vitro, 
this finding was not confirmed in the whole animal studies of Houston et al, 
(197^ -b). Furthermore no evidence for intestinal metabolism was found in 
the in situ absorption experiments and thus ^ it is probable that the major 
site of this metabolism is the liver. The possible role of the intestinal 
mucosa in the metabolism of these compounds could be elucidated by 
comparing the femoral vein data with that produced by hepatic portal vein 
administration of the same dose. The latter route is effectively ecpial to 
intraduodenal administration but bypasses the intestinal mucosa.
Although the use of only four carbamates may -to some extent have , 
limited the interpretation of the comparisons of the plasma level-time 
curves, the overall metabolic fate of the carbamates could be explained 
by proposing two competing routes of metabolism. The hydrolytic route 
appears to be favoured by the shorter chain carbamates whereas various 
metabolic transformations on the intact carbamate molecule take place 
extensively for the longer chain carbamates. The identification of the 
major metabolites and their concentrations in the plasma and urine would, 
provide more conclusive information in this area. Moreover the use,-in - - 
further experiments, of the carbamate homologues not used in these 
pharmacokinetic studies will enable the factors controlling distribution 
to be more readily identified. Such studies would also provide further 
information on the processes governing the routes of metabolism of these 
compounds.
The various investigations discussed in this chapter indicate the 
0 .
lmp^eJtance of establishing the fundamental factors that affect the kinetics 
of absorption, distribution, metabolism and excretion of foreign compounds. 
The ultimate goal of these and similar studies is the prediction of the
fate of foreign compounds in the whole body, but only when series of
Acompounds, such as the homologous series of carbmates are used cant\
incremental changes be made to the parent compound and the effects of a 
single substituent be demonstrated.
In view of the usefulness of the .aliphatic carbamate series as model 
compounds for elucidating the fundamental relationships between structure 
and membrane penetration, it would seem appropriate to repeat this work 
using, a series of compounds containing an aromatic nucleus. Such studies
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would be particularly important since the majority of drugs contain an 
aromatic centre in their structure. Using such compounds the effects of 
substitution on the benzene ring could be investigated and this area of 
study has been sadly neglected. The information derived from such studies 
would be extremely useful in the prediction of the passage of drug 
molecules through biological membranes and may ultimately lead to the 
rational design of new drugs.
160
REFERENCES
ADAMS, P. & BARON, F.A. (1965) Chem.Rev., Jd59 567.
ALBERT, A. (l97l) Ann.Rev. Pharmacol., 11, 1-3.
ALI, M.A. & ROUTH, J.I. (1969) Clin.Chem., 15, 1027.
AMIN, Y.M. & NAGWEKAR, J.B. (1975) J.Pharm.Sci., 6b, 180U.
ANTON, A.H. (i960) J.Pharmacol.Exp.Ther., 129» 282.
ARIENS, E.J., SIMONIS, A.M., & van ROSSUM, J.M. (196M  "Molecular Pharmacology" 
Academic, London 
AXELROD, J. (1955) J.Biol.Chem., 2lH, 753.
BANGHAM, A.D. (1967) Chem.Phys. Lipids, 1, 225.
BANGHAM, A.D. (1968) Progress in Biophysics, 2, 29.
BANGHAM, A.D. (1972) Ann.Rev.Biochem., Ul, 753.
BANGHAM, A.D. , STANDISH, M.M. & WATKINS, J.C. (1965a) J.Mol.Biol. 13, 238.
BANGHAM, A.D. , STANDISH, M.M. & MILLER, N. (1965b) Nature, 238, 1295*
BANGHAM, A.D. , STANDISH, M.M. & WEISSMANN, G. (1965c) J.Mol.Biol., 13, 253.
BARR, W.H. & REIGELMAN, S. (1970) J.Pharm.Sci.,^59, 15^.
BECKETT, A.H., ROWLAND, M. & TURNER, P. (1965) Lancet, 1, 303.
BENNETT, H.S. (1963) J.Histochem. Cytochem., 3A, lU.
BERNHARD, R. (1969) Scientific Res., b, 25.
BIANCHINE, J.R. (l97l) Ann.N.Y. Acad.Sci., 179, 126.
BINDER, H.J. (1970) Biochem.Biophys. Acta, 219, 503. .■
BINDER, H. (197^) Gastroenterology, 67, UUl.
BLANCHARD, J. (1975) Am.J.Pharmacy, 1^7, 135.
BOCK, K.W. , FROHLING, W. , REMMER, H. & REXER, Bjl (1973) Biochim.Biophys.
Acta, 327, b6.
BOCK, K.W. & WINNE, D. (197^) Biochem.Pharmac., 2U, 859*
BOGGS, J.B., ROTH, S.H._, YOUNG, T., WONG, E. & HSIA, J.C. (1976) Mol.Pharm.,
12, 136.
BOYLAND, E. & NERY, R. (1965) Biochem.J., 9b, 198.
BOYLAND, E. , NERY, R. , PEGGIE, K.S. & WILLIAMS, K. (1963a) Biochem.J. , V'.:
89, 113P.
BRANDT, P.W. (1962) Circulation, 26, 1075- 
BRAUER, R.W. (1959) J.Am.Med.Soc. , 169, 1*162.
BRODIE, B.B. (1965) Proc.Roy.Soc.Med. j>8, 9^6.
BRODIE, B.B. & GILLETTE, J.R. (l97l) "Handbook of Exp.Pharmacol. -
Concepts in Biochem.Pharmacol. Vol.2", Springer -Verlag, Berlin.
BRODIE, B.B. , GILLETTE, J.R. & LaDu, B.N. (1958) Ann.Rev.Biochem. , 21, 
h2J.
BRODIE, B.B. & H0GBEN, C.A.M. (1957) J.Pharm.Pharmacol., 91, 3U5.
162
BRODIE, B.B. & MAIKEL, D. (1962) "Proc. First Int. Pharmacological Meeting 
Vol VI, Pergamon, London..
BYRON, P.R. & NOTARI, R.E. (1976) J.Pharm.Sci., 65, llUo.
CAFRUNY, E.J. (l97l) in "Fundamentals of drug metabolism and drug
disposition", Eds, La Du, B.N., Mandel, H.G. & Way, E.L., Williams 
and Wilkins, Baltimore.
CAMPBELL, T.C. & HAYES, J.R.■(197*0 Pharmacol. Revs., 26, 171.
CASSANO, G.B., SJOSTRAND, S. E. HANSSON, E.,Arch.Int.Pharmacodyn., 156, 
kQ. . . .  ■
CHAPLIN, M.D. -& MANNERING, G.J. (1970) Mol.Pharmacol. , 6, 631.
CHESSEAUD, L.F. (1970) in "Foreign Compound Metabolism in Mammals, Vol. I" 
Chem.Soc., London.
CHESSEAUD, L.F., & TAYLOR, T. (197*0 Ann.Rev.Pharmacol., lU, 35- 
CHIOUS, W.L. (1975) J.Pharmaco and Biopharm., 3., 193.
COLLANDER, R. (1937) Trans.Faraday Soc., 33, 985.
COLLANDER, R. (l9*+9) Physiol. Plant., 2 , 300..
COLLANDER, R. (195*0 Physiol. Plant, 7, **20.
COLLANDER, R, & BARLUND, H. (1933) Acta. Bot.Fern., 11, 1.
COLLEY, R.M. & RYMAN, B.E. (1975) Biochem. Soc. Trans., _3, 157*
C0NS0L0, S., MORSELLI, P.L. & ZACCALA, M. (1970) Europ.J. Pharmacol.,
10, 239. . L ..
COSTER, H.G.L. & HOPE, A.B. (197*0 Proc.Austral. Physiol. & Pharmacol.Soc.
5, 2 .
CROUTHAMEL, W.G. & KNOX, V.D. (1975) Anal.Biochem., 6 6, 23**.
CRUM-BROWN, A. & FRASER, T. (1868) Trans.R.Soc. Edinburgh, 25, 151. ;
CUMMINGS, J.H. (1975) Digestion, 13, 232.
CUMMINGS, A.J., KING, M.L. & MARTIN, B.K. (1967). Br.J.Pharmac. 29, 150. 
CURRAN, P.F. & MACINTOSH, J.R. (1962) Nature, 193, 3**7- 
CURRAN, P.F. & SOLOMAN, A.K. (1957) J.Gen.Physiol., **1, 1**3.
DAMM, K.H., GROSSHAUSER, A. & ERTMANN, R.R. (1975) N .S.Arch.Pharmacol. , 
289, 217.,
DANIELLI, J.L. & HARVEY, E.N. (1935) J.Cell.Comp.Physiol., j>, ^85.
DANIELLI, J.L. & DAVSON, H. (1935) J.Cell.Comp.Physiol., 5., **95- 
DAVIES, D.S. & THORGEIRSSON, S.S. (1971) Acta Pharmacol, et Toxicol.,
2£ (Supp 3), 181.
DELANEY, J.P. & CUSTER, J. (1965) Circulation Res., 17, 39*+.
DE MARCO, T.J. & LEVINE, R.R. (1969) J.Pharm.Exp.Ther., 169, 1**2.
■DIAMOND, L. , DOLUISIO, J.T. & CROUTHAMEL, W.J. (1970) Europ. J. Pharmacol.,
DITTERT, L.W. & HIGUCHI, T. (1963) J.Pharm.Sci., 52, 852.
DOLUISIO, J.T., BILLUPS, N.F., DITTERT, L.W., SUGITA, E.T. & SWINTOSKY, J.V. 
(1969) J.Pharm.Sci., 58, II96.
DOROUGH, H.W. (1970) J.Agr.Food Chem., 18,1015.
DOST, F.H., (1969) in "Advances in the Biosciences", Vol.59 EdiG.Raspe, 
Pergamon, Oxford.
DRASAR, B.S., HILL, M.H. & WILLIAMS, R.E.O. (1970) in "Metabolic Aspects 
of Food Safety" Ed. F.J.C. Roe, Blackwells, Oxford.
EDMONDS, C.J. & PILCHER, D. (1972) in "Transport Across the Intestine: ' ~
A Glaxo Symposium" Eds. Burland, W.L. , & Samuel, P.D., Churchill 
Livingstone, London
EGER, E. (1963) in "Uptake and Distribution of Anaesthetic Agents", Papper, 
E.M. & Kitz, R.J. Eds. McGraw-Hill, London.
EISEN, M.J. (196U) J.Am.Med.Soc., 1§9, 6k.
EVANS, D.A.P. (1971) Acta Pharmacol, et Toxicol.,29, (Suppl 3), 156.
EXNER, T. , RICKARD, K.A. & KRONENBERG, H. (1976) Science Tools, 23, 1.
EYTAN, G., MATHESON, M.J. & RACKER, E. (1975) Febs Letters, 51, 121.
FALOON, W.W. , PAES, I.C., W00LF0LK, D. , NANKIN, H., WALLACE, K. & HARO, E.N. 
(1969) Ann.N.Y.Acad.Sci., 132, 879-
FELDMAN, S. & GIBALDI, M. (1969) J.Pharm.Sci. 58, U25.
FELDMEISTER, A. (1972) J.Pharm.Sci., 6l, 151. - - — - - —
FISHER, R.B. & PARSONS, D.S. (1950) J.Anat., jft, 272.
FISHMAN, W.H. (1970) Ed. "Metabolic Hydrolysis and Conjugation" Vols. 1,2 
and 3} Academic, London.
FLYNN, G.L. & SMITH, R.W. (1972) J.Pharm.Sci., 6l, 6l.
FORDTRAN, J.S. & DIETSCHY, J.M. (1966) Gastroenterology, 50, 263.
FORDTRAN, J.S. & INGELFINGER, C. (1968) in "Hankbook of Physiology - Section 
6, Alimentary Canal" Vol III Ed. C.F. Code. 'American Physiological 
Society, Washington.
FORDTRAN, J.S., RECTOR, F.C., EWTON, M.F., SOTER, N. & KINNEY, J. (1965)
J.Clin.Invest., J+U, 1935-
FOUTS, J.R. (1970) Toxicol.Appl.Pharmacol. 17, 80U.
FUKUTO, T.R. (1972) Drug Metab.Revs., 1, 117. - -
GALEAZZI, R.L. & BENET, L.Z. (1976) Clin.Pharmacol.Ther., 20, 278.
GARRETT, E.R. (l97l) Acta Pharmacol.Toxicol., 2£, 1.
GEBER, W.F. (i960) Am.J.Physiol., 217, 835*
GIBALDI, M. (1970) in "Theory and Practice of Industrial Pharmacy", Lachman,
L. , Lieberman, H.A. & Kanig, J.L., Eds. Lea and Febiger, Philadelphia.
164
GIBALDI, M. (1970) Fed.Proc., 29, 13*13.
GIBALDI, M. & FELDMAN, S. (1970) J.Pharm.Sci., j>9, 579-
GIBALDI, M. & GRUNDHOFER, B. (1973) J.Pharm.Sci., _62, 3^3.
GIBALDI, M..& PERRIER, D. (1975) "Pharmacokinetics", Marcel Dekker, New.
York.
GIBALDI, M. , NAGASHIMA, R. & LEVY, G. (1969) J.Pharm.Sci., _58, 193- 
GILLETTE, J.R. BRODIE, B.B. & La Du, B.N. (1957) J.Pharmacol.Exp.Ther.
119, 532..
GILLETTE, J.R. , DAVIS, D.C. & SASAME, H.A. (1972) Ann.Rev.Pharmacol.,
. 12, 57.
GOODHART, F.W. & EICHMAN, M.L. (1976) J.Pharm.Sci., 6 5, 935*
GOLDBAUM, L.R. & SMITH, P.K. (19^8) Fed.Proc. , 7, 222.
GOODHEAD, B. (1969) Am.J.Physiol., 217, 835.
GORTER, E. & GRENDEL, F. (1925) J.Exp.Med., *kL, H39-
GUGLER, R. & AZARNOFF, D.L. (1976) Clin.Pharmacokinet., 1, 25.
HALL, L.H., KIER, L.B. & MURRAY, W.J. (1975) J.Pharm.Sci., 6k, 197*^
HANNGREN, A. , HANSSON, E. , SUARTZ, N.' & ULLBERG, S. (1963) Acta Med.Scand.
173, 61.
HANSCH, C. (1971) "Drug Design" Vol. 1, Ed E.J. Ariens, Academic, London.
HANSCH, C. (1972) Drug Met.Rev., 1, 1.
HANSCH, C. (1976) J.Med.Chem. , 1£, 1. > :■:
HANSCH, C. & DUNN, W.J. (1972) J.Pharm.Sci., 6l, 1. -
HANSCH, C., DEUTSCH, E.W. , & SMITH, R.N.\ (1965a) J. Am. Chem. Soc., 87, 2738.
HANSCH, C., STEWARD, A.R., IWASA, J., & DEUTSCH, E.W. (1965b) Mol.Pharmac.
1, 205.
HARRIS, T.A.B. (1951) "Mode of Action of Anaesthetics" Livingstone, 
Edinburgh.
HARRIS, P.A. & RIEGELMAN, S. (1969) J.Pharm.Sci., 58, 71- 
HAYAISHI, 0. (1962) "Oxygenases", Academic, London.
HEAP, R.B., SYMONS, A.M. & WATKINS, J.C. (1970) Biochim.Biophys. Acta.
218, *182.
HEAP, R.B. , SYMDNS, A.M. & WATKINS, J.C. (1971) Biochim.Biophys.Acta.,
233, 307.
HEATON, W.J. (1972) Am.J.Dig.Dis., 17, 7-
HIKAL, A.H., DYER, L. & WONG, S.W. (1976) J.Pharm.Sci. , 65, 621.
HILL, M.J. & DRASAR, B.S. (1975) Gut, l6, 318.
HIROM, P.C., HUGHES, R.D. & MILLBURN, P. (197*0 Biochem.Soc. Trans., 2,
!2.
HIROM, P.C., MILLBURN, P., SMITH, R.L. & TLELLIAMS, R.T. (1972a) 
Xenobiotica, 2 , 205*
165
HIROM, P.C. , MILLBURN, P. , SMITH, R.L. & WILLIAMS, R.T. (1972b) Biochem.
J., 129, 1071.
HIROM, P.O., MILLBURN, P. & SMITH, R.L. (1976) Xenobiotica, 6, 55- 
HOBER, R. & HOBER, J. (1937) J.Cell.Comp.Physiol., 10, U01.
HOGBEN, C.A.M. , TOCCO, D.J., BRODIE, B.B. & SCHANKER, L.S. (1959). J- 
Pharmacol.Exp.Ther., 125, 275*
HOLLANDER, D. , MURALIEHARA, A.S. & LIM, E. (1976) Am.J.Physiol. , 230, 251. 
HOLLANDER, D. & TRUSCOTTE, T.C. (l97^a) J.Clin.Invest., 83, 6U8 .
HOLLANDER, D. & TRUSCOTTE, T.C. (l97^b) Am. J.Physiol., 226, 1516. . A r
HOUSTON, B.J. (1973) PhD Thesis, University of Surrey.
HOUSTON, J.B., UPSHALL, D.G. & BRIDGES, J.W. (197*0 J.Pharm.Exp.Ther. ,
189, 2kb.
HOUSTON, J.B., UPSHALL, D.G. & BRIDGES, J.W. (l97^b) Xenobiotica,
5, 631.
HOUSTON, J.B. , UPSHALL, D.G. & BRIDGES, J.W. (1975a) J.Pharm.Exp.Ther. , 195,
'67. -
HUANG, M-T., WEST, S.B. & LU, A.Y.H. (1976) J.Biol.Chem. , 251, U659- 
HUCKER, H.B. (1970) Ann.Rev.Pharmacol., 10, 99- 
HUNT, J.N. (1959) Physiol.Rev., 39, U91.
ICHIKAWA, Y., YAMONO, T. & FUJISHIMURA, Y. (1969) Biochim.Biophys.
Acta, 171, 32.
INUI, K. ,: HORIGUCHI, M. , KIMURA, T. , MURANISHI, S. & SEZAKI, H. (197*0 
Chem.Pharm. Bull., 22, 1781.
ITO, S. (1965) J.Cell.Biol., 27, 1+75- 
ITO, S. (1969) Fed.Proc., 28, 12.
JIRGENSONS, B. & STRAUMANIS, M.E. (1962) in "A Short Textbook of Colloid 
Chemistry", Pergamon, Oxford.
JOHNSON, C.F. (1967) Science, 155, 1670.
JOHNSON, S.M. & MILLER, K.W. (1970) Nature, 228, 75-
KAJINA, S., SMITH, R.B., CROUTHAMEL, W.G. & DOLUSIO, J.T. (1972) J.Pharm, 
Sci., 6l, 106l.
KAKEMI, K. , ARITA, T. , HORI, R., & KONISHI, R. (1967) Chem.Pharm.Bull.
15, 153^.
KAKEMI, K. , ARITA, T. , HORI, R. & KONISHI, R. (1967a) Chem.Pharm.Bull. ,
15, 1883.
KAKEMI, K. , SEZAKI, H. , KITAZAWA, S. & OMURA, K. (1967b) Chem.Pharm.Bull. , 
15, 1287.
KAKEMI, K. , ARITA, T. , HORI, R. & KONISHI, R. (19.67c) Chem.Pharm.Bull.
15* 1705.
166
KAMP, J.D. & NEUMAN, H.G. (1915) Xenobiotica, jp, TIT-
KATO, R. , TAKANATA, A. & ONADA, K.I. (19TO) Jap.J.Pharmacol., 20, 5T2.
KEEN, P.M. (i960) Biochem.Pharmacol. , 15>, IAt*
KELLEY, E.G. & KANEGIS, L.A. (196T) Toxicol.Appl.Pharmacol., 11, llU. 
LIER, L.B. , HALL, L.H. , MURRAY, W.J. & RANDIC, M. (19T5) J-Pharm.Sci. , 
6k, 19T1*
KIERi L.B., WALLACE, J.M. , RANDIC, M. & HALL, L.H. (19T6) J.Pharm.Sci.
65, 1226.
KITAZAWA, S., ITO, H. & SEZAKI, H. (19T1*) Chem.Pharm.Bull., 23, 1856. 
KLOTZ, I.M. (1950) "Chemical Thermodynamics", Prentice-Hall, Englewood 
Cliffs.
KOELLE, G.B. (19T5) "The Pharmacological Basis of Therapeutics" Eds 
Goodman, L.S. & Gilman, A., Macmillan, New York.
KOIZUMI, T., ARITA, T. & KAKEMI, K. (196T) Chem.Pharm.Bull., 12, k21.  
KOSTENBAUDER, H.B., PORTNOFF, J.B., & SWINTOSKY, J.V. (1962) J.Pharm.Sci. 
51, 108U.
KUNTZMAN,R. (l9Tl) Ann.Rhv.Pharmacol., 11, 21.
LAUTERBACH, F. (1969) N.S.Arch.Pharm., 26k, 2 6 j .
LAWRENCE, D.K. & GILL, E.W. (19T5) Mol.Pharm., 11, 280.
LEVINE, R.R., McNARY, W.F., KORNGUTH, P.J. & LeBLANC, R. (19T0) Eur.
J.Pharmacol. , 9_, 211. _ _ _
LEVINE, R.R. & PELIKAN, E.W. (196*0 Ann.Rev.Pharmacol. , _U, 69.
LEVITAN, R. & BILLICH, C.O. (1968) Clin.Res., l6, 28T-
LEVITAN, R.-, FORDTRAN, J.S., BURROWS, B.A. & INGELFINGER, F.J. (1962)
J.Clin.Invest., Ul, 1T5^- 
LEVY, G. (19T6) J.Pharm.Sci., 65, 126k.
LINDERMANN, B. & SOLOMON, A.K. (1962) J.Gen.Physiol., k5, 801.
LOGE, J.P., & BUNDLES, R.W. (1951) Blood, k, 201.
LOO, J.C.K. & RIEGELMAN, S. (1968) J.Pharm.Sci. J5T, 918.
LUDWIG, B.J. & POTTERFIELD, J.R. (19T1) Adv.Pharmac.Chemother. , 9, 1T3- 
LUNGREN, 0. (196T) Acta Physiol.Scand.Suppl., 303, 1.
MANNINEN, V., APAJALAHTI, A. & MELIN, J. (19T3) Lancet, 1, 398.
MARTIN, D.K. (1965) Nature, 20T, 2 lh .
MARTIN, Y. & HACKBARTH, E. (19T6) J.med.Chem. (in press).
MARTIN, Y. & HANSCH, C. (l9Tl) J.med.Chem., jA, TTT*
MASON, H. (1965) Ann.Rev.Biochem., 3**, 595-
MAYERSOHN, M. & GIBALDI, M. (l9Tl) Am.J.Pharm.Educ. , 35, 19-
MELLETT, L.B. (1969) Prog. Drug. Res., _13, 136.
167
MEYER, M.C. 8s GUTTMAN, D.E. (1968) J.Pharm.Sci., 57, 895- 
MICHELS, H. , BITTIGHOFER, P. & KURZ, H. (197*0 Naunyn.Schmeid.Arch.
Pharmacol., 282, Suppl 282, R66.
MILLER, K.W. & PANG, K-Y.Y. (1976) Nature, 263, 253.
MORRIS, J.S. & HEATON, K.W. (1974) Scand.J.Gastroenterol., _9, 33.
MURRAY, W.J. , HALL, L.H. & Kier, L.B. (1975) J.Pharm.Sci. , _64, 1978..
NAGASHIMA, R. , LEVY, G. & O'REILLY, R.A. (1968) J.Pharm.Sci.,57, 1888.
NAJJAR, V.A. & HOLT, L.E. (1943) J.Am.Med.Ass. , 123, 683.
NERY, R. , (1968) Biochem. J., 106, 1. .1 — r_Y
NIMMO, J. , HEADING, R.C. & TOTHILL, P. (1973) Br.Med.J. , 1, 587.
NOTARI, R.E. (1973) J.Pharm.Sci., _62, 865.
OCHSENFAHRT* H. (1971) in "Gastrointestinal Motility" Eds. Demling, L.
& Ottenjann, R., Academic, London.
OCHSENFAHRT', H. & WINNE, D. (1968) Life Sciences, 7, 493-
OESCH, F. , JERMA, P.M. & DALY, J. (1971) Biochim.Biophys. Acta, 227,
685.
O'REILLY, I. & NELSON, E. (1959) Unpublished Data, quoted by Bates 8s
Gibaldi in "Current Concepts in Pharmaceutical Sciences - Biopharmaceutics" 
Lea and Febiger, Philadelphia.
ORR, J.M. 8: BENET, L.Z. (1975) Am.J.Dig.Dis., 20, 858.
OVERO, K.F. (1973) J.Pharm.Pharmac. , 25, 957. /; ^
OVERTON, E. (1899) Vischer,Naturf.Gks., 44, 88.
OVERTON, E. (l90l) "Studien uber die Narkose", Fischer, Jena, Germany.
PARKE, D.W. (1968) "Biochemistry of Foreign Compounds", Pergamon, London.
PAPAHADJOPOULOS, D. & MILLER, N. (1967) Biochim.Biophys. Act a, 135, 624.
PATERSON, E., THOMAS, I.A. , HADDOW, H. 8: WILKINSON, J.M. (1946) Lancet,
1, 677.;' ■
PEKAS, J.C. (1971a) Am.J.Physiol., 220 , 2008.
PEKAS, J.C. (l971"b) Can.J.Physiol.Pharmac. , *19,14.
PELZMAN, K.S. & HAVEMEYER, R.N. (1972) J.Pharm.Sci., 6l, 110.
PENNISTON, J.T., BECKETT, L., BENTLEY, D.L. & HANSCH, C. (1969) Mol.
Pharmacol., j>., 333*
PIHL, B.G. , GLOTZER, D.J. & PATTERSON, J.F. (1966) J.App.Physiol., 21, 1059- 
POSTE, G. & PAPAHADJOPOULOS, D. (1976) Nature, .261, 699.
POUND, A.W. (1967) Aust.J.Exp.Biol.Med.Sci., 45 , 507.
POWELL, G.M., MILLER, J.J., OLAVESEN, A.H. & CURTIS, C.G. (1974) Nature,
252, 234.
PRESCOTT, L.F. (1974) Br.J.Clin.Pharmac., 1, 189*;
PURCELL, W.P. 8: CLAYTON, J.M. (1971) Advan.Chem.Series, 108,123.
RADOMSKI, J.L., DEICHMAN, W.B. , CLIZER, E.E. 8: REY, A. (1968) Food Cosmetic . 
Toxicol. , <5, 209.
168
RANDIC, M. (1975) J.Am.Chem.Soc. , 97, 6609.
REMMER, H. (1975) in "Lung Metabolism", Academic, London. . •
REMMER, H. (1970) Proc.Europ.Soc.Study of Drug Toxicity, 11, 1^.
REMMER, H. , SCHENKMAN, J. , ESTABR00K, R.W. , SESAME, H. GILLETTE, J.R. ,
NARASIM-HULU, S., COOPER, D.Y. & ROSENTHAL, 0. (1966) Mol.Pharmacol 
2 , 187.
RESCIGNO, A. Sc SEGRE, G. (1966) "Drug and Tracer Kinetics", Blaisdell,
New York.
REUMNG, R.H. 8s LEVY, G., (1967) J.Pharm.Sci., j>6, 8^3. - ■
RIFAAT, M.K. , ISERI, O.A. & GOTTLIEB, L.S. (1965) Gastroenterol., il8, 593 
RIGGS, D.S. (1963) "Mathematical Approach to Physiological Problems", 
Baltimore; Williams 8s Wilkins.
RIEGELMAN, S. , LOO, J.C.K. , 8= ROWLAND, M. (1968) J.Pharm.Sci., 57, 117- 
RIEGELMAN, S.LOO,' J.C.K. Sc ROWLAND, M. (1968) J.Pharm.Sci., 57, 128. 
ROBINSON, J.W.L. , LUISIER, A.L. 8s MIRKOVITCH, V. (1973) Pflugers.Arch. 
3lL5, 317. ■
ROGERS, K.S. Sc CAMMARATA, A. (1969) Biochim, Biophys.Acta. , 193, 22. 
ROSENBERG, P.H., EIBL, H. 8s STIER, A. (1975) Mol.Pharmacol., 11, 879- 
RUIZ-TORRES, A. Sc OHLMEER, J. (1970) Arzneim., 20, 522.
SCHANKER, L.S. (1959) J.Pharm.Exp.Ther., 126, 283.
SCHANKER, L.S. (1971) In "Concepts in Biochemical Pharmacology, Part 1"-- 
Eds' Brodie, B.B. 8s Gillette, J.R. Springer-Verlag.
SCHANKER, L.S. 8: JEFFREY, J.J. (1961) Nature, 190 , 727- 
SCHELINE,R.E. (1973) Pharmac.Rev., £5, ^52.
SCHIFF, E.R., SMALL, N.C. 8s DIETSCHY, J.M. (1972) J.Clin.Invest., 51, 
!351. ; : /
SHOEMAN, D.W. 8s AZARNOFF, D.L. (1975) J .Pharmacol.Exp.Ther. , 195, 8 b . '
SHORE, P.A., BRODIE, B.B. Sc HOGBEN, C.A.M. (1957) J.Pharm.Exp.Ther.,
119, 36l.
SIEBER, S.M., COHN, V.H. 8s WYNN, W.T. (197*0 Xenobiotica, 265. 
SIMMDNDS, W.J., REDGRAVE, T.G., 8s WILLIX, R.L.S. (1968) J.Clin.Invest., 
V[, 1015. 7
SINGER, S.J. 8s NICHOLSON, G.L. (1972) Science, 175, 720.
SKIPPER, H.E., RENNET, L.L. BRYAN, C.E., WHITE, L., NEWTON, M.A. 8s
SIMPSON, L. (1951) Cancer.Res., 11, H6.
SLATER, T.F. 8s GRIFFITHS, D.B. (1965) in "The Biliary System", Ed.
W. Raylor, Blackwells, Oxford.
SMOLEN, V.F. (1973) J.Pharm.Sci., 62, 77-
SPERBER, I. (1965) in "The Biliary System", Ed. W. Raylor, Blackwells, 
Oxford.
169
SPINKS, A. (1973) Chem.Ind. (London), 885.
STEHLE, E.G. & HIGUCHI, W.I. (1972a) J.Pharm.Sci., 6l, 1922.
STEHLE, R.G. & HIGUCHI, W.I. (1972b) J.Pharm.Sci., 6l, 1931.
STEINER, S.H. & MEULLER-; G.C.E. (1961) Circulation Res.,£, 99.
SUZUKI, E., TSUKIGI, M. , MURANISHI, S., SEZAKI, H. & KAKEMI, K. (1972) 
J.'Pharm. Pharmacol., 2b, 138.
SYMONS, A.M. (1976) Biochem.Pharmacol., 25, 15^5*
TEXTER, E.C., CHOU, C.C., LAURETA, H.C. & VANTRAPPEN, G.R. (1968) 
"Physiology of the Intestinal Tract", Mosby, St. Louis.
TREADWELL, C.R. & VAHOUNY, G.V. (1968) "Handbook of Physiology" Section 6, 
American Physiological Soc., Washington D.C.
TURI, J.S., HO, N.F.H., HIGUCHI, W.I. & SHIPMAN, C. (1975a) J.Pharm.Sci.
6b, 622. .
TURI, J.S., HO, N.F.H., HIGUCHI, W.I. & SHIPMAN, C. (1975b) J.Pharm.Sci.,
6b, -627.
TURI, J.S., HO, N.F.H., HIGUCHI, W.I. & SHIPMAN, C. (1975c) J.Pharm.Sci.,
’ 631. . . ,■
TUTE, M.S. (1970) Rep.Prog.App.Chem., 55, 570.
VERLOOP, A. (1972) "Drug Design", Vol. 3. Ed. Ariens, E.J., Academic, 
London.
WAGNER, J.G. (1971) "Biopharmacuetics and Revelent Pharmacokinetics",- 
Drug Intelligence, Illinois.
WAGNER, J.G. (1975) "Fundamentals of Clinical Pharmacokinetics", Drug 
Intelligence Publications, Illinois.
WAGNER, J.G. & NELSON, E. (1963) J.Pharm.Sci., 52, 6l0.
WAGNER, J.G., NOVAK, E., LESLIE, L.G. & METLLER, C.M. (1968) Int.J.Clin.
Pharmacol. , JL, 26l.
WAN, L.S.C. & LEE, P.F.S. (197^) J.Pharm.Sci., 63, 136.
WELLS, P.R. (1968), "Linear Free-Energy Relationships" Academic, London. 
WILLIAMS, R.T. (1959) "Detoxication Mechanisms", Chapman and Hall, London. 
WILSON, T.H. (1962) in "Intestinal Absorption", Saunders, Philadelphia. 
WINNE, D. (1966) N.S.Arch.Pharmacol., _25U, 199-
WOOD-SMITH, F.G., VICKERS*, M.D. & STEWART, H.C. (1973) in "Drugs in 
Anaesthetic Practice", Butterworths, London.
YAMADA, H. & YAMAMOTO, R. (1965) Chem.Pharm.Bull., 13, 1279- 
ZUTPHEN, H. , VAN DEENEN, L.L.M. & KINSY, S.C. (1966) B.B.Res.Comm. ,
